Imidazopyrazine modifiers of AKT1 and uses thereof

Abstract

Provided herein are non-covalent modifiers of AKT1 of Formula (I), (I-A), (I-C), (I-D), (II), (II-A), (II-B), (III), (III-A), (III-B), (III-C), (III-D), (IV-A), (IV-B), or (IV-C) and pharmaceutical compositions thereof. In some embodiments, the present disclosure provides methods of modulating wild-type AKT1 using a compound or salt of Formula (I), (I-A), (I-C), (I-D), (II), (II-A), (II-B), (III), (III-A), (III-B), (III-C), (III-D), (IV-A), (IV-B), or (IV-C), and pharmaceutical compositions thereof.

Description

WSGR Docket No. 61402-727.601IMIDAZOPYRAZINE MODIFIERS OF AKT1 AND USES THEREOF CROSS REFERENCE

[0001] This application claims the benefit of U. S. Provisional Application No. 63 / 777475 filed on March 25, 2025, U. S. Provisional Application No. 63 / 823404 filed on June 13, 2025, and U. S. Provisional Application No. 63 / 895899 filed on October 8, 2025, the entirety of each of which is incorporated herein by reference.BACKGROUND OF THE INVENTION

[0002] The AKT or Protein Kinase B (PKB) family of serine / threonine protein kinases is comprised of 3 highly homologous members, AKT1, AKT2 and AKT3. The family of AKT proteins are involved in signal transduction pathways that regulate cellular processes including apoptosis, proliferation, differentiation, and metabolism. The AKT1 pathway is the most frequently dysregulated signaling pathways in human cancers. Enhanced activation of all the isoforms can be implicated in tumor development and progression, and has been demonstrated in breast, ovarian, pancreatic, and prostate cancers among others (Song et al., 2019). In cancer cells, AKT1 is involved in proliferation and growth, promoting tumor initiation, and suppressing apoptosis, whereas AKT2 regulates cytoskeleton dynamics, favoring local tissue invasion and metastasis. The role of AKT3 hyperactivation in cancer is hypothesized to be involved with possible stimulation of cell proliferation (Hinz et al., Cell Commun Signal 2019, 17(1), 154; Pascual et al., Ann. Oncol. 2019, 30(7), 1051-1060). Expression of these AKT family members is altered in many human malignant carcinomas including gastric, breast, prostate, ovarian, and pancreatic. AKT family members are rarely mutated however, the most common mutation is AKT1 E17K which has been reported in 6-8% of breast cancers, 2-6% of colorectal cancers, and in 6% of meningiomas, in humans (Yu et al., PLoS One 2015, 10 (10), No. e0140479). Thus, there is a need to develop new treatments for the modulation of AKT1 and mutants thereof.SUMMARY OF THE INVENTION

[0003] In one aspect, the present disclosure provides a compound represented by the structure of Formula (I):or a pharmaceutically acceptable salt thereof, wherein:WSGR Docket No. 61402-727.601R2is selected from (a) and (b):a) halogen, -OR13, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN; and b) C3-12 carbocycle and 3- to 12-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, - N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, - N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, - C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, - OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, - S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -N02, -CN, Ci-6 alkyl, and Ci-6 haloalkyl;Ring B is selected from C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR11, -SR11, -N(Rn)2, -C(0)Rn, -C(0)N(Rn)2, -N(R11)C(0)R11, - C(0)0Rn, -0C(0)Rn, -N(R11)C(0)0R11, -0C(0)N(Rn)2, -N(R11)C(0)N(R11)2, - S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(R11)2, -NO2, and -CN; andCi-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(0)Rn, -C(0)N(Rn)2, -N(R11)C(0)R11, -C(0)0Rn, -0C(0)Rn, -N R^C^OR11, -0C(0)N(Rn)2, -N(R11)C(0)N(R11)2, - S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(R11)2, =0, =S, =N(Rn), -NO2, and -CN; R1is selected from:hydrogen, halogen, -OR12, -SR12, -N(R12)2, -C(0)R12, -C(O)N(R12)2, - N(R12)C(O)R12, -C(0)0R12, -0C(0)R12, -N(R12)C(O)OR12, -OC(O)N(R12)2, - N(R12)C(O)N(R12)2, -S(O)R12, -S(O)2R12, -N(R12)S(O)2R12, -S(O)2N(R12)2, -N02, and - CN; andWSGR Docket No. 61402-727.601Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR12, -SR12, -N(R12)2, -C(O)R12, -C(O)N(R12)2, -N(R12)C(O)R12, -C(O)OR12, -OC(O)R12, -N(R12)C(O)OR12, -OC(O)N(R12)2, -N(R12)C(O)N(R12)2, - S(O)R12, -S(O)2R12, -N(R12)S(O)2R12, -S(O)2N(R12)2, -NO2, and -CN;R3is selected from (i), (ii), and (iii):i. halogen, -OR15, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN;ii. Ci-6 alkyl optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, - N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, - N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl; andiii. C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, - N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, - N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andCi-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, - C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, - OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, - S(O)2N(R14)2, -NO2, and -CN; andC3-6 carbocycle and 3- to 6-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2,WSGR Docket No. 61402-727.601-S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN;each R13and R15is independently selected from:Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR16, -SR16, -N(R16)2, -C(O)R16, -C(O)N(R16)2, -N(R16)C(O)R16, -C(O)OR16, -OC(O)R16, -N(R16)C(O)OR16, -OC(O)N(R16)2, -N(R16)C(O)N(R16)2, - S(O)R16, -S(O)2R16, -N(R16)S(O)2R16, -S(O)2N(R16)2, -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR16, - SR16, -N(R16)2, -C(O)R16, -C(O)N(R16)2, -N(R16)C(O)R16, -C(O)OR16, -OC(O)R16, - N(R16)C(O)OR16, -OC(O)N(R16)2, -N(R16)C(O)N(R16)2, -S(O)R16, -S(O)2R16, - N(R16)S(O)2R16, -S(O)2N(R16)2, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl; andR10, R11, R12, R14, and R16are each independently selected at each occurrence from:hydrogen;Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, -NH2, -NO2, =0, -CN, C3-10 carbocycle, and 3- to 10-membered heterocycle, the C3-10 carbocycle and 3- to 10- membered heterocycle are each optionally substituted with one or more substituents independently selected from: halogen, -OH, C1-6 alkyl, C1-6 haloalkyl, -O-Ci-6 alkyl, -O- C1-6 haloalkyl, -NH2, -N02, =0, and -CN; andC3-10 carbocycle and 3- to 10-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OH, Ci- 6 alkyl, C1-6 haloalkyl, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, -NH2, -N02, =0, and -CN.

[0004] In one aspect, the present disclosure provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of Formula (I), (I- A), (I-C), (I-D), (II), (ILA), (ILB), (III), (III- A), (IILB), (III-C), (IILD), (IV- A), (IV-B), or (IV-C), or a pharmaceutically acceptable salt thereof.

[0005] In one aspect, the present disclosure provides a method of modulating activity of wildtype AKT1 comprising, administering to a subject in need thereof a compound of Formula (I), (I-A), (LC), (LD), (II), (ILA), (ILB), (III), (IILA), (IILB), (III-C), (IILD), (IV-A), (IV-B), or (IV-C), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure comprising a pharmaceutically acceptable excipient and a compound of Formula (I), (LA), (LC), (LD), (II), (ILA), (ILB), (III), (IILA), (IILB), (IILC), (IILD), (IV-A), (IV-B), or (IV-C), or a pharmaceutically acceptable salt thereof. In one aspect, the present disclosure provides a method of modulating activity of a mutant AKT1 comprising,WSGR Docket No. 61402-727.601administering to a subject in need thereof a compound of Formula (I), (I- A), (LC), (I-D), (II), (ILA), (ILB), (III), (IILA), (IILB), (IILC), (IILD), (IV- A), (IV-B), or (IV-C), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure comprising a pharmaceutically acceptable excipient and a compound of Formula (I), (I-A), (LC), (LD), (II), (ILA), (ILB), (III), (IILA), (IILB), (IILC), (IILD), (IV-A), (IV-B), or (IV-C), or a pharmaceutically acceptable salt thereof. In some embodiments, the mutant AKT1 is AKT1 E17K.

[0006] In one aspect, the present disclosure provides a method of selectively modulating activity of wild-type AKT1 over wild-type AKT2 comprising administering to a subject in need thereof a compound of Formula (I), (LA), (LC), (LD), (II), (ILA), (ILB), (III), (IILA), (IILB), (III-C), (IILD), (IV-A), (IV-B), or (IV-C), or pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure comprising a pharmaceutically acceptable excipient and a compound of Formula (I), (LA), (LC), (LD), (II), (ILA), (ILB), (III), (IILA), (IILB), (IILC), (IILD), (IV-A), (IV-B), or (IV-C), or a pharmaceutically acceptable salt thereof.

[0007] In one aspect, the present disclosure provides a method of selectively modulating activity of a mutant AKT1 over wild-type AKT2 comprising administering to a subject in need thereof a compound of Formula (I), (LA), (LC), (LD), (II), (ILA), (ILB), (III), (IILA), (IILB), (IILC), (IILD), (IV-A), (IV-B), or (IV-C), or pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure comprising a pharmaceutically acceptable excipient and a compound of For Formula (I), (LA), (LC), (LD), (II), (ILA), (ILB), (III), (III-A), (IILB), (IILC), (IILD), (IV-A), (IV-B), or (IV-C), or a pharmaceutically acceptable salt thereof. In some embodiments, the mutant AKT1 is AKT1 E17K.

[0008] In one aspect, the present disclosure provides a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a compound of Formula (I), (I-A), (LC), (LD), (II), (ILA), (ILB), (III), (IILA), (IILB), (IILC), (IILD), (IV-A), (IV-B), or (IV-C), or pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure comprising a pharmaceutically acceptable excipient and a compound of Formula (I), (LA), (LC), (LD), (II), (ILA), (ILB), (III), (IILA), (IILB), (IILC), (IILD), (IV-A), (IV-B), or (IV-C), or a pharmaceutically acceptable salt thereof. In some embodiments, the cancer is selected from breast cancer, colorectal cancer, and meningioma. In some embodiments, the administration modulates activity of wild-type AKT1. In some embodiments, the administration modulates activity of a mutant AKT1. In some embodiments, the mutant AKT1 is AKT1 E17K.WSGR Docket No. 61402-727.601INCORPORATION BY REFERENCE

[0009] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference for the specific purposes identified herein.DETAILED DESCRIPTION OF THE INVENTION

[0010] The AKT or Protein Kinase B (PKB) family of serine / threonine protein kinases regulate a myriad of key cellular functions, including apoptosis, proliferation, differentiation and metabolism. The AKT family is comprised of 3 highly homologous members, AKT1, AKT2 and AKT3, and each member possesses a unique tissue distribution and may perform a unique set of biological functions. Aberrant expression and / or activation of all AKT isoforms has been implicated in tumor development, including breast, ovarian, pancreatic, and prostate cancers among others.

[0011] Inhibitors of AKT proteins have been developed for the treatment of cancer, including the two major classes of small-molecule AKT inhibitors being investigated in the clinic: allosteric and ATP-competitive inhibitors. First, allosteric inhibitors (such as miransertib (ARQ 092) and MK-2206) interfere with PH-domain mediated membrane recruitment (the first step in AKT activation) and inhibit AKT kinase activation and AKT phosphorylation. Second, ATP-competitive inhibitors of AKT (such as ipatasertib and capivasertib) bind to the active kinase, in which the PH-domain has shifted from the kinase domain and exposed the ATP -binding pocket site, thus inhibiting ATP binding.

[0012] Provided herein are compounds for modulating (e.g., inhibiting) AKT1 function, as well as methods and compositions for using compounds of the present disclosure in the treatment of cancer.

[0013] Definitions

[0014] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs. All patents and publications referred to herein are incorporated by reference.

[0015] As used in the specification and claims, the singular form “a,” “an,” and “the” includes plural references unless the context clearly dictates otherwise.

[0016] “Alkyl” refers to a straight or branched hydrocarbon chain monovalent radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, and preferably having from one to twelve carbon atoms (i.e., C1-12 alkyl). The alkyl is attached to the remainder of the molecule through a single bond. An alkyl chain may be optionally substituted by one or more substituents such as those substituents described herein. In certain embodiments, an alkyl comprises one to twelve carbon atoms (i.e., C1-12 alkyl). In certain embodiments, an alkylWSGR Docket No. 61402-727.601comprises one to eight carbon atoms (i.e., Ci-8 alkyl). In other embodiments, an alkyl comprises one to five carbon atoms (i.e., C1-5 alkyl). In other embodiments, an alkyl comprises one to four carbon atoms (i.e., Ci-4 alkyl). In other embodiments, an alkyl comprises one to three carbon atoms (i.e., C1-3 alkyl). In other embodiments, an alkyl comprises one to two carbon atoms (i.e., C1-2 alkyl). In other embodiments, an alkyl comprises one carbon atom (i.e., Ci alkyl). In other embodiments, an alkyl comprises five to fifteen carbon atoms (i.e., C5-15 alkyl). In other embodiments, an alkyl comprises five to eight carbon atoms (i.e., C5-8 alkyl). In other embodiments, an alkyl comprises two to five carbon atoms (i.e., C2-5 alkyl). In other embodiments, an alkyl comprises three to five carbon atoms (i.e., C3-5 alkyl). For example, the alkyl group may be attached to the rest of the molecule by a single bond, such as, methyl, ethyl, 1 -propyl ( / / -propyl), 1 -methylethyl ( / .w-propyl), 1 -butyl ( / / -butyl), 1 -methylpropyl (.scc-butyl), 2-methylpropyl ( / .w-butyl), 1,1 -dimethylethyl (Zc / 7-butyl), 1 -pentyl ( / / -pentyl), and the like.

[0017] “Alkenyl” refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one carbon-carbon double bond, and preferably having from two to twelve carbon atoms (i.e., C2-12 alkenyl). An alkenyl chain may be optionally substituted by one or more substituents such as those substituents described herein. In certain embodiments, an alkenyl comprises two to eight carbon atoms (i.e., C2-8 alkenyl). In certain embodiments, an alkenyl comprises two to six carbon atoms (i.e., C2-6 alkenyl). In other embodiments, an alkenyl comprises two to four carbon atoms (i.e., C2-4 alkenyl). The alkenyl is attached to the rest of the molecule by a single bond, for example, ethenyl (i.e., vinyl), prop-l-enyl (i.e., allyl), but-l-enyl, pent-l-enyl, penta- 1,4-dienyl, and the like.

[0018] “Alkynyl” refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one carbon— carbon triple bond, and preferably having from two to twelve carbon atoms (i.e., C2-12 alkynyl). An alkynyl chain may be optionally substituted by one or more substituents such as those substituents described herein. In certain embodiments, an alkynyl comprises two to eight carbon atoms (i.e., C2-8 alkynyl). In other embodiments, an alkynyl comprises two to six carbon atoms (i.e., C2-6 alkynyl). In other embodiments, an alkynyl comprises two to four carbon atoms (i.e., C2-4 alkynyl). The alkynyl is attached to the rest of the molecule by a single bond, for example, ethynyl, propynyl, butynyl, pentynyl, hexynyl, and the like.

[0019] “Alkylene” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing no unsaturation, and preferably having from one to twelve carbon atoms, for example, methylene, ethylene, propylene, (methyl)ethylene, butylene, and the like. The alkylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond. AnWSGR Docket No. 61402-727.601alkylene chain may be optionally substituted by one or more substituents such as those substituents described herein. In certain embodiments, an alkylene comprises one to ten carbon atoms (i.e., Ci-io alkylene). In certain embodiments, an alkylene comprises one to eight carbon atoms (i.e., Ci-8 alkylene). In other embodiments, an alkylene comprises one to five carbon atoms (i.e., C1-5 alkylene). In other embodiments, an alkylene comprises one to four carbon atoms (i.e., Ci-4 alkylene). In other embodiments, an alkylene comprises one to three carbon atoms (i.e., C1-3 alkylene). In other embodiments, an alkylene comprises one to two carbon atoms (i.e., C1-2 alkylene). In other embodiments, an alkylene comprises one carbon atom (i.e., Ci alkylene). In other embodiments, an alkylene comprises five to eight carbon atoms (i.e., C5-8 alkylene). In other embodiments, an alkylene comprises two to five carbon atoms (i.e., C2-5 alkylene). In other embodiments, an alkylene comprises three to five carbon atoms (i.e., C3-5 alkylene).

[0020] “Alkenylene” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing at least one carbon-carbon double bond, and preferably having from two to twelve carbon atoms. The alkenylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond. An alkenylene chain may be optionally substituted by one or more substituents such as those substituents described herein. In certain embodiments, an alkenylene comprises two to ten carbon atoms (i.e., C2-10 alkenylene). In certain embodiments, an alkenylene comprises two to eight carbon atoms (i.e., C2-8 alkenylene). In other embodiments, an alkenylene comprises two to five carbon atoms (i.e., C2-5 alkenylene). In other embodiments, an alkenylene comprises two to four carbon atoms (i.e., C2-4 alkenylene). In other embodiments, an alkenylene comprises two to three carbon atoms (i.e., C2-3 alkenylene). In other embodiments, an alkenylene comprises two carbon atoms (i.e., C2 alkenylene). In other embodiments, an alkenylene comprises five to eight carbon atoms (i.e., C5-8 alkenylene). In other embodiments, an alkenylene comprises three to five carbon atoms (i.e., C3-5 alkenylene).

[0021] “Alkynylene” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing at least one carbon-carbon triple bond, and preferably having from two to twelve carbon atoms. The alkynylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond. An alkynylene chain may be optionally substituted by one or more substituents such as those substituents described herein. In certain embodiments, an alkynylene comprises two to ten carbon atoms (i.e., C2-10 alkynylene). In certain embodiments, an alkynylene comprises two to eight carbon atoms (i.e., C2-8 alkynylene). In other embodiments, an alkynylene comprises two to five carbon atoms (i.e., C2-5 alkynylene). In otherWSGR Docket No. 61402-727.601embodiments, an alkynylene comprises two to four carbon atoms (i.e., C2-4 alkynylene). In other embodiments, an alkynylene comprises two to three carbon atoms (i.e., C2-3 alkynylene). In other embodiments, an alkynylene comprises two carbon atoms (i.e., C2 alkynylene). In other embodiments, an alkynylene comprises five to eight carbon atoms (i.e., C5-8 alkynylene). In other embodiments, an alkynylene comprises three to five carbon atoms (i.e., C3-5 alkynylene).

[0022] The term “Cx-y” when used in conjunction with a chemical moiety, such as alkyl, alkenyl, or alkynyl is meant to include groups that contain from x to y carbons in the chain. For example, the term “C1-6 alkyl” refers to saturated hydrocarbon groups, including straight-chain alkyl and branched-chain alkyl groups that contain from 1 to 6 carbons. The term -Cx-y alkylene- refers to an alkylene chain with from x to y carbons in the alkylene chain. For example, -C1-6 alkylene- may be selected from methylene, ethylene, propylene, butylene, pentylene, and hexylene, any one of which may be optionally substituted.

[0023] The terms “Cx-y alkenyl” and “Cx-y alkynyl” refer to unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond, respectively. The term -Cx-y alkenylene- refers to a alkenylene chain with from x to y carbons in the alkenylene chain. For example, -C2-6 alkenylene- may be selected from ethenylene, propenylene, butenylene, pentenylene, and hexenylene, any one of which may be optionally substituted. An alkenylene chain may have one double bond or more than one double bond in the alkenylene chain. The term -Cx-y alkynylene- refers to a alkynylene chain with from x to y carbons in the alkynylene chain. For example, -C2-6 alkynylene- may be selected from ethynylene, propynylene, butynylene, pentynylene, and hexynylene, any one of which may be optionally substituted. An alkynylene chain may have one triple bond or more than one triple bond in the alkynylene chain.

[0024] The term “carbocycle” as used herein refers to a saturated, unsaturated or aromatic ring in which each atom of the ring is carbon. Carbocycle includes 3- to 10-membered monocyclic rings and polycyclic rings (e.g., 6- to 12-membered bicyclic rings). Each ring of a polycyclic carbocycle may be selected from saturated, unsaturated, and aromatic rings. Polycyclic carbocycles may be fused, bridged or spiro-ring systems. Each ring of a bicyclic carbocycle may be selected from saturated, unsaturated, and aromatic rings. Bicyclic carbocycles may be fused, bridged or spiro-ring systems. In some embodiments, the carbocycle is an aryl. In some embodiments, the carbocycle is a cycloalkyl. In some embodiments, the carbocycle is a cycloalkenyl. In an exemplary embodiment, an aromatic ring, e.g., phenyl, may be fused to a saturated or unsaturated ring, e.g., cyclohexane, cyclopentane, or cyclohexene. Any combination of saturated, unsaturated and aromatic bicyclic rings, as valence permits, are included in the definition of carbocyclic. Exemplary carbocycles include cyclopentyl, cyclohexyl, cyclohexenyl,WSGR Docket No. 61402-727.601adamantyl, phenyl, indanyl, and naphthyl. Carbocycle may be optionally substituted by one or more substituents such as those substituents described herein.

[0025] The term “carbocyclene” as used herein refers to a divalent saturated, unsaturated or aromatic ring in which each atom of the ring is carbon. The carbocyclene is attached to the rest of the molecule through a single bond and to the radical group through a single bond. A carbocyclene may be optionally substituted by one or more substituents such as those substituents described herein. Carbocyclene includes divalent 3- to 10-membered monocyclic rings and divalent polycyclic rings (e.g., 6- to 12-membered bicyclic rings). Each ring of a polycyclic carbocyclene may be selected from saturated, unsaturated, and aromatic rings.Polycyclic carbocyclenes may be fused, bridged or spiro-ring systems. Polycyclic carbocyclenes may be fused, bridged or spiro-ring systems. The single bond connecting the carbocyclene to the rest of the molecule and the single bond connecting the carbocyclene to the radical group may be located on the same ring or different rings of a polycyclic carbocyclene. In some embodiments, the carbocycle is an arylene, for example, a phenylene. A “phenylene” as used herein refers to a divalent benzene group. The phenylene is attached to the rest of the molecule through a single bond and to the radical group through a single bond. A phenylene may be optionally substituted by one or more substituents such as those substituents described herein.

[0026] “Cycloalkyl” refers to a stable fully saturated monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, which includes fused, bridged, or spiro-ring systems, and preferably having from three to twelve carbon atoms (i.e., C3-12 cycloalkyl). In certain embodiments, a cycloalkyl comprises three to ten carbon atoms (i.e., C3-10 cycloalkyl). In other embodiments, a cycloalkyl comprises five to seven carbon atoms (i.e., C5-7 cycloalkyl). The cycloalkyl may be attached to the rest of the molecule by a single bond. Examples of monocyclic cycloalkyls include, e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic cycloalkyl radicals include, for example, adamantyl, norbomyl (i.e., bicyclo[2.2.1]heptanyl), norbornenyl, decalinyl,7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like. Cycloalkyl may be optionally substituted by one or more substituents such as those substituents described herein.

[0027] “Aryl” refers to a radical derived from an aromatic monocyclic or aromatic polycyclic hydrocarbon ring system by removing a hydrogen atom from a ring carbon atom. The aromatic monocyclic or aromatic multicyclic hydrocarbon ring system contains only hydrogen and carbon and from five to eighteen carbon atoms, where at least one of the rings in the ring system is aromatic, i.e., it contains a cyclic, delocalized (4n+2) p-electron system in accordance with the Huckel theory. The ring system from which aryl groups are derived include, but are not limitedWSGR Docket No. 61402-727.601to, groups such as benzene, fluorene, indane, indene, tetralin and naphthalene. Aryl may be optionally substituted by one or more substituents such as those substituents described herein.

[0028] A “Cx-y carbocycle” is meant to include groups that contain from x to y carbons in a ring. For example, the term “C3-6 carbocycle” can be a saturated, unsaturated or aromatic ring system that contains from 3 to 6 carbon atoms — any one of which may be optionally substituted as provided herein.

[0029] The term “heterocycle” as used herein refers to a saturated, unsaturated, non-aromatic or aromatic ring comprising one or more heteroatoms. Exemplary heteroatoms include N, O, Si, P, B, and S atoms. Heterocycles include 3- to 10-membered monocyclic rings and polycyclic rings (e.g., 6- to 12-membered bicyclic rings). Polycyclic heterocycles may be fused, bridged or spiro-ring systems. Each ring of a polycyclic heterocycle may be selected from saturated, unsaturated, and aromatic rings. In some embodiments, the heterocycle comprises at least one heteroatom selected from oxygen, nitrogen, sulfur, or any combination thereof. In some embodiments, the heterocycle comprises at least one heteroatom selected from oxygen, nitrogen, or any combination thereof. In some embodiments, the heterocycle comprises at least one heteroatom selected from oxygen, sulfur, or any combination thereof. In some embodiments, the heterocycle comprises at least one heteroatom selected from nitrogen, sulfur, or any combination thereof. The heterocycle may be attached to the rest of the molecule through any atom of the heterocycle, valence permitting, such as a carbon or nitrogen atom of the heterocycle. In some embodiments, the heterocycle is a heteroaryl. In some embodiments, the heterocycle is a heterocycloalkyl. Exemplary heterocycles include pyrrolidinyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, piperidinyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, thiophenyl, oxazolyl, thiazolyl, morpholinyl, indazolyl, indolyl, and quinolinyl. Heterocycle may be optionally substituted by one or more substituents such as those substituents described herein. Bicyclic heterocycles may be fused, bridged or spiro-ring systems. In an exemplary embodiment, a heterocycle, e.g., pyridyl, may be fused to a saturated or unsaturated ring, e.g., cyclohexane, cyclopentane, or cyclohexene. Heterocycle may be optionally substituted by one or more substituents such as those substituents described herein.

[0030] The term “heterocyclene” as used herein refers to a divalent saturated, unsaturated, non-aromatic or aromatic ring comprising one or more heteroatoms. Exemplary heteroatoms include N, O, Si, P, B, and S atoms. The heterocyclene is attached to the rest of the molecule through a single bond and to the radical group through a single bond. The single bond attaching the heterocyclene group to the rest of the molecule and the single bond attaching the heterocyclene group to the radical group may be each independently connected through any atom of the heterocyclene as valency permits, including a carbon atom in the heterocyclene ringWSGR Docket No. 61402-727.601or a heteroatom in the heterocyclene ring. A heterocyclene may be optionally substituted by one or more substituents such as those substituents described herein. Heterocyclenes include 3- to 10-membered monocyclic rings and polycyclic rings (e.g., 6- to 12-membered bicyclic rings). Each ring of a polycyclic heterocyclene may be selected from saturated, unsaturated, and aromatic rings. Polycyclic heterocyclenes may be fused, bridged or spiro-ring systems. The single bond connecting the heterocyclene to the rest of the molecule and the single bond connecting the heterocyclene to the radical group may be located on the same ring or different rings of a polycyclic heterocyclene and may be attached to the rest of the molecule or the radical group through any atom of the heterocyclene, valence permitting, such as a carbon or nitrogen atom of the heterocycle. In some embodiments, the heterocyclene comprises at least one heteroatom selected from oxygen, nitrogen, sulfur, or any combination thereof. In some embodiments, the heterocyclene comprises at least one heteroatom selected from oxygen, nitrogen, or any combination thereof. In some embodiments, the heterocyclene comprises at least one heteroatom selected from oxygen, sulfur, or any combination thereof. In some embodiments, the heterocyclene comprises at least one heteroatom selected from nitrogen, sulfur, or any combination thereof. In some embodiments, the heterocyclene is a heteroarylene. In some embodiments, the heterocyclene is a heterocycloalkylene.

[0031] “Heterocycloalkyl” refers to a stable 3 to 12 membered non-aromatic ring radical that comprises two to twelve carbon atoms and at least one heteroatom wherein each heteroatom may be selected from N, O, Si, P, B, and S atoms. In some embodiments, the heterocycloalkyl comprises at least one heteroatom selected from oxygen, nitrogen, sulfur, or any combination thereof. In some embodiments, the heterocycloalkyl comprises at least one heteroatom selected from oxygen, nitrogen, or any combination thereof. In some embodiments, the heterocycloalkyl comprises at least one heteroatom selected from oxygen, sulfur, or any combination thereof. In some embodiments, the heterocycloalkyl comprises at least one heteroatom selected from nitrogen, sulfur, or any combination thereof. The heterocycloalkyl may be selected from monocyclic or bicyclic, and fused, bridged, or spiro-ring systems. The heteroatoms in the heterocycloalkyl radical are optionally oxidized. One or more nitrogen atoms, if present, are optionally quatemized. The heterocycloalkyl radical is partially or fully saturated. The heterocycloalkyl is attached to the rest of the molecule through any atom of the heterocycloalkyl, valence permitting, such as any carbon or nitrogen atoms of the heterocycloalkyl. Examples of heterocycloalkyl radicals include, but are not limited to, dioxolanyl, thienyl[l,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl,2-oxopiperazinyl, 2oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl,WSGR Docket No. 61402-727.6014-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxothiomorpholinyl, and 1,1-dioxothiomorpholinyl. Heterocycloalkyl may be optionally substituted by one or more substituents such as those substituents described herein.

[0032] The term “heteroaryl” refers to a radical derived from a 5- to 12-membered aromatic ring radical whose ring structure comprise at least one heteroatom, preferably between one to four heteroatoms. In some embodiments, the heteroaryl comprises at least one heteroatom selected from oxygen, nitrogen, sulfur, or any combination thereof. In some embodiments, the heteroaryl comprises at least one heteroatom selected from oxygen, nitrogen, or any combination thereof. In some embodiments, the heteroaryl comprises at least one heteroatom selected from oxygen, sulfur, or any combination thereof. In some embodiments, the heteroaryl comprises at least one heteroatom selected from nitrogen, sulfur, or any combination thereof. As used herein, the heteroaryl ring may be selected from monocyclic or bicyclic and fused or bridged ring systems wherein at least one of the rings in the ring system is aromatic, i.e., it contains a cyclic, delocalized (4n+2) p-electron system in accordance with the Hiickel theory. The heteroatom(s) in the heteroaryl radical may be optionally oxidized. One or more nitrogen atoms, if present, are optionally quaternized. The heteroaryl may be attached to the rest of the molecule through any atom of the heteroaryl, valence permitting, such as a carbon or nitrogen atom of the heteroaryl. Heteroaryl includes aromatic single ring structures, preferably 5- to 6-membered rings, whose ring structures include at least one heteroatom, preferably one to four heteroatoms, more preferably one or two heteroatoms. Heteroaryl groups include, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrazine, pyridazine, and pyrimidine, and the like. Heteroaryl may be optionally substituted by one or more substituents such as those substituents described herein. Heteroaryl also includes polycyclic ring systems having two or more rings in which two or more atoms are common to two adjoining rings wherein at least one of the rings is heteroaromatic, e.g., the other rings can be aromatic or non-aromatic carbocyclic, or heterocyclic. Heteroaryl may be optionally substituted by one or more substituents such as those substituents described herein.

[0033] An “X-membered heterocycle” refers to the number of endocyclic atoms, i.e., X, in the ring. For example, a 5-membered heteroaryl ring or 5-membered aromatic heterocycle has 5 endocyclic atoms, e.g., triazole, oxazole, thiophene, etc.

[0034] “Alkoxy” refers to a radical bonded through an oxygen atom of the formula: -O-alkyl, where alkyl is an alkyl chain as defined above.

[0035] “Halo” or “halogen” refers to halogen substituents such as bromo, chloro, fluoro, and iodo substituents.WSGR Docket No. 61402-727.601

[0036] As used herein, the term “haloalkyl” or “haloalkane” refers to an alkyl radical, as defined above, that is substituted by one or more halogen radicals, for example, trifluoromethyl, di chloromethyl, bromomethyl, 2,2,2-trifluoroethyl, l-fluoromethyl-2-fluoroethyl, and the like. In some embodiments, the alkyl part of the fluoroalkyl radical is optionally further substituted. Examples of halogen substituted alkanes (“haloalkanes”) include halomethane (e.g., chloromethane, bromomethane, fluoromethane, iodomethane), di -and trihalomethane (e.g., tri chloromethane, tribromomethane, trifluoromethane, triiodomethane), 1-haloethane, 2-haloethane, 1,2-dihaloethane, 1-halopropane, 2-halopropane, 3-halopropane, 1,2-dihalopropane, 1,3-dihalopropane, 2,3-dihalopropane, 1,2,3-trihalopropane, and any other suitable combinations of alkanes (or substituted alkanes) and halogens (e.g., Cl, Br, F, and I). When an alkyl group is substituted with more than one halogen radical, each halogen may be independently selected for example, l-chloro,2-fluoroethane.

[0037] The term “substituted” refers to moieties having substituents replacing a hydrogen on one or more carbons or substitutable heteroatoms, e.g., an NH or NH2 of a compound. Unless specified otherwise (e.g., by using the terms “substituted” or “optionally substituted,” or by the inclusion of an “-R” group), chemical groups described herein are unsubstituted. It will be understood that “substitution” or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, i.e., a compound which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc. In certain embodiments, substituted refers to moieties having substituents replacing two hydrogen atoms on the same carbon atom, such as substituting the two hydrogen atoms on a single carbon with an oxo, imino, or thioxo group. As used herein, the term “substituted” is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, and aromatic and non-aromatic substituents of organic compounds. The permissible substituents can be one or more and the same or different for appropriate organic compounds.

[0038] In some embodiments, substituents may include any substituents described herein, for example: halogen, hydroxy, oxo (=0), thioxo (=S), cyano (-CN), nitro (-NO2), imino (=N-H), oximo (=N-0H), hydrazino (=N-NH2), -Rb-ORa, -Rb-OC(O)Ra, -Rb-OC(O)ORa,-Rb-OC(O)N(Ra)2, -Rb-N(Ra)2, -Rb-C(O)Ra, -Rb-C(O)ORa, -Rb-C(O)N(Ra)2,-Rb-O-Rc-C(O)N(Ra)2, -Rb-N(Ra)C(O)ORa, -Rb-N(Ra)C(O)Ra, -Rb-N(Ra)S(O)tRa(where t is 1 or 2), -Rb-S(O)tRa(where t is 0, 1, or 2), -Rb-S(O)tORa(where t is 1 or 2), -Rb-S(O)tN(Ra)2 (where t is 1 or 2), and -P(O)(Ra)2; and alkyl, alkenyl, alkynyl, aryl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, andWSGR Docket No. 61402-727.601heteroarylalkyl any one of which may be optionally substituted by alkyl, alkenyl, alkynyl, halogen, haloalkyl, haloalkenyl, haloalkynyl, oxo (=0), thioxo (=S), cyano (-CN), nitro (-NO2), imino (=N-H), oximo(=N-OH), hydrazine(=N-NH2), -Rb-0Ra, -Rb-0C(0)Ra, -Rb-0C(0)0Ra, -Rb-0C(0)N(Ra)2, -Rb-N(Ra)2, -Rb-C(0)Ra, -Rb-C(0)0Ra, -Rb-C(0)N(Ra)2,-Rb-0-Rc-C(0)N(Ra)2, -Rb-N(Ra)C(0)0Ra, -Rb-N(Ra)C(0)Ra, -Rb-N(Ra)S(O)tRa(where t is 1 or 2), -Rb-S(O)tRa(where t is 0, 1, or 2), -Rb-S(O)tORa(where t is 1 or 2), -Rb-S(O)tN(Ra)2 (where t is 1 or 2), and -P(O)(Ra)2; wherein each Rais independently selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, or heteroarylalkyl, wherein each Ra, valence permitting, may be optionally substituted with alkyl, alkenyl, alkynyl, halogen, haloalkyl, haloalkenyl, haloalkynyl, oxo (=0), thioxo (=S), cyano (-CN), nitro (-NO2), imino (=N-H), oximo (=N-0H), hydrazine (=N-NH2), -Rb-0Ra,-Rb-0C(0)-Ra, -Rb-0C(0)-0Ra, -Rb-0C(0)-N(Ra)2, -Rb-N(Ra)2, -Rb-C(0)Ra, -Rb-C(0)0Ra, -Rb-C(0)N(Ra)2, -Rb-0-Rc-C(0)N(Ra)2, -Rb-N(Ra)C(0)0Ra, -Rb-N(Ra)C(0)Ra, -Rb-N(Ra)S(O)tRa(where t is 1 or 2), -Rb-S(O)tRa(where t is 0, 1, or 2), -Rb-S(O)tORa(where t is 1 or2), -Rb-S(O)tN(Ra)2 (where t is 1 or 2), and -P(O)(Ra)2; and wherein each Rbis independently selected from a direct bond or a straight or branched alkylene, alkenylene, or alkynylene chain, and each Rcis a straight or branched alkylene, alkenylene or alkynylene chain. It will be understood by those skilled in the art that substituents can themselves be substituted, if appropriate.

[0039] The term “salt” or “pharmaceutically acceptable salt” refers to salts derived from a variety of organic and inorganic counter ions well known in the art. Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids. Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.

[0040] The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.

[0041] The phrase “pharmaceutically acceptable excipient” or “pharmaceutically acceptable carrier” as used herein means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.

[0042] The terms “subject,” “individual,” and “patient” may be used interchangeably and refer to humans as well as non-human mammals (e.g., non-human primates, canines, equines, felines,WSGR Docket No. 61402-727.601porcines, bovines, ungulates, lagomorphs, and the like). In various embodiments, the subject can be a human (e.g., adult male, adult female, adolescent male, adolescent female, male child, female child) under the care of a physician or other health worker in a hospital, as an outpatient, or other clinical context. In certain embodiments, the subject may not be under the care or prescription of a physician or other health worker.

[0043] As used herein, the phrase “a subject in need thereof’ refers to a subject, as described infra, that suffers from, or is at risk for, a pathology to be prophylactically or therapeutically treated with a compound or salt described herein.

[0044] The terms “administer,” “administered,” “administers,” and “administering” are defined as providing a composition to a subject via a route known in the art, including but not limited to intravenous, intraarterial, oral, parenteral, buccal, topical, transdermal, rectal, intramuscular, subcutaneous, intraosseous, transmucosal, or intraperitoneal routes of administration. In certain embodiments, oral routes of administering a composition can be used. The terms “administer,” “administered,” “administers,” and “administering” a compound should be understood to mean providing a compound or salt of the invention or a prodrug of a compound or salt of the invention to the individual in need.

[0045] As used herein, “treatment” or “treating” refers to an approach for obtaining beneficial or desired results with respect to a disease, disorder, or medical condition including, but not limited to, a therapeutic benefit and / or a prophylactic benefit. In certain embodiments, treatment or treating involves administering a compound or composition disclosed herein to a subject. A therapeutic benefit may include the eradication or amelioration of the underlying disorder being treated. Also, a therapeutic benefit may be achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder, such as observing an improvement in the subject, notwithstanding that the subject may still be afflicted with the underlying disorder. In certain embodiments, for prophylactic benefit, the compositions are administered to a subject at risk of developing a particular disease, or to a subject reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease may not have been made. Treating can include, for example, reducing, delaying or alleviating the severity of one or more symptoms of the disease or condition, or it can include reducing the frequency with which symptoms of a disease, defect, disorder, or adverse condition, and the like, are experienced by a patient. Treating can be used herein to refer to a method that results in some level of treatment or amelioration of the disease or condition and can contemplate a range of results directed to that end, including but not restricted to prevention of the condition entirely.

[0046] In certain embodiments, the term “prevent” or “preventing” as related to a disease or disorder may refer to a compound that, in a statistical sample, reduces the occurrence of theWSGR Docket No. 61402-727.601disorder or condition in the treated sample relative to an untreated control sample, or delays the onset or reduces the severity of one or more symptoms of the disorder or condition relative to the untreated control sample.

[0047] A “therapeutic effect,” as that term is used herein, encompasses a therapeutic benefit and / or a prophylactic benefit as described above. A prophylactic effect includes delaying or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, halting, or reversing the progression of a disease or condition, or any combination thereof.

[0048] Compounds

[0049] In some aspects, the present disclosure provides compounds represented by the structure of Formula (I):or a pharmaceutically acceptable salt thereof, wherein:R2is selected from (a) and (b):a) halogen, -OR13, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN; and b) C3-12 carbocycle and 3- to 12-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, - N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, - N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, - C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, - OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, - S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected fromWSGR Docket No. 61402-727.601halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, -CN, CI-6 alkyl, and Ci-6 haloalkyl;Ring B is selected from C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -N(R11)C(O)R11, - C(O)ORn, -OC(O)Rn, -N(R11)C(O)OR11, -OC(O)N(Rn)2, -N(R11)C(O)N(R11)2, -S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, -NO2, and -CN; and Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -N(R11)C(O)R11, -C(O)ORn, -OC(O)Rn, -N R^C^OR11, -OC(O)N(Rn)2, -N(R11)C(O)N(R11)2, - S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(R11)2, =0, =S, =N(Rn), -NO2, and -CN; R1is selected from:hydrogen, halogen, -OR12, -SR12, -N(R12)2, -C(0)R12, -C(O)N(R12)2, - N(R12)C(O)R12, -C(0)0R12, -0C(0)R12, -N(R12)C(O)OR12, -OC(O)N(R12)2, - N(R12)C(O)N(R12)2, -S(O)R12, -S(O)2R12, -N(R12)S(O)2R12, -S(O)2N(R12)2, -N02, and - CN; andCi-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR12, -SR12, -N(R12)2, -C(O)R12, -C(O)N(R12)2, -N(R12)C(O)R12, -C(O)OR12, -OC(O)R12, -N(R12)C(O)OR12, -OC(O)N(R12)2, -N(R12)C(O)N(R12)2, - S(O)R12, -S(O)2R12, -N(R12)S(O)2R12, -S(O)2N(R12)2, -NO2, and -CN;R3is selected from (i), (ii), and (iii):i. halogen, -OR15, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN;ii. Ci-6 alkyl optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, - N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, - N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -WSGR Docket No. 61402-727.601C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -N02, -CN, CI-6 alkyl, and Ci-6 haloalkyl; andiii. C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, - N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, - N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andCi-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, - C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, - OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, - S(O)2N(R14)2, -NO2, and -CN; andC3-6 carbocycle and 3- to 6-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN;each R13and R15is independently selected from:C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR16, -SR16, -N(R16)2, -C(O)R16, -C(O)N(R16)2, -N(R16)C(O)R16, -C(O)OR16, -OC(O)R16, -N(R16)C(O)OR16, -OC(O)N(R16)2, -N(R16)C(O)N(R16)2, - S(O)R16, -S(O)2R16, -N(R16)S(O)2R16, -S(O)2N(R16)2, -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR16, - SR16, -N(R16)2, -C(O)R16, -C(O)N(R16)2, -N(R16)C(O)R16, -C(O)OR16, -OC(O)R16, - N(R16)C(O)OR16, -OC(O)N(R16)2, -N(R16)C(O)N(R16)2, -S(O)R16, -S(O)2R16, - N(R16)S(O)2R16, -S(O)2N(R16)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl; andR10, R11, R12, R14, and R16are each independently selected at each occurrence from:hydrogen;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -O-C1-6 alkyl, -O-C1-6 haloalkyl, -NH2, -NO2, =0, -CN, C3-10 carbocycle, and 3- to 10-membered heterocycle, the C3-10 carbocycle and 3- to 10- membered heterocycle are each optionally substituted with one or more substituentsWSGR Docket No. 61402-727.601independently selected from: halogen, -OH, Ci-6 alkyl, Ci-6 haloalkyl, -O-Ci-6 alkyl, -O- Ci-6 haloalkyl, -NH2, -NO2, =0, and -CN; andC3-10 carbocycle and 3- to 10-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OH, Ci- 6 alkyl, C1-6 haloalkyl, -O-C1-6 alkyl, -O-C1-6 haloalkyl, -NH2, -NO2, =0, and -CN.

[0050] In some embodiments, for the compound or salt of Formula (I), R2is selected from (a) and (b):a) -OR13; andb) C3-12 carbocycle and 3- to 12-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, - N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, - N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, - C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, - OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, - S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl.

[0051] In some embodiments, for the compound or salt of Formula (I), R3is selected from C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andWSGR Docket No. 61402-727.601C3-6 carbocycle and 3- to 6-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, - SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, - N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, - N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN.

[0052] In some embodiments, for the compound or salt of Formula (I), R3is selected from 3- to 12-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andC3-6 carbocycle and 3- to 6-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, - SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, - N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, - N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN.

[0053] In some embodiments, for the compound or salt of Formula (I), R3is selected from 3- to 12-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andC3-6 carbocycle and 3- to 6-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, - SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -NO2, and -CN.

[0054] In some embodiments, for the compound or salt of Formula (I), R3is selected from 3- to 12-membered heterocycle optionally substituted with one or more substituents independentlyWSGR Docket No. 61402-727.601selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN;Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, - OC(O)R14, -NO2, and -CN; andC3-6 carbocycle and 3- to 6-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, - SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -NO2, and -CN.

[0055] In some embodiments, for the compound or salt of Formula (I), R3is selected from 3- to 12-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, - OC(O)R14, -NO2, and -CN;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, - OC(O)R14, -NO2, and -CN; andC3-6 carbocycle and 3- to 6-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, - SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -NO2, and -CN.

[0056] In some embodiments, for the compound or salt of Formula (I), R3is selected from 3- to 9-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, - OC(O)R14, -NO2, and -CN;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, - OC(O)R14, -NO2, and -CN; andC3-6 carbocycle and 3- to 6-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, - SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -NO2, and -CN.

[0057] In some embodiments, for the compound or salt of Formula (I), R3is selected from 3- to 6-membered heterocycle optionally substituted with one or more substituents independently selected from:WSGR Docket No. 61402-727.601halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, - OC(O)R14, -NO2, and -CN;Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, - OC(O)R14, -NO2, and -CN; andC3-6 carbocycle and 3- to 6-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, - SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -NO2, and -CN.

[0058] In some embodiments, for the compound or salt of Formula (I), R3is selected from C5-12carbocycle optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andC3-6 carbocycle and 3- to 6-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, - SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, - N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, - N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN.

[0059] In some embodiments, for the compound or salt of Formula (I), R3is selected from C3-9 carbocycle optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andC3-6 carbocycle and 3- to 6-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, - SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, - N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -WSGR Docket No. 61402-727.601N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN.

[0060] In some embodiments, for the compound or salt of Formula (I), R3is selected from C3-6 carbocycle optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andC3-6 carbocycle and 3- to 6-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, - SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, - N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, - N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN.

[0061] In some embodiments, for the compound or salt of Formula (I), R3is selected from C3-12 carbocycle optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andC3-6 carbocycle and 3- to 6-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, - SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -NO2, and -CN.

[0062] In some embodiments, for the compound or salt of Formula (I), R3is selected from C3-12 carbocycle optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, - OC(O)R14, -NO2, and -CN; andWSGR Docket No. 61402-727.601C3-6 carbocycle and 3- to 6-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, - SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -NO2, and -CN.

[0063] In some embodiments, for the compound or salt of Formula (I), R3is selected from C3-12 carbocycle optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, - OC(O)R14, -NO2, and -CN;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, - OC(O)R14, -NO2, and -CN; andC3-6 carbocycle and 3- to 6-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, - SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -NO2, and -CN.

[0064] In some embodiments, for the compound or salt of Formula (I), R3is selected from C3-9 carbocycle optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, - OC(O)R14, -NO2, and -CN;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, - OC(O)R14, -NO2, and -CN; andC3-6 carbocycle and 3- to 6-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, - SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -NO2, and -CN.

[0065] In some embodiments, for the compound or salt of Formula (I), R3is selected from C3-6 carbocycle optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, - OC(O)R14, -NO2, and -CN;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, - OC(O)R14, -NO2, and -CN; andC3-6 carbocycle and 3- to 6-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, - SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -NO2, and -CN.

[0066] In some embodiments, for the compound or salt of Formula (I), R3is selected from C3-12 carbocycle optionally substituted with one or more substituents independently selected fromWSGR Docket No. 61402-727.601halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -NO2, and -CN, Ci-6 alkyl, Ci-6 haloalkyl, C3-6 carbocycle, and 3- to 6-membered heterocycle. In some embodiments, R3is selected from C3-9 carbocycle optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -NO2, -CN, C1-6 alkyl, C1-6 haloalkyl, C3-6 carbocycle, and 3- to 6-membered heterocycle. In some embodiments, R3is selected from C3-9 carbocycle optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -NO2, -CN, C1-6 alkyl, C1-6 haloalkyl, C3-6 carbocycle, and 3- to 6-membered heterocycle. In some embodiments, R3is selected from C3-9 carbocycle optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -NO2, -CN, C1-3 alkyl, C1-3 haloalkyl, and C3-6 carbocycle.

[0067] In some embodiments, for the compound or salt of Formula (I), R3is selected from C3-6 carbocycle optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -NO2, -CN, C1-6 alkyl, Ci-6 haloalkyl, C3-6 carbocycle, and 3- to 6-membered heterocycle. In some embodiments, R3is selected from C3-6 carbocycle optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -NO2, -CN, C1-6 alkyl, C1-6 haloalkyl, C3-6 carbocycle, and 3- to 6-membered heterocycle. In some embodiments, R3is C4 carbocycle optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -NO2, -CN, C1-6 alkyl, C1-6 haloalkyl, C3-6 carbocycle, and 3- to 6-membered heterocycle. In some embodiments, R3is cyclobutyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -NO2, -CN, C1-6 alkyl, C1-6 haloalkyl, C3-6 carbocycle, and 3- to 6-membered heterocycle. In some embodiments, R3is cyclobutyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -N(R14)2, -CN, C1-6 alkyl, C1-6 haloalkyl, and C3-6 carbocycle. In some embodiments, R3is cyclobutyl optionally substituted with one or more substituents independently selected from -OR14, -N(R14)2, and C3-6 carbocycle. In some embodiments, R3is cyclobutyl optionally substituted with one or more substituents independently selected from -OH, -NH2, and cyclopropyl. In some embodiments, R3is" TNH2HO \7

[0068] In some embodiments, the structure of Formula (I) is represented by the structure of Formula (I- A):WSGR Docket No. 61402-727.601or a pharmaceutically acceptable salt thereof, wherein:R2is selected from (a) and (b):a) halogen, -OR13, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN; and b) C3-12 carbocycle and 3- to 12-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, - N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, - N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, - C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, - OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, - S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -N02, -CN, Ci-6 alkyl, and Ci-6 haloalkyl;Ring B is selected from C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR11, -SR11, -N(Rn)2, -C(0)Rn, -C(0)N(Rn)2, -N(R11)C(0)R11, - C(0)0Rn, -0C(0)Rn, -N(R11)C(0)0R11, -0C(0)N(Rn)2, -N(R11)C(0)N(R11)2, -S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, -NO2, and -CN; and Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(0)Rn, -C(0)N(Rn)2, -N(R11)C(0)R11, -C(0)0Rn, -0C(0)Rn, -N R^C^OR11, -0C(0)N(Rn)2, -N(R11)C(0)N(R11)2, -WSGR Docket No. 61402-727.601S(O)R11, -S(O)2R11, -N(R11)S(O)2R11, -S(O)2N(R11)2, =O, =S, =N(R11), -NO2, and -CN; R1is selected from:hydrogen, halogen, -OR12, -SR12, -N(R12)2, -C(0)R12, -C(O)N(R12)2, - N(R12)C(O)R12, -C(0)0R12, -0C(0)R12, -N(R12)C(O)OR12, -OC(O)N(R12)2, - N(R12)C(O)N(R12)2, -S(O)R12, -S(O)2R12, -N(R12)S(O)2R12, -S(O)2N(R12)2, -NO2, and - CN; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR12, -SR12, -N(R12)2, -C(O)R12, -C(O)N(R12)2, -N(R12)C(O)R12, -C(O)OR12, -OC(O)R12, -N(R12)C(O)OR12, -OC(O)N(R12)2, -N(R12)C(O)N(R12)2, - S(O)R12, -S(O)2R12, -N(R12)S(O)2R12, -S(O)2N(R12)2, -NO2, and -CN;R3is selected from (i), (ii), and (iii):i. halogen, -OR15, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, and -NO2;ii. C1-6 alkyl optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, - N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, - N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, and - NO2; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, C1-6 alkyl, and C1-6 haloalkyl; andiii. C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, - N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, - N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, and - NO2; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, - C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -WSGR Docket No. 61402-727.601OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, - S(O)2N(R14)2, and -NO2; andC3-6 carbocycle and 3- to 6-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, and -NO2;each R13and R15is independently selected from:C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR16, -SR16, -N(R16)2, -C(O)R16, -C(O)N(R16)2, -N(R16)C(O)R16, -C(O)OR16, -OC(O)R16, -N(R16)C(O)OR16, -OC(O)N(R16)2, -N(R16)C(O)N(R16)2, - S(O)R16, -S(O)2R16, -N(R16)S(O)2R16, -S(O)2N(R16)2, and -NO2; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR16, - SR16, -N(R16)2, -C(O)R16, -C(O)N(R16)2, -N(R16)C(O)R16, -C(O)OR16, -OC(O)R16, - N(R16)C(O)OR16, -OC(O)N(R16)2, -N(R16)C(O)N(R16)2, -S(O)R16, -S(O)2R16, - N(R16)S(O)2R16, -S(O)2N(R16)2, -NO2, C1-6 alkyl, and C1-6 haloalkyl;R10, R11, and R12are each independently selected at each occurrence from:hydrogen;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -O-C1-6 alkyl, -O-C1-6 haloalkyl, -NH2, -NO2, =0, -CN, C3-10 carbocycle, and 3- to 10-membered heterocycle, the C3-10 carbocycle and 3- to 10- membered heterocycle are each optionally substituted with one or more substituents independently selected from: halogen, -OH, C1-6 alkyl, C1-6 haloalkyl, -O-C1-6 alkyl, -O- C1-6 haloalkyl, -NH2, -NO2, =0, and -CN; andC3-10 carbocycle and 3- to 10-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OH, Ci- 6 alkyl, C1-6 haloalkyl, -O-C1-6 alkyl, -O-C1-6 haloalkyl, -NH2, -NO2, =0, and -CN; and R14and R16are each independently selected at each occurrence from:hydrogen;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -O-C1-6 alkyl, -O-C1-6 haloalkyl, -NH2, -NO2, C3-10 carbocycle, and 3- to 10-membered heterocycle, the C3-10 carbocycle and 3- to 10-membered heterocycle are each optionally substituted with one or more substituents independently selected from: halogen, -OH, C1-6 alkyl, C1-6 haloalkyl, -O-C1-6 alkyl, -O-C1-6 haloalkyl, -WSGR Docket No. 61402-727.601NH2, and -NO2; andC3-10 carbocycle and 3- to 10-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OH, Ci- 6 alkyl, C1-6 haloalkyl, -O-C1-6 alkyl, -O-C1-6 haloalkyl, -NH2, and -NO2.

[0069] In some embodiments, the structure of Formula (I) or (I-A) is represented by the structure of Formula (I-B):or a pharmaceutically acceptable salt thereof, wherein:R2is selected from (a) and (b):a) halogen, -OR13, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN; and b) C3-12 carbocycle and 3- to 12-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, - N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, - N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, - C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, - OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, - S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl;Ring B is selected from C3-12 carbocycle and 3- to 12-membered heterocycle, each of which isWSGR Docket No. 61402-727.601optionally substituted with one or more substituents independently selected from:halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(0)N(Rn)2, -N(R11)C(O)R11, - C(O)ORn, -OC(O)Rn, -N(R11)C(O)OR11, -0C(0)N(Rn)2, -N(R11)C(O)N(R11)2, -S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, -NO2, and -CN; and C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(0)N(Rn)2, -N(R11)C(O)R11, -C(O)ORn, -OC(O)Rn, -N(R11)C(O)OR11, -OC(O)N(Rn)2, -N(R11)C(O)N(R11)2, -S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, =0, =S, =N(Rn), -NO2, and -CN; R1is selected from:hydrogen, halogen, -OR12, -SR12, -N(R12)2, -C(O)R12, -C(O)N(R12)2, - N(R12)C(O)R12, -C(O)OR12, -OC(O)R12, -N(R12)C(O)OR12, -OC(O)N(R12)2, - N(R12)C(O)N(R12)2, -S(O)R12, -S(O)2R12, -N(R12)S(O)2R12, -S(O)2N(R12)2, -NO2, and - CN; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR12, -SR12, -N(R12)2, -C(O)R12, -C(O)N(R12)2, -N(R12)C(O)R12, -C(O)OR12, -OC(O)R12, -N(R12)C(O)OR12, -OC(O)N(R12)2, -N(R12)C(O)N(R12)2, - S(O)R12, -S(O)2R12, -N(R12)S(O)2R12, -S(O)2N(R12)2, -NO2, and -CN;R3is selected from C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, and -NO2;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, and -NO2; andC3-6 carbocycle and 3- to 6-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, - SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, - N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, - N(R14)S(O)2R14, -S(O)2N(R14)2, and -NO2;R13is independently selected from:C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR16, -SR16, -N(R16)2, -C(O)R16, -C(O)N(R16)2, -N(R16)C(O)R16, -C(O)OR16, -OC(O)R16, -N(R16)C(O)OR16, -OC(O)N(R16)2, -N(R16)C(O)N(R16)2, -WSGR Docket No. 61402-727.601S(O)R16, -S(O)2R16, -N(R16)S(O)2R16, -S(O)2N(R16)2, and -N02; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR16, - SR16, -N(R16)2, -C(O)R16, -C(O)N(R16)2, -N(R16)C(O)R16, -C(O)OR16, -OC(O)R16, - N(R16)C(O)OR16, -OC(O)N(R16)2, -N(R16)C(O)N(R16)2, -S(O)R16, -S(O)2R16, - N(R16)S(O)2R16, -S(O)2N(R16)2, -NO2, CI-6 alkyl, and Ci-6 haloalkyl;R10, R11, and R12are each independently selected at each occurrence from:hydrogen;Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, -NH2, -NO2, =0, -CN, C3-10 carbocycle, and 3- to 10-membered heterocycle, the C3-10 carbocycle and 3- to 10- membered heterocycle are each optionally substituted with one or more substituents independently selected from: halogen, -OH, C1-6 alkyl, C1-6 haloalkyl, -O-Ci-6 alkyl, -O- C1-6 haloalkyl, -NH2, -N02, =0, and -CN; andC3-10 carbocycle and 3- to 10-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OH, Ci- 6 alkyl, C1-6 haloalkyl, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, -NH2, -N02, =0, and -CN; and R14and R16are each independently selected at each occurrence from:hydrogen;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, -NH2, -N02, C3-10 carbocycle, and 3- to 10-membered heterocycle, the C3-10 carbocycle and 3- to 10-membered heterocycle are each optionally substituted with one or more substituents independently selected from: halogen, -OH, C1-6 alkyl, C1-6 haloalkyl, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, - NH2, and -N02; andC3-10 carbocycle and 3- to 10-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OH, Ci- 6 alkyl, C1-6 haloalkyl, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, -NH2, and -N02.

[0070] In some embodiments, the structure of Formula (I), (I-A), or (I-B) is represented by the structure of Formula (I-C):WSGR Docket No. 61402-727.601or a pharmaceutically acceptable salt thereof, wherein:R2is selected from (a) and (b):a) halogen, -OR13, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN; and b) C3-12 carbocycle and 3- to 12-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, - N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, - N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, - C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, - OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, - S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -N02, -CN, Ci-6 alkyl, and Ci-6 haloalkyl;Ring B is selected from C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR11, -SR11, -N(Rn)2, -C(0)Rn, -C(0)N(Rn)2, -N(R11)C(0)R11, - C(0)0Rn, -0C(0)Rn, -N(R11)C(0)0R11, -0C(0)N(Rn)2, -N(R11)C(0)N(R11)2, - S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(R11)2, -NO2, and -CN; andCi-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(0)Rn, -C(0)N(Rn)2, -N(R11)C(0)R11,WSGR Docket No. 61402-727.601-C(O)ORn, -OC(O)Rn, -N R^ C OR11, -OC(O)N(Rn)2, -N(R11)C(O)N(R11)2, - S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, =0, =S, =N(Rn), -NO2, and -CN; R1is selected from:hydrogen, halogen, -OR12, -SR12, -N(R12)2, -C(O)R12, -C(O)N(R12)2, - N(R12)C(O)R12, -C(O)OR12, -OC(O)R12, -N(R12)C(O)OR12, -OC(O)N(R12)2, - N(R12)C(O)N(R12)2, -S(O)R12, -S(O)2R12, -N(R12)S(O)2R12, -S(O)2N(R12)2, -NO2, and - CN; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR12, -SR12, -N(R12)2, -C(O)R12, -C(O)N(R12)2, -N(R12)C(O)R12, -C(O)OR12, -OC(O)R12, -N(R12)C(O)OR12, -OC(O)N(R12)2, -N(R12)C(O)N(R12)2, - S(O)R12, -S(O)2R12, -N(R12)S(O)2R12, -S(O)2N(R12)2, -NO2, and -CN;R13is independently selected from:C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR16, -SR16, -N(R16)2, -C(O)R16, -C(O)N(R16)2, -N(R16)C(O)R16, -C(O)OR16, -OC(O)R16, -N(R16)C(O)OR16, -OC(O)N(R16)2, -N(R16)C(O)N(R16)2, - S(O)R16, -S(O)2R16, -N(R16)S(O)2R16, -S(O)2N(R16)2, and -NO2; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR16, - SR16, -N(R16)2, -C(O)R16, -C(O)N(R16)2, -N(R16)C(O)R16, -C(O)OR16, -OC(O)R16, - N(R16)C(O)OR16, -OC(O)N(R16)2, -N(R16)C(O)N(R16)2, -S(O)R16, -S(O)2R16, - N(R16)S(O)2R16, -S(O)2N(R16)2, -NO2, C1-6 alkyl, and C1-6 haloalkyl;R10, R11, and R12are each independently selected at each occurrence from:hydrogen;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -O-C1-6 alkyl, -O-C1-6 haloalkyl, -NH2, -NO2, =0, -CN, C3-10 carbocycle, and 3- to 10-membered heterocycle, the C3-10 carbocycle and 3- to 10- membered heterocycle are each optionally substituted with one or more substituents independently selected from: halogen, -OH, C1-6 alkyl, C1-6 haloalkyl, -O-C1-6 alkyl, -O- C1-6 haloalkyl, -NH2, -NO2, =0, and -CN; andC3-10 carbocycle and 3- to 10-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OH, Ci- 6 alkyl, C1-6 haloalkyl, -O-C1-6 alkyl, -O-C1-6 haloalkyl, -NH2, -NO2, =0, and -CN; and R14and R16are each independently selected at each occurrence from:hydrogen;C1-6 alkyl optionally substituted with one or more substituents independentlyWSGR Docket No. 61402-727.601selected from halogen, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, -NH2, -NO2, C3-10 carbocycle, and 3- to 10-membered heterocycle, the C3-10 carbocycle and 3- to 10-membered heterocycle are each optionally substituted with one or more substituents independently selected from: halogen, -OH, C1-6 alkyl, C1-6 haloalkyl, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, - NH2, and -NO2; andC3-10 carbocycle and 3- to 10-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OH, Ci- 6 alkyl, C1-6 haloalkyl, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, -NH2, and -NO2.

[0071] In some embodiments, the structure of Formula (I) or (I-A) is represented by the structure of Formula (I-D):R2is selected from (a) and (b):a) halogen, -OR13, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN; and b) C3-12 carbocycle and 3- to 12-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, - N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, - N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, - C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, - OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, - S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2,WSGR Docket No. 61402-727.601-S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -N02, -CN, CI-6 alkyl, and Ci-6 haloalkyl;Ring B is selected from C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -N(R11)C(O)R11, - C(O)ORn, -OC(O)Rn, -N(R11)C(O)OR11, -OC(O)N(Rn)2, -N(R11)C(O)N(R11)2, - S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(R11)2, -NO2, and -CN; andCi-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -N(R11)C(O)R11, -C(O)ORn, -OC(O)Rn, -N(R11)C(O)OR11, -OC(O)N(Rn)2, -N(R11)C(O)N(R11)2, - S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(R11)2, =0, =S, =N(Rn), -NO2, and -CN; R1is selected from:hydrogen, halogen, -OR12, -SR12, -N(R12)2, -C(0)R12, -C(O)N(R12)2, - N(R12)C(O)R12, -C(0)0R12, -0C(0)R12, -N(R12)C(O)OR12, -OC(O)N(R12)2, - N(R12)C(O)N(R12)2, -S(O)R12, -S(O)2R12, -N(R12)S(O)2R12, -S(O)2N(R12)2, -N02, and - CN; andCi-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR12, -SR12, -N(R12)2, -C(O)R12, -C(O)N(R12)2, -N(R12)C(O)R12, -C(O)OR12, -OC(O)R12, -N(R12)C(O)OR12, -OC(O)N(R12)2, -N(R12)C(O)N(R12)2, - S(O)R12, -S(O)2R12, -N(R12)S(O)2R12, -S(O)2N(R12)2, -NO2, and -CN;each R13and R15is independently selected from:Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR16, -SR16, -N(R16)2, -C(O)R16, -C(O)N(R16)2, -N(R16)C(O)R16, -C(O)OR16, -OC(O)R16, -N(R16)C(O)OR16, -OC(O)N(R16)2, -N(R16)C(O)N(R16)2, - S(O)R16, -S(O)2R16, -N(R16)S(O)2R16, -S(O)2N(R16)2, and -N02; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR16, - SR16, -N(R16)2, -C(O)R16, -C(O)N(R16)2, -N(R16)C(O)R16, -C(O)OR16, -OC(O)R16, - N(R16)C(O)OR16, -OC(O)N(R16)2, -N(R16)C(O)N(R16)2, -S(O)R16, -S(O)2R16, - N(R16)S(O)2R16, -S(O)2N(R16)2, -N02, CI-6 alkyl, and Ci-6 haloalkyl;R10, R11, and R12are each independently selected at each occurrence from:hydrogen;Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, -NH2, -N02, =0, -CN, C3-10 carbocycle, and 3- to 10-membered heterocycle, the C3-10 carbocycle and 3- to 10-WSGR Docket No. 61402-727.601membered heterocycle are each optionally substituted with one or more substituents independently selected from: halogen, -OH, Ci-6 alkyl, Ci-6 haloalkyl, -O-Ci-6 alkyl, -O- Ci-6 haloalkyl, -NH2, -NO2, =0, and -CN; andC3-10 carbocycle and 3- to 10-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OH, Ci- 6 alkyl, C1-6 haloalkyl, -O-C1-6 alkyl, -O-C1-6 haloalkyl, -NH2, -NO2, =0, and -CN; and R16is independently selected at each occurrence from:hydrogen;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -O-C1-6 alkyl, -O-C1-6 haloalkyl, -NH2, -NO2, C3-10 carbocycle, and 3- to 10-membered heterocycle, the C3-10 carbocycle and 3- to 10-membered heterocycle are each optionally substituted with one or more substituents independently selected from: halogen, -OH, C1-6 alkyl, C1-6 haloalkyl, -O-C1-6 alkyl, -O-C1-6 haloalkyl, - NH2, and -NO2; andC3-10 carbocycle and 3- to 10-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OH, Ci- 6 alkyl, C1-6 haloalkyl, -O-C1-6 alkyl, -O-C1-6 haloalkyl, -NH2, and -NO2.

[0072] In some aspects, the present disclosure provides compounds represented by the structure of Formula (II):or a pharmaceutically acceptable salt thereof, wherein:R2is selected from (a) and (b):a) halogen, -OR13, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN; and b) C3-12 carbocycle and 3- to 12-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, - N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, - N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;WSGR Docket No. 61402-727.601Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, - C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, - OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, - S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl;Ring B is selected from C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR11, -SR11, -N(Rn)2, -C(0)Rn, -C(0)N(Rn)2, -N(R11)C(0)R11, - C(0)0Rn, -0C(0)Rn, -N(R11)C(0)0R11, -0C(0)N(Rn)2, -N(R11)C(0)N(R11)2, -S(O)Rn, -S(0)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, -NO2, and -CN; and C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(0)Rn, -C(0)N(Rn)2, -N(R11)C(0)R11, -C(0)0Rn, -0C(0)Rn, -N(R11)C(O)OR11, -0C(0)N(Rn)2, -N(R11)C(0)N(R11)2, - S(O)R11, -S(O)2R11, -N(R11)S(O)2R11, -S(O)2N(R11)2, =O, =S, =N(R11), -NO2, and -CN; R1is selected from:hydrogen, halogen, -OR12, -SR12, -N(R12)2, -C(0)R12, -C(O)N(R12)2, - N(R12)C(O)R12, -C(0)0R12, -0C(0)R12, -N(R12)C(O)OR12, -OC(O)N(R12)2, - N(R12)C(O)N(R12)2, -S(O)R12, -S(O)2R12, -N(R12)S(O)2R12, -S(O)2N(R12)2, -NO2, and - CN; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR12, -SR12, -N(R12)2, -C(O)R12, -C(O)N(R12)2, -N(R12)C(O)R12, -C(O)OR12, -OC(O)R12, -N(R12)C(O)OR12, -OC(O)N(R12)2, -N(R12)C(O)N(R12)2, - S(O)R12, -S(O)2R12, -N(R12)S(O)2R12, -S(O)2N(R12)2, -NO2, and -CN;R3is selected from (i), (ii), and (iii):i. halogen, -OR15, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN;ii. C1-6 alkyl optionally substituted with one or more substituents independently selected from:WSGR Docket No. 61402-727.601halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, - N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, - N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl; andiii. C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, - N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, - N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andCi-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, - C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, - OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, - S(O)2N(R14)2, -NO2, and -CN;each R13and R15is independently selected from:Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR16, -SR16, -N(R16)2, -C(O)R16, -C(O)N(R16)2, -N(R16)C(O)R16, -C(O)OR16, -OC(O)R16, -N(R16)C(O)OR16, -OC(O)N(R16)2, -N(R16)C(O)N(R16)2, - S(O)R16, -S(O)2R16, -N(R16)S(O)2R16, -S(O)2N(R16)2, -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR16, - SR16, -N(R16)2, -C(O)R16, -C(O)N(R16)2, -N(R16)C(O)R16, -C(O)OR16, -OC(O)R16, - N(R16)C(O)OR16, -OC(O)N(R16)2, -N(R16)C(O)N(R16)2, -S(O)R16, -S(O)2R16, - N(R16)S(O)2R16, -S(O)2N(R16)2, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl; andR10, R11, R12, R14, and R16are each independently selected at each occurrence from:hydrogen;Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, -NH2, -NO2, =0, -CN, C3-10WSGR Docket No. 61402-727.601carbocycle, and 3- to 10-membered heterocycle, the C3-10 carbocycle and 3- to 10- membered heterocycle are each optionally substituted with one or more substituents independently selected from: halogen, -OH, C1-6 alkyl, C1-6 haloalkyl, -O-C1-6 alkyl, -O- C1-6 haloalkyl, -NH2, -NO2, =0, and -CN; andC3-10 carbocycle and 3- to 10-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OH, Ci- 6 alkyl, C1-6 haloalkyl, -O-C1-6 alkyl, -O-C1-6 haloalkyl, -NH2, -NO2, =0, and -CN.

[0073] In some embodiments, the structure of Formula (I) or (II) is represented by the structure of Formula (II- A):or a pharmaceutically acceptable salt thereof, wherein:R2is selected from (a) and (b):a) -OR13; andb) C3-12 carbocycle and 3- to 12-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, - N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, - N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, - C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, - OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, - S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl;Ring B is selected from C3-12 carbocycle and 3- to 12-membered heterocycle, each of which isWSGR Docket No. 61402-727.601optionally substituted with one or more substituents independently selected from:halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(0)N(Rn)2, -N(R11)C(O)R11, - C(O)ORn, -OC(O)Rn, -N(R11)C(O)OR11, -0C(0)N(Rn)2, -N(R11)C(O)N(R11)2, -S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, -NO2, and -CN; and C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(0)N(Rn)2, -N(R11)C(O)R11, -C(O)ORn, -OC(O)Rn, -N(R11)C(O)OR11, -OC(O)N(Rn)2, -N(R11)C(O)N(R11)2, -S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, =0, =S, =N(Rn), -NO2, and -CN; R1is selected from:hydrogen, halogen, -OR12, -SR12, -N(R12)2, -C(O)R12, -C(O)N(R12)2, - N(R12)C(O)R12, -C(O)OR12, -OC(O)R12, -N(R12)C(O)OR12, -OC(O)N(R12)2, - N(R12)C(O)N(R12)2, -S(O)R12, -S(O)2R12, -N(R12)S(O)2R12, -S(O)2N(R12)2, -NO2, and - CN; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR12, -SR12, -N(R12)2, -C(O)R12, -C(O)N(R12)2, -N(R12)C(O)R12, -C(O)OR12, -OC(O)R12, -N(R12)C(O)OR12, -OC(O)N(R12)2, -N(R12)C(O)N(R12)2, - S(O)R12, -S(O)2R12, -N(R12)S(O)2R12, -S(O)2N(R12)2, -NO2, and -CN;R3is selected from (i), (ii), and (iii):i. halogen, -OR15, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN;ii. C1-6 alkyl optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, - N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, - N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl; andiii. C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from:WSGR Docket No. 61402-727.601halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, - N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, - N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andCi-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, - C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, - OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, - S(O)2N(R14)2, -NO2, and -CN;each R13and R15is independently selected from:Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR16, -SR16, -N(R16)2, -C(O)R16, -C(O)N(R16)2, -N(R16)C(O)R16, -C(O)OR16, -OC(O)R16, -N(R16)C(O)OR16, -OC(O)N(R16)2, -N(R16)C(O)N(R16)2, - S(O)R16, -S(O)2R16, -N(R16)S(O)2R16, -S(O)2N(R16)2, -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR16, - SR16, -N(R16)2, -C(O)R16, -C(O)N(R16)2, -N(R16)C(O)R16, -C(O)OR16, -OC(O)R16, - N(R16)C(O)OR16, -OC(O)N(R16)2, -N(R16)C(O)N(R16)2, -S(O)R16, -S(O)2R16, - N(R16)S(O)2R16, -S(O)2N(R16)2, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl; andR10, R11, R12, R14, and R16are each independently selected at each occurrence from:hydrogen;Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, -NH2, -NO2, =0, -CN, C3-10 carbocycle, and 3- to 10-membered heterocycle, the C3-10 carbocycle and 3- to 10- membered heterocycle are each optionally substituted with one or more substituents independently selected from: halogen, -OH, C1-6 alkyl, C1-6 haloalkyl, -O-Ci-6 alkyl, -O- C1-6 haloalkyl, -NH2, -N02, =0, and -CN; andC3-10 carbocycle and 3- to 10-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OH, Ci- 6 alkyl, C1-6 haloalkyl, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, -NH2, -N02, =0, and -CN.

[0074] In some embodiments, the structure of Formula (I), (I-A), (II), or (II-A) is represented by Formula (II-B):WSGR Docket No. 61402-727.601or a pharmaceutically acceptable salt thereof.

[0075] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (II-A), or (II-B), Ring B is C3-12 carbocycle. In some embodiments, Ring B is C3-12 saturated carbocycle. In some embodiments, Ring B is C3-12 unsaturated carbocycle. In some embodiments, Ring B is C6-12 aryl. In some embodiments, Ring B is selected from C3 carbocycle, C4 carbocycle, Cs carbocycle, Ce carbocycle, C7 carbocycle, Cs carbocycle, C9 carbocycle, C10 carbocycle, C11 carbocycle, and C12 carbocycle, each of which is optionally substituted with substituents as defined in Formula (I), (I-A), (I-B), (I-C), (I-D), (II), (II-A), or (II-B). In some embodiments, RingB is selected from C3-4 carbocycle, C3-5 carbocycle, C3-6 carbocycle, C3-7 carbocycle, C3-8 carbocycle, C3-9 carbocycle, C3-10 carbocycle, C3-11 carbocycle, and C3-12 carbocycle, each of which is optionally substituted with substituents as defined in Formula (I), (I-A), (I-B), (I-C), (I-D), (II), (II-A), or (II-B). In some embodiments, Ring B is selected from C3-8 monocyclic carbocycle and C4-12 bicyclic carbocycle, each of which is optionally substituted with substituents as defined in Formula (I), (I-A), (I-B), (I-C), (I-D), (II), (II-A), or (II-B). In some embodiments, the C3-8 monocyclic carbocycle of Ring B is selected from C3-8 cycloalkyl and phenyl, each of which is optionally substituted with substituents as defined in Formula (I), (I-A), (I-B), (I-C), (I-D), (II), (II-A), or (II-B). In some embodiments, the C4-12 bicyclic carbocycle of Ring B is selected from C4-12 fused carbocycle, C4-12 bridged carbocycle, and C4-12 spirocyclic carbocycle, each of which is optionally substituted with substituents as defined in Formula (I), (I-A), (I-B), (I-C), (I-D), (II), (II-A), or (II-B).

[0076] In some embodiments, for the compound or salt of Formula (I), (I-A), (I-B), (I-C), (I-D), (II), (II-A), or (II-B), Ring B is C3-12 carbocycle optionally substituted with one or more substituents independently selected from:halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -N(R11)C(O)R11, - C(O)ORn, -OC(O)Rn, -N(R11)C(O)OR11, -OC(O)N(Rn)2, -N(R11)C(O)N(R11)2, -S(O)Rn, -S(O)2Rn, -NtR^StO^R11, -S(O)2N(Rn)2, -NO2, and -CN; and C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -N(R11)C(O)R11, -C(O)ORn, -OC(O)Rn, -N(R.'1)C(O)OR1\ -OC(O)N(R.")2, -N(R11)C(O)N(R11)2, -WSGR Docket No. 61402-727.601S(O)Rn, -S(0)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, =0, =S, =N(Rn), -NO2, and -CN.

[0077] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (II-A), or (II-B), Ring B is C3-9 carbocycle optionally substituted with one or more substituents independently selected from:halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -N(R11)C(O)R11, - C(O)ORn, -OC(O)Rn, -N(R11)C(O)OR11, -OC(O)N(Rn)2, -N(R11)C(O)N(R11)2, - S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, -NO2, and -CN; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -N(R11)C(O)R11, -C(O)ORn, -OC(O)Rn, -N(R11)C(O)OR11, -OC(O)N(Rn)2, -N(R11)C(O)N(R11)2, - S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, =0, =S, =N(Rn), -NO2, and -CN.

[0078] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (II-A), or (II-B), Ring B is C3-9 carbocycle optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -C(O)ORn, -OC(O)Rn, -NO2, and -CN; and C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -C(O)ORn, -OC(O)Rn, =0, =S, =N(Rn), -NO2, and -CN. In some embodiments, Ring B is C3-9 carbocycle optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -C(O)ORn, -OC(O)Rn, -NO2, and -CN; and C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, =0, -NO2, and -CN.

[0079] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (II-A), or (II-B), Ring B is C3-6 carbocycle optionally substituted with one or more substituents independently selected from:halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -N(R11)C(O)R11, - C(O)ORn, -OC(O)Rn, -N(R11)C(O)OR11, -OC(O)N(Rn)2, -N(R11)C(0)N(R11)2, - S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(Rn)2, -NO2, and -CN; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -N(R11)C(O)R11, -C(O)ORn, -OC(O)Rn, -N(R'1)C(O)OR1\ -OC(O)N(Rn)2, -N(R11)C(0)N(R11)2, - S(O)Rn, -S(O)2Rn, -N(R' ^(O^R1-S(O)2N(Rn)2, =0, =S, =N(Rn), -NO2, and -CN.

[0080] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (II-A), or (II-B), Ring B is C3-6 carbocycle optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -C(O)ORn, -OC(O)Rn, -NO2, and -CN; and C1-6 alkyl optionally substituted withWSGR Docket No. 61402-727.601one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -C(O)ORn, -OC(O)Rn, =0, =S, =N(Rn), -NO2, and -CN. In some embodiments, Ring B is C3-6 carbocycle optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(0)N(Rn)2, -C(O)ORn, -OC(O)Rn, -NO2, and -CN; and C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, =0, -NO2, and -CN.

[0081] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (II-A), or (II-B), Ring B is C5-6 carbocycle optionally substituted with one or more substituents independently selected from:halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -N(R11)C(O)R11, - C(O)ORn, -OC(O)Rn, -N(R11)C(O)OR11, -OC(O)N(Rn)2, -N(R11)C(0)N(R11)2, -S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, -NO2, and -CN; and C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -N(R11)C(0)R11, -C(O)ORn, -OC(O)Rn, -N(R11)C(O)OR11, -OC(O)N(Rn)2, -N(R11)C(0)N(R11)2, -S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, =0, =S, =N(Rn), -NO2, and -CN.

[0082] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (II-A), or (II-B), Ring B is C5-6 carbocycle optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -C(O)ORn, -OC(O)Rn, -NO2, and -CN; and C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -C(O)ORn, -OC(O)Rn, =0, =S, =N(Rn), -NO2, and -CN. In some embodiments, Ring B is C5-6 carbocycle optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -C(O)ORn, -OC(O)Rn, -NO2, and -CN; and C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, =0, -NO2, and -CN.

[0083] In some embodiments, for the compound or salt of Formula (I), (I- A), (II), (II-A), or (II-B), (I-B), (I-C), (I-D), Ring B is C5-6 carbocycle optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -N R^ O11, -C(O)ORn, -OC(O)Rn, -N^C^OR11, -OC(O)N(Rn)2, -N(R11)C(0)N(R11)2, -S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(Rn)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, Ring B is C5-6 carbocycle optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -C(O)ORn, -OC(O)Rn, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, Ring B is C5-6 carbocycle optionally substituted with one or moreWSGR Docket No. 61402-727.601substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, Ring B is C5-6 carbocycle optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -NO2, -CN, C1-3 alkyl, and C1-3 haloalkyl.

[0084] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (II- A), or (II-B), Ring B is phenyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -N(R11)C(O)R11, -C(O)ORn, -OC(O)Rn, -N(R11)C(O)OR11, -OC(O)N(Rn)2, -N(R11)C(O)N(R11)2, -S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, -NO2, and -CN; and C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -N(R11)C(O)R11, -C(O)ORn, -OC(O)Rn, -N(R11)C(O)OR11, -OC(O)N(Rn)2, -N(R11)C(O)N(R11)2, -S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, =0, =S, =N(Rn), -NO2, and -CN.

[0085] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (II- A), or (II-B), Ring B is phenyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -N R^QO11, -C(O)ORn, -OC(O)Rn, -N R^C^OR11, -OC(O)N(Rn)2, -N(R11)C(O)N(R11)2, -S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, Ring B is phenyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -C(O)ORn, -OC(O)Rn, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, Ring B is phenyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, Ring B is phenyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -NO2, -CN, C1-3 alkyl, and C1-3 haloalkyl.

[0086] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (II- A), or (II-B), Ring B is phenyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -N R^QO11, -C(O)ORn, -OC(O)Rn, -N R^C^OR11, -OC(O)N(Rn)2, -N(R11)C(O)N(R11)2, -S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(Rn)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, Ring B is phenyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -C(O)ORn, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, Ring B is phenyl optionally substituted with one or more substituents independently selectedWSGR Docket No. 61402-727.601from halogen, -OR11, -SR11, -N(Rn)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, Ring B is phenyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -N(Rn)2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, Ring B is phenyl optionally substituted with one or more substituents independently selected from halogen, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, Ring B is phenyl optionally substituted with one or more substituents independently selected from halogen and C1-6 alkyl. In some embodiments, Ring B is phenyl optionally substituted with one or more substituents independently selected from fluoro. In some embodiments, Ring B is F.phenyl. In some embodiments, Ring B is selected fromand.

[0087] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (II-A), or (II-B), Ring B is 3- to 12-membered heterocycle. In some embodiments, Ring B is 3- to 12-membered heterocycle comprising at least one heteroatom selected from oxygen, nitrogen, and sulfur. In some embodiments, Ring B is 3- to 12-membered unsaturated heterocycle. In some embodiments, Ring B is 3- to 12-membered heteroaryl. In some embodiments, RingB is selected from 3 -membered heterocycle, 4-membered heterocycle, 5-membered heterocycle, 6-membered heterocycle, 7-membered heterocycle, 8-membered heterocycle, 9-membered heterocycle, 10-membered heterocycle, and 11 -membered heterocycle, each of which is optionally substituted with substituents as defined in Formula (I), (I-A), (I-B), (I-C), (I-D), (II), (II-A), or (II-B). In some embodiments, Ring B is selected from 3-to 4-membered heterocycle, 3- to 5-membered heterocycle, 3- to 6-membered heterocycle, 3- to 7-membered heterocycle, 3- to 8-membered heterocycle, 3- to 9-membered heterocycle, 3- to 10-membered heterocycle, 3- to 11 -membered heterocycle, and 3- to 12-membered heterocycle, each of which is optionally substituted with substituents as defined in Formula (I), (I-A), (I-B), (I-C), (I-D), (II), (II-A), or (II-B). In some embodiments, Ring B is selected from 3- to 8-membered monocyclic heterocycle and 4- to 12-membered bicyclic heterocycle, each of which is optionally substituted with substituents as defined in Formula (I), (I-A), (I-B), (I-C), (I-D), (II), (II-A), or (II-B). In some embodiments, Ring B is selected from 3- to 8-membered monocyclic heterocycle and 8- to 12-membered bicyclic heterocycle, each of which is optionally substituted with substituents as defined in Formula (I), (I-A), (I-B), (I-C), (I-D), (II), (II-A), or (II-B). In some embodiments, Ring B is selected from 3- to 8-membered monocyclic heterocycle and 8- to 12-membered bicyclic heterocycle. In some embodiments, the 4- to 12-membered bicyclic heterocycle of Ring B is selected from 4- to 12-membered fused heterocycle, 4- to 12-membered bridged heterocycle, and 4- to 12-membered spirocyclic heterocycle, each of which isWSGR Docket No. 61402-727.601optionally substituted with substituents as defined in Formula (I), (I-A), (I-B), (I-C), (I-D), (II), (ILA), or (ILB).

[0088] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (ILA), or (ILB), Ring B is selected from a 3- to 12-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -N(R11)C(O)R11, - C(O)ORn, -OC(O)Rn, -N(R11)C(O)OR11, -OC(O)N(Rn)2, -N(R11)C(O)N(R11)2, -S(O)Rn, -S(O)2Rn, -NtR^StO^R11, -S(O)2N(Rn)2, -NO2, and -CN; and C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -N(R11)C(O)R11, -C(O)ORn, -OC(O)Rn, -N(R.'1)C(O)OR1\ -OC(O)N(R.")2, -N(R11)C(O)N(R11)2, -S(O)Rn, -S(O)2Rn, -NtR^StO^R11, -S(O)2N(Rn)2, =0, =S, =N(Rn), -NO2, and -CN.

[0089] In some embodiments, for the compound or salt of Formula (I), (LA), (LB), (I-C), (I-D), (II), (ILA), or (ILB), Ring B is selected from a 3- to 10-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -N(R11)C(O)R11, - C(O)ORn, -OC(O)Rn, -N(R11)C(O)OR11, -OC(O)N(Rn)2, -N(R11)C(O)N(R11)2, - S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(Rn)2, -NO2, and -CN; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -N(R11)C(O)R11, -C(O)ORn, -OC(O)Rn, -N(R.'1)C(O)OR1-OC(O)N(R.")2, -N(R11)C(O)N(R11)2, - S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(Rn)2, =0, =S, =N(Rn), -NO2, and -CN.

[0090] In some embodiments, for the compound or salt of Formula (I), (LA), (LB), (I-C), (I-D), (II), (ILA), or (ILB), Ring B is selected from a 3- to 6-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -N(R11)C(O)R11, - C(O)ORn, -OC(O)Rn, -N(R11)C(O)OR11, -OC(O)N(Rn)2, -N(R11)C(O)N(R11)2, -S(O)Rn, -S(O)2Rn, -NtR^StO^R11, -S(O)2N(Rn)2, -NO2, and -CN; and C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -N(R11)C(O)R11, -C(O)ORn, -OC(O)Rn, -N(R.'1)C(O)OR1\ -OC(O)N(R.")2, -N(R11)C(O)N(R11)2, -S(O)Rn, -S(O)2Rn, -NtR^StO^R11, -S(O)2N(Rn)2, =0, =S, =N(Rn), -NO2, and -CN.

[0091] In some embodiments, for the compound or salt of Formula (I), (LA), (LB), (I-C), (I-D), (II), (ILA), or (ILB), Ring B is selected from a 5- to 6-membered heterocycle optionally substituted with one or more substituents independently selected from:WSGR Docket No. 61402-727.601halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(0)N(Rn)2, -N(R11)C(O)R11, - C(O)ORn, -OC(O)Rn, -N(R11)C(O)OR11, -0C(0)N(Rn)2, -N(R11)C(O)N(R11)2, - S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, -NO2, and -CN; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(0)N(Rn)2, -N(R11)C(O)R11, -C(O)ORn, -OC(O)Rn, -N(R11)C(O)OR11, -OC(O)N(Rn)2, -N(R11)C(O)N(R11)2, - S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, =0, =S, =N(Rn), -NO2, and -CN.

[0092] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (II-A), or (II-B), Ring B is selected from a 5- to 6-membered heteroaryl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(RU)2, -C(O)Rn, -C(O)N(Rn)2, -NCR^QOX11, -C(O)ORn, -OC(O)Rn, -N(R11)C(O)OR11, -OC(O)N(Rn)2, -N(R11)C(O)N(R11)2, -S(O)Rn, -S(O)2RU, -N(R11)S(O)2R11, -S(O)2N(RU)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, Ring B is selected from a 5- to 6-membered heteroaryl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -C(O)ORn, -OC(O)Rn, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, Ring B is selected from a 5- to 6-membered heteroaryl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, Ring B is selected from a 5- to 6-membered heteroaryl optionally substituted with one or more substituents independently selected from halogen, -OR11, -N(Rn)2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, Ring B is selected from a 5- to 6-membered heteroaryl optionally substituted with one or more substituents independently selected from halogen, -OR11, -N(Rn)2, -CN, C1-3 alkyl, and C1-3 haloalkyl.

[0093] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (II-A), or (II-B), Ring B is selected from pyrrolyl, pyridyl, and pyrazinyl, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -N(R11)C(O)R11, - C(O)ORn, -OC(O)Rn, -N(R11)C(O)OR11, -OC(O)N(Rn)2, -N(R11)C(O)N(R11)2, -S(O)Rn, -S(O)2Rn, -NtR^StO^R11, -S(O)2N(Rn)2, -NO2, and -CN; and C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -N(R11)C(O)R11, -C(O)ORn, -OC(O)Rn, -N(R.'1)C(O)OR1-OC(O)N(R.")2, -N(R11)C(O)N(R11)2, - S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(Rn)2, =0, =S, =N(Rn), -NO2, and -CN.

[0094] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (II-A), or (II-B), Ring B is selected from pyrrolyl, pyridyl, and pyrazinyl, each of whichWSGR Docket No. 61402-727.601is optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(0)N(RU)2, -N(R11)C(O)R11, -C(O)ORn, -OC(O)Rn, -N R^QC OR11, -OC(O)N(Rn)2, -N(RU)C(0)N(R11)2, -S(O)Rn, -S(O)2RU, -N(R11)S(O)2R11, -S(O)2N(Rn)2, -NO2, and -CN; and C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, =0, -NO2, and -CN.

[0095] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (II-A), or (II-B), Ring B is selected from pyrrolyl, pyridyl, and pyrazinyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(RU)2, -N(R11)C(O)R11, -C(O)ORn, -OC(O)Rn, -N R^QC OR11, -OC(O)N(Rn)2, -N(RU)C(O)N(R11)2, -S(O)Rn, -S(O)2RU, -N(R11)S(O)2R11, -S(O)2N(Rn)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, Ring B is selected from pyrrolyl, pyridyl, and pyrazinyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -C(O)ORn, -OC(O)Rn, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl.

[0096] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (II-A), or (II-B), Ring B is selected from pyrrolyl, pyridyl, and pyrazinyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(RU)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, Ring B is selected from pyrrolyl, pyridyl, and pyrazinyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR11, -N(Rn)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, Ring B is selected from pyrrolyl, pyridyl, and pyrazinyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR11, -N(Rn)2, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, Ring B is selected from pyrrolyl, pyridyl, and pyrazinyl, each of which is optionally substituted with one or more substituents independently selected fromfluoro, -NH2, and methyl. In some embodiments, Ring B is selected fromHoNH2NIn some embodiments, Ring B is. In someWSGR Docket No. 61402-727.601embodiments, Ring B is selected fromH, Nembodiments, RingB is

[0097] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (II-A), or (II-B), Ring B is pyridyl optionally substituted with one or more substituents independently selected from:halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -N(R11)C(O)R11, - C(O)ORn, -OC(O)Rn, -N(R11)C(O)OR11, -OC(O)N(Rn)2, -N(R11)C(O)N(R11)2, - S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, -NO2, and -CN; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -N(R11)C(O)R11, -C(O)ORn, -OC(O)Rn, -N(R11)C(O)OR11, -OC(O)N(Rn)2, -N(R11)C(O)N(R11)2, - S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, =0, =S, =N(Rn), -NO2, and -CN.

[0098] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (II-A), or (II-B), Ring B is pyridyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -N(R11)C(O)R11, -C(O)ORn, -OC(O)Rn, -N(R11)C(O)OR11, -OC(O)N(Rn)2, -N(R11)C(O)N(R11)2, -S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, Ring B is pyridyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -C(O)ORn, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, Ring B is pyridyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, Ring B is pyridyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -N(Rn)2, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, Ring B is pyridyl optionally substituted with one or more substituents independently selected from halogen, -N(Rn)2, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, Ring B is pyridyl optionally substituted with one or more substituents independently selected from halogen, -N(Rn)2, C1-3 alkyl, and C1-3 haloalkyl. In some embodiments, Ring B is pyridyl optionally substituted with one or more substituents independently selected from halogen, -N(Rn)2, and C1-3 alkyl. In some embodiments, Ring B is pyridyl optionally substituted with one or more substituents independently selected from -NH2.WSGR Docket No. 61402-727.601In some embodiments, Ring B is \= / substituted with -NH2. In some embodiments, Ring H2NNB is

[0099] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (II- A), or (II-B), Ring B is pyridyl substituted with -N(Rn)2. In some embodiments,Ring B is substituted with -N(Rn)2. In some embodiments, Ring B issubstituted with -NH2.

[0100] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-ND), (II), (ILA), or (ILB), Ring Bis

[0101] In some embodiments, for the compound or salt Formula (I), (LA), (LB), (I-C), (LD),(II), (ILA), or (ILB), Ring B is selected fromI2I

[0102] In some embodiments, the compound or salt of Formula (I), (LA), (LB), (II), (ILA), or (ILB) is represented by the structure of Formula (III):(III).

[0103] In some embodiments, for the compound or salt of Formula (I), (LA), (LB), (I-C), (I-D), (II), (ILA), (ILB), or (III), R1is selected from hydrogen, halogen, -OR12, -SR12, -N(R12)2, -C(O)R12, -C(O)N(R12)2, -N(R12)C(O)R12, -C(O)OR12, -OC(O)R12, -N(R12)C(O)OR12, -OC(O)N(R12)2, -N(R12)C(O)N(R12)2, -S(O)R12, -S(O)2R12, -N(R12)S(O)2R12, -S(O)2N(R12)2, -NO2, and -CN; and C1-6 alkyl optionally substituted with one or more substituents independentlyWSGR Docket No. 61402-727.601selected from halogen, -OR12, -SR12, -N(R12)2, -C(O)R12, -C(O)N(R12)2, -C(O)OR12, -OC(O)R12, -NO2, and -CN. In some embodiments, R1is selected from hydrogen, halogen, -OR12, -SR12, -N(R12)2, -C(O)R12, -C(O)N(R12)2, -C(O)OR12, -OC(O)R12, -NO2, and -CN; and Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR12, -SR12, -N(R12)2, -C(O)R12, -C(O)N(R12)2, -C(O)OR12, -OC(O)R12, -NO2, and -CN.

[0104] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (II-A), (II-B), or (III), R1is selected from hydrogen, halogen, -OR12, -SR12, -N(R12)2, -C(O)R12, -C(O)N(R12)2, -N(R12)C(O)R12, -C(O)OR12, -OC(O)R12, -N(R12)C(O)OR12, -OC(O)N(R12)2, -N(R12)C(O)N(R12)2, -S(O)R12, -S(O)2R12, -N(R12)S(O)2R12, -S(O)2N(R12)2, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl. In some embodiments, R1is selected from hydrogen, halogen, -OR12, -SR12, -N(R12)2, -C(O)R12, -C(O)N(R12)2, -C(O)OR12, -OC(O)R12, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl. In some embodiments, R1is selected from hydrogen, halogen, -OR12, -SR12, -N(R12)2, -C(O)R12, -C(O)N(R12)2, -C(O)OR12, -OC(O)R12, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl. In some embodiments, R1is selected from hydrogen, halogen, -OR12, -SR12, -N(R12)2, -C(O)R12, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl. In some embodiments, R1is selected from hydrogen, halogen, -OR12, -N(R12)2, -C(O)R12, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl. In some embodiments, R1is selected from hydrogen, halogen, Ci-6 alkyl, and Ci-6 haloalkyl. In some embodiments, R1is selected from hydrogen, halogen, and Ci-6 alkyl. In some embodiments, R1is selected from hydrogen, halogen, and C1-3 alkyl. In some embodiments, R1is halogen. In some embodiments, R1is C1-3 alkyl. In some embodiments, R1is selected from hydrogen and methyl. In some embodiments, R1is hydrogen. In some embodiments, R1is methyl.

[0105] In some embodiments, the compound or salt of Formula (I), (I- A), (II), (II-A), (II-B), or (III) is represented by the structure of Formula (III- A):H2NR2^N^NoR3(in-A).

[0106] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is 3- to 12-membered heterocycle. In some embodiments, R3is 3-to 12-membered heterocycle comprising at least one heteroatom selected from oxygen, nitrogen, and sulfur. In some embodiments, R3is 3- to 12-membered unsaturated heterocycle. In some embodiments, R3is 3- to 12-membered heteroaryl. In some embodiments, R3is selected from 3-WSGR Docket No. 61402-727.601membered heterocycle, 4-membered heterocycle, 5-membered heterocycle, 6-membered heterocycle, 7-membered heterocycle, 8-membered heterocycle, 9-membered heterocycle, 10-membered heterocycle, and 11 -membered heterocycle, each of which is optionally substituted with substituents as defined in Formula (I). In some embodiments, R3is selected from 3- to 4-membered heterocycle, 3- to 5-membered heterocycle, 3- to 6-membered heterocycle, 3- to 7-membered heterocycle, 3- to 8-membered heterocycle, 3- to 9-membered heterocycle, 3- to 10-membered heterocycle, 3- to 11 -membered heterocycle, and 3- to 12-membered heterocycle, each of which is optionally substituted with substituents as defined in Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), or (III-A). In some embodiments, R3is selected from 3- to 8-membered monocyclic heterocycle and 4- to 12-membered bicyclic heterocycle, each of which is optionally substituted with substituents as defined in Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), or (III-A). In some embodiments, R3is selected from 3- to 8-membered monocyclic heterocycle and 8- to 12-membered bicyclic heterocycle, each of which is optionally substituted with substituents as defined in Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), or (III-A). In some embodiments, R3is selected from 3- to 8-membered monocyclic heterocycle and 8- to 12-membered bicyclic heterocycle. In some embodiments, the 4- to 12-membered bicyclic heterocycle of R3is selected from 4- to 12-membered fused heterocycle, 4- to 12-membered bridged heterocycle, and 4- to 12-membered spirocyclic heterocycle, each of which is optionally substituted with substituents as defined in Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), or (III-A).

[0107] In some embodiments, for the compound or salt of Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is selected from C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN.

[0108] In some embodiments, for the compound or salt of Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is 3- to 12-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -WSGR Docket No. 61402-727.601C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andCi-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN.

[0109] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III- A), R3is 3- to 8-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andCi-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN.

[0110] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is 3- to 8-membered heterocycle optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl. In some embodiments, R3is 3- to 8-membered heterocycle optionally substituted with one or more substituents independently selected from halogen, -OR14, -N(R14)2, -C(O)R14, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl. In some embodiments, R3is 3- to 8-membered heterocycle optionally substituted with one or more substituents independently selected from halogen, -OR14, -N(R14)2, Ci-6 alkyl, and Ci-6 haloalkyl.

[0111] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is selected from azetidinyl, oxetanyl, pyrrolidinyl, tetrahydropyranyl, and 2-oxa-5-azabicyclo[2.2.2]octanyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl. In some embodiments, R3is selected from azetidinyl, oxetanyl, pyrrolidinyl, tetrahydropyranyl, and 2-oxa-5-azabicyclo[2.2.2]octanyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, -N(R14)2, -C(O)R14, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl. In some embodiments, R3is selected from azetidinyl, oxetanyl, pyrrolidinyl, tetrahydropyranyl, and 2-oxa-5-azabicyclo[2.2.2]octanyl, each of which isWSGR Docket No. 61402-727.601optionally substituted with one or more substituents independently selected from halogen, -OR14, -N(R14)2, CI-6 alkyl, and Ci-6 haloalkyl. In some embodiments, R3is selected from azetidinyl, oxetanyl, pyrrolidinyl, tetrahydropyranyl, and 2-oxa-5-azabicyclo[2.2.2]octanyl, each of which is optionally substituted with one or more substituents independently selected from -H2NV\ < 4 / ^Nu NH2 and methyl. In some embodiments, R3is selected fromH O,NH2,

[0112] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III- A), R3is 3- to 8-membered heterocycle optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -OC(O)R14, -NO2, and -CN; and C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -OC(O)R14, -NO2, and -CN. In some embodiments, R3is 3- to 8-membered heterocycle optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -OC(O)R14, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R3is 3- to 8-membered heterocycle optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R3is 3- to 8-membered heterocycle optionally substituted with one or more substituents independently selected from halogen, -OR14, -N(R14)2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R3is 3- to 8-membered heterocycle optionally substituted with one or more substituents independently selected from halogen, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R3is 3- to 8-membered heterocycle optionally substituted with one or more substituents independently selected from halogen and C1-6 alkyl.

[0113] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is C3-12 carbocycle. In some embodiments, R3is C3-12 saturated carbocycle. In some embodiments, R3is C3-12 unsaturated carbocycle. In some embodiments, R3is C6-12 aryl. In some embodiments, R3is selected from C3 carbocycle, C4 carbocycle, Cs carbocycle, Ce carbocycle, C7 carbocycle, Cs carbocycle, C9 carbocycle, C 10 carbocycle, C11WSGR Docket No. 61402-727.601carbocycle, and C12 carbocycle, each of which is optionally substituted with substituents as defined in Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), or (III-A). In some embodiments, R3is selected from C3-4 carbocycle, C3-5 carbocycle, C3-6 carbocycle, C3-7 carbocycle, C3-8 carbocycle, C3-9 carbocycle, C3-10 carbocycle, C3-11 carbocycle, and C3-12 carbocycle, each of which is optionally substituted with substituents as defined in Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), or (III-A). In some embodiments, R3is selected from C3-8 monocyclic carbocycle and C4-12 bicyclic carbocycle, each of which is optionally substituted with substituents as defined in Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), or (III-A). In some embodiments, the C3-8 monocyclic carbocycle of R3is selected from C3-8 cycloalkyl and phenyl, each of which is optionally substituted with substituents as defined in Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), or (III-A). In some embodiments, the C4-12 bicyclic carbocycle of R3is selected from C4-12 fused carbocycle, C4-12 bridged carbocycle, and C4-12 spirocyclic carbocycle, each of which is optionally substituted with substituents as defined in Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), or (III-A).

[0114] In some embodiments, for the compound or salt of Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is C3-12 carbocycle optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN.

[0115] In some embodiments, for the compound or salt of Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is C3-8 carbocycle optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN.WSGR Docket No. 61402-727.601

[0116] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and spiro[2.3]hexanyl, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andCi-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN.

[0117] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and spiro[2.3]hexanyl, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andCi-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, - OC(O)R14, -NO2, and -CN.

[0118] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and spiro[2.3]hexanyl, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andCi-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -N(R14)2, -C(O)R14, -NO2, and -CN.

[0119] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and spiro[2.3]hexanyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -WSGR Docket No. 61402-727.601N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -N02, -CN, CI-6 alkyl, and Ci-6 haloalkyl. In some embodiments, R3is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and spiro[2.3]hexanyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl. In some embodiments, R3is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and spiro[2.3]hexanyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, -N(R14)2, -C(O)R14, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl. In some embodiments, R3is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and spiro[2.3]hexanyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, -N(R14)2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl. In some embodiments, R3is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and spiro[2.3]hexanyl, each of which is optionally substituted with one or more substituents independently selected from fluoro, -OH, -OCH3, -NH2, methyl, and ethyl. In some embodiments, R3is selected fromH2NA >4H2,andVy.

[0120] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is C3-8 carbocycle optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -OC(O)R14, -NO2, and -CN; and C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -OC(O)R14, -NO2, and -CN.

[0121] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is C3-8 carbocycle optionally substituted with one or more substituents independently selected from: halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -OC(O)R14, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R3is C3-8 carbocycle optionally substituted with one or more substituents independently selected from: halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -NO2, -CN, C1-6 alkyl,WSGR Docket No. 61402-727.601and Ci-6 haloalkyl. In some embodiments, R3is C3-8 carbocycle optionally substituted with one or more substituents independently selected from: halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl.

[0122] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is cyclobutyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -OC(O)R14, -NO2, and -CN; and C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -OC(O)R14, -NO2, and -CN.

[0123] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is cyclobutyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -OC(O)R14, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R3is cyclobutyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R3is cyclobutyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl.

[0124] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is cyclobutyl optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN.

[0125] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is cyclobutyl substituted with -N(R14)2 and further optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, - OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, - S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andC1-6 alkyl optionally substituted with one or more substituents independentlyWSGR Docket No. 61402-727.601selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN.

[0126] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is cyclobutyl substituted with -N(R14)2and further optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -OC(O)R14, -NO2, and -CN; and Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -OC(O)R14, -NO2, and -CN.

[0127] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is cyclobutyl substituted with -N(R14)2and further optionally substituted with one or more substituents independently selected from: halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -OC(O)R14, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl. In some embodiments, R3is cyclobutyl substituted with -N(R14)2and further optionally substituted with one or more substituents independently selected from: halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl. In some embodiments, R3is cyclobutyl substituted with -N(R14)2and further optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl.

[0128] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is cyclobutyl substituted with -NH2and further optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -OC(O)R14, -NO2, and -CN; and Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -OC(O)R14, -NO2, and -CN.

[0129] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is cyclobutyl substituted with -NH2and further optionally substituted with one or more substituents independently selected from: halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -OC(O)R14, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl. In some embodiments, R3is cyclobutyl substituted with -NH2and further optionally substituted with one or more substituents independently selected from: halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl. In some embodiments, R3is cyclobutyl substituted with -NH2and further optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl.WSGR Docket No. 61402-727.601

[0130] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-N - / _A), (II-B), (III), or (III-A), R3isR and further optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, - OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, - S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN.

[0131] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is selected from C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, and -NO2; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, and -NO2.

[0132] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is 3- to 12-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, and -NO2; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, and -NO2.WSGR Docket No. 61402-727.601

[0133] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III- A), R3is 3- to 8-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, and -NO2; andCi-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, and -NO2.

[0134] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is 3- to 8-membered heterocycle optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -NO2, CI-6 alkyl, and Ci-6 haloalkyl. In some embodiments, R3is 3- to 8-membered heterocycle optionally substituted with one or more substituents independently selected from halogen, -OR14, -N(R14)2, -C(O)R14, -NO2, Ci-6 alkyl, and Ci-6 haloalkyl. In some embodiments, R3is 3- to 8-membered heterocycle optionally substituted with one or more substituents independently selected from halogen, -OR14, -N(R14)2, Ci-6 alkyl, and Ci-6 haloalkyl.

[0135] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is selected from azetidinyl, oxetanyl, pyrrolidinyl, tetrahydropyranyl, and 2-oxa-5-azabicyclo[2.2.2]octanyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -NO2, CI-6 alkyl, and Ci-6 haloalkyl. In some embodiments, R3is selected from azetidinyl, oxetanyl, pyrrolidinyl, tetrahydropyranyl, and 2-oxa-5-azabicyclo[2.2.2]octanyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, -N(R14)2, -C(O)R14, -NO2, Ci-6 alkyl, and Ci-6 haloalkyl. In some embodiments, R3is selected from azetidinyl, oxetanyl, pyrrolidinyl, tetrahydropyranyl, and 2-oxa-5-azabicyclo[2.2.2]octanyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, -N(R14)2, Ci-6 alkyl, and Ci-6 haloalkyl. In some embodiments, R3is selected from azetidinyl, oxetanyl, pyrrolidinyl, tetrahydropyranyl, and 2-oxa-5-azabicyclo[2.2.2]octanyl, each of which is optionally substituted with one or more substituents independently selected from -NH2and methyl. In someembodiments, R3is selected fromHWSGR Docket No. 61402-727.601In some embodiments, R3is selected from HIn some embodiments, R3is

[0136] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III- A), R3is 3- to 8-membered heterocycle optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -OC(O)R14, and -NO2; and C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -OC(O)R14, and -NO2. In some embodiments, R3is 3- to 8-membered heterocycle optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -OC(O)R14, -NO2, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R3is 3- to 8-membered heterocycle optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -NO2, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R3is 3- to 8-membered heterocycle optionally substituted with one or more substituents independently selected from halogen, -OR14, -N(R14)2, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R3is 3- to 8-membered heterocycle optionally substituted with one or more substituents independently selected from halogen, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R3is 3- to 8-membered heterocycle optionally substituted with one or more substituents independently selected from halogen and C1-6 alkyl.

[0137] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is C3-12 carbocycle. In some embodiments, R3is C3-12 saturated carbocycle. In some embodiments, R3is C3-12 unsaturated carbocycle. In some embodiments, R3is C6-12 aryl. In some embodiments, R3is selected from C3 carbocycle, C4 carbocycle, Cs carbocycle, Ce carbocycle, C7 carbocycle, Cs carbocycle, C9 carbocycle, C 10 carbocycle, C11 carbocycle, and C12 carbocycle, each of which is optionally substituted with substituents as defined in Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), or (III-A). In some embodiments, R3is selected from C3-4 carbocycle, C3-5 carbocycle, C3-6 carbocycle, C3-7 carbocycle, C3-8 carbocycle, C3-9 carbocycle, C3-10 carbocycle, C3-11 carbocycle, and C3-12 carbocycle, each of which is optionally substituted with substituents as defined in Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), or (III-A). In some embodiments, R3is selected from C3-8 monocyclic carbocycle and C4-12 bicyclic carbocycle, each of which is optionally substituted withWSGR Docket No. 61402-727.601substituents as defined in Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), or (III-A). In some embodiments, the C3-8 monocyclic carbocycle of R3is selected from C3-8 cycloalkyl and phenyl, each of which is optionally substituted with substituents as defined in Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), or (III-A). In some embodiments, the C4-12 bicyclic carbocycle of R3is selected from C4-12 fused carbocycle, C4-12 bridged carbocycle, and C4-12 spirocyclic carbocycle, each of which is optionally substituted with substituents as defined in Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), or (III-A).

[0138] In some embodiments, for the compound or salt of Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is C3-12 carbocycle optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, and -NO2; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, and -NO2.

[0139] In some embodiments, for the compound or salt of Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is C3-8 carbocycle optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, and -NO2; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, and -NO2.

[0140] In some embodiments, for the compound or salt of Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and spiro[2.3]hexanyl, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, and -NO2; andC1-6 alkyl optionally substituted with one or more substituents independentlyWSGR Docket No. 61402-727.601selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, and -NO2.

[0141] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and spiro[2.3]hexanyl, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, and -NO2; andCi-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, - OC(O)R14, and -NO2.

[0142] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and spiro[2.3]hexanyl, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, and -NO2; andCi-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -N(R14)2, -C(O)R14, and -NO2.

[0143] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and spiro[2.3]hexanyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, CI-6 alkyl, and Ci-6 haloalkyl. In some embodiments, R3is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and spiro[2.3]hexanyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -NO2, CI-6 alkyl, and Ci-6 haloalkyl. In some embodiments, R3is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and spiro[2.3]hexanyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, -N(R14)2, -C(O)R14, -NO2, CI-6 alkyl, and Ci-6 haloalkyl. In some embodiments, R3is cyclopropyl,WSGR Docket No. 61402-727.601cyclobutyl, cyclopentyl, cyclohexyl, and spiro[2.3]hexanyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, -N(R14)2, Ci-6 alkyl, and Ci-6 haloalkyl. In some embodiments, R3is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and spiro[2.3]hexanyl, each of which is optionally substituted with one or more substituents independently selected from fluoro, -OH, -OCH3, -NH2, methyl, and ethyl. In some

[0144] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is C3-8 carbocycle optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -OC(O)R14, and -NO2; and C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -OC(O)R14, and -NO2.

[0145] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is C3-8 carbocycle optionally substituted with one or more substituents independently selected from: halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -OC(O)R14, -NO2, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R3is C3-8 carbocycle optionally substituted with one or more substituents independently selected from: halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -NO2, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R3is C3-8 carbocycle optionally substituted with one or more substituents independently selected from: halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -NO2, C1-6 alkyl, and C1-6 haloalkyl.

[0146] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is cyclobutyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -OC(O)R14, and -NO2; and C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -OC(O)R14, and -NO2.

[0147] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is cyclobutyl optionally substituted with one or more substituentsWSGR Docket No. 61402-727.601independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -OC(O)R14, -NO2, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R3is cyclobutyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -NO2, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R3is cyclobutyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -NO2, C1-6 alkyl, and Ci-6 haloalkyl.

[0148] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is cyclobutyl optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, and -NO2; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, and -NO2.

[0149] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (II), (II-A), (II-B), (III), or (III-A), R3is cyclobutyl substituted with -N(R14)2 and further optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, - OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, - S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, and -NO2; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, and -NO2.

[0150] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (II), (II-A), (II-B), (III), or (III-A), R3is cyclobutyl substituted with -N(R14)2 and further optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -OC(O)R14, and -NO2; and C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -OC(O)R14, and -NO2.

[0151] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (II), (II-A), (II-B), (III), or (III-A), R3is cyclobutyl substituted with -N(R14)2 and further optionallyWSGR Docket No. 61402-727.601substituted with one or more substituents independently selected from: halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -OC(O)R14, -NO2, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R3is cyclobutyl substituted with -N(R14)2and further optionally substituted with one or more substituents independently selected from: halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -NO2, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R3is cyclobutyl substituted with -N(R14)2and further optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -NO2, C1-6 alkyl, and Ci-6 haloalkyl.

[0152] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (II), (II-A), (II-B), (III), or (III-A), R3is cyclobutyl substituted with -NH2and further optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -OC(O)R14, and -NO2; and C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -OC(O)R14, and -NO2.

[0153] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (II), (II-A), (II-B), (III), or (III-A), R3is cyclobutyl substituted with -NH2and further optionally substituted with one or more substituents independently selected from: halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -OC(O)R14, -NO2, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R3is cyclobutyl substituted with -NH2and further optionally substituted with one or more substituents independently selected from: halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -NO2, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R3is cyclobutyl substituted with -NH2and further optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -NO2, C1-6 alkyl, and Ci-6 haloalkyl.

[0154] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (II),R!4^N - / _(II-A), (II-B), (III), or (III-A), R3isR and further optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, - OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, - S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, and -NO2; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -WSGR Docket No. 61402-727.601S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, and -NO2.

[0155] In some embodiments, the compound or salt of Formula (I), (I- A), (I-B), (I-C), (II), (II-A), (II-B), (III), or (III-A), is represented by Formula (III-B):R2NN(III-B);Ri4^rN - / _whereinR is further optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, - OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, - S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN.

[0156] In some embodiments, for the compound or salt of Formula (I-C) or (III-B),R14.N / R14is further optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, - OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, - S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, - OC(O)R14, -NO2, and -CN.WSGR Docket No. 61402-727.601

[0157] In some embodiments, for the compound or salt of Formula (I-C) or (III-B),R!4N^ - / . J y| _R is further optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -OC(O)R14, -NO2, and -CN; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, - OC(O)R14, -NO2, and -CN.

[0158] In some embodiments, for the compound or salt of Formula (I-C) or (III-B), Rl4^N - / _R is further optionally substituted with one or more substituents independently selected from: halogen, -OR14, -SR14, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -OC(O)R14, -NO2, - R14^N - / _CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R is further optionally substituted with one or more substituents independently selected from: halogen, -OR14, -SR14, -C(O)R14, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl.

[0159] In some embodiments, for the compound or salt of Formula (I-C) or (III-B), the one or R?^VN - / _more optional substituents for R are selected from halogen, -OR14, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, the one or more optional substituents are selected from halogen, -OR14, -NO2, -CN, C1-3 alkyl, and C1-3 haloalkyl. In some embodiments, the one or more optional substituents are selected from halogen, -OR14, C1-3 alkyl, and C1-3 haloalkyl. In some embodiments, the one or more optional substituents are selected from halogen, -OR14, and C1-3 alkyl. In some embodiments, the one or more optional substituents are selected from halogen and C1-3 alkyl. In some embodiments, the one or more optional substituents are selected from hydroxy and methyl. In some embodiments, R14is selected from hydrogen, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R14is selected from hydrogen and C1-6 alkyl. In some embodiments, R14is selected from hydrogen and C1-3 alkyl.

[0160] In some embodiments, the compound or salt of Formula (I), (I- A), (I-B), (I-C), (II), (II-A), (II-B), (III), (III-A), or (III-B), is represented by Formula (III-C):WSGR Docket No. 61402-727.601whereinis further optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, - OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, - S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN.H2N-X—

[0161] In some embodiments, for the compound or salt of Formula (III-C), I — I is further optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, - OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, - S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, - OC(O)R14, -NO2, and -CN.

[0162] In some embodiments, for the compound or salt of Formula (III-C),1—1is further optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -OC(O)R14, -NO2, and -CN; andC1-6 alkyl optionally substituted with one or more substituents independentlyWSGR Docket No. 61402-727.601selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, - OC(O)R14, -NO2, and -CN.

[0163] In some embodiments, for the compound or salt of Formula (III-C),further optionally substituted with one or more substituents independently selected from: halogen, -OR14, -SR14, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -OC(O)R14, -NO2, -CN, Ci-6 alkyl,and Ci-6 haloalkyl. In some embodiments,— is further optionally substituted with one or more substituents independently selected from: halogen, -OR14, -SR14, -C(O)R14, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl.

[0164] In some embodiments, for the compound or salt of Formula (IILC), the one or moreoptional substituents forare selected from halogen, -OR14, -NO2, -CN, C1-6 alkyl, and Ci-6 haloalkyl. In some embodiments, the one or more optional substituents are selected from halogen, -OR14, -NO2, -CN, C1-3 alkyl, and C1-3 haloalkyl. In some embodiments, the one or more optional substituents are selected from halogen, -OR14, C1-3 alkyl, and C1-3 haloalkyl. In some embodiments, the one or more optional substituents are selected from halogen, -OR14, and C1-3 alkyl. In some embodiments, the one or more optional substituents are selected from halogen and C1-3 alkyl. In some embodiments, the one or more optional substituents are selected from hydroxy and methyl.

[0165] In some embodiments, for the compound or salt of Formula (I-C), the optionally

[0166] In some embodiments, for the compound or salt of Formula (I), (LA), (LB), (LC), (II),OH(ILA), (ILB), (III), (in-A), (in-B), or (IILC), R3is selected fromOHWSGR Docket No. 61402-727.601OHIn some embodiments, R3is selected fromand OH. Insome embodiments,R3is

[0167] In some embodiments, the compound or salt of Formula (I), (I- A), (I-D), (II), (II- A), (II-B), (III), or (III-A), is represented by Formula (III-D):(III-D);R2is selected from (a) and (b):a) halogen, -OR13, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN; and b) C3-12 carbocycle and 3- to 12-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, - N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, - N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, - C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, - OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, - S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -N02, -CN, Ci-6 alkyl, and Ci-6 haloalkyl;WSGR Docket No. 61402-727.601each R13and R15is independently selected from:Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR16, -SR16, -N(R16)2, -C(O)R16, -C(O)N(R16)2, -N(R16)C(O)R16, -C(O)OR16, -OC(O)R16, -N(R16)C(O)OR16, -OC(O)N(R16)2, -N(R16)C(O)N(R16)2, - S(O)R16, -S(O)2R16, -N(R16)S(O)2R16, -S(O)2N(R16)2, and -NO2; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR16, - SR16, -N(R16)2, -C(O)R16, -C(O)N(R16)2, -N(R16)C(O)R16, -C(O)OR16, -OC(O)R16, - N(R16)C(O)OR16, -OC(O)N(R16)2, -N(R16)C(O)N(R16)2, -S(O)R16, -S(O)2R16, - N(R16)S(O)2R16, -S(O)2N(R16)2, -NO2, CI-6 alkyl, and Ci-6 haloalkyl;R10, R11, and R12are each independently selected at each occurrence from:hydrogen;Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, -NH2, -NO2, =0, -CN, C3-10 carbocycle, and 3- to 10-membered heterocycle, the C3-10 carbocycle and 3- to 10- membered heterocycle are each optionally substituted with one or more substituents independently selected from: halogen, -OH, C1-6 alkyl, C1-6 haloalkyl, -O-Ci-6 alkyl, -O- C1-6 haloalkyl, -NH2, -N02, =0, and -CN; andC3-10 carbocycle and 3- to 10-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OH, Ci- 6 alkyl, C1-6 haloalkyl, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, -NH2, -N02, =0, and -CN; and R10, R11, and R12are each independently selected at each occurrence from:hydrogen;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, -NH2, -N02, =0, -CN, C3-10 carbocycle, and 3- to 10-membered heterocycle, the C3-10 carbocycle and 3- to 10- membered heterocycle are each optionally substituted with one or more substituents independently selected from: halogen, -OH, C1-6 alkyl, C1-6 haloalkyl, -O-Ci-6 alkyl, -O- C1-6 haloalkyl, -NH2, -N02, =0, and -CN; andC3-10 carbocycle and 3- to 10-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OH, Ci- 6 alkyl, C1-6 haloalkyl, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, -NH2, -N02, =0, and -CN; and R16are each independently selected at each occurrence from:hydrogen;C1-6 alkyl optionally substituted with one or more substituents independentlyWSGR Docket No. 61402-727.601selected from halogen, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, -NH2, -NO2, C3-10 carbocycle, and 3- to 10-membered heterocycle, the C3-10 carbocycle and 3- to 10-membered heterocycle are each optionally substituted with one or more substituents independently selected from: halogen, -OH, C1-6 alkyl, C1-6 haloalkyl, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, - NH2, and -NO2; andC3-10 carbocycle and 3- to 10-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OH, Ci- 6 alkyl, C1-6 haloalkyl, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, -NH2, and -NO2.

[0168] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is selected from halogen, -OR15, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN. In some embodiments, R3is selected from halogen, -OR15, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -OC(O)R14, -NO2, and -CN. In some embodiments, R3is selected from halogen, -OR15, -SR14, -N(R14)2, -C(O)R14, -NO2, and -CN. In some embodiments, R3is selected from halogen, -OR15, -N(R14)2, -NO2, and -CN.

[0169] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is selected from halogen, -OR15, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -NO2, and -CN. In some embodiments, R3is selected from halogen, -OR15, -SR14, -N(R14)2, -C(O)R14, -NO2, and -CN. In some embodiments, R3is selected from halogen, -OR15, -N(R14)2, -NO2, and -CN. In some embodiments, R3is selected from -OR15. In some embodiments, R3is selected from -OR15; and R15is selected from C3-6 carbocycle optionally substituted with one or more substituents independently selected from halogen, -OR16, -N(R16)2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R3is selected from -OR15; and R15is selected from cyclobutyl optionally substituted with one or more substituents independently selected from halogen, -OR16, -N(R16)2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R3is selected from -OR15; and R15is selected from cyclobutyl optionally substituted with one or more substituents independently selected from -NH2. In some H2NJJembodiments,R3is

[0170] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is selected from C1-6 alkyl optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -WSGR Docket No. 61402-727.601C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andC3-i2 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, - SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, - N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, - N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl.

[0171] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is selected from Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -OC(O)R14, -NO2, and -CN; and C3-i2 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -OC(O)R14, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl. In some embodiments, R3is selected from Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -OC(O)R14, -NO2, -CN, C3-i2carbocycle, and 3- to 12-membered heterocycle. In some embodiments, R3is selected from Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -NO2, -CN, C3-i2 carbocycle, and 3- to 12-membered heterocycle. In some embodiments, R3is selected from Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -N(R14)2, -CN, C3-i2carbocycle, and 3- to 12-membered heterocycle. In some embodiments, R3is selected from Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -N(R14)2, -CN, and C3-i2carbocycle.

[0172] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (II), (II-A), (II-B), (III), or (III-A), R3is selected from Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, -CN, C3-12carbocycle, and 3- to 12-membered heterocycle. In some embodiments, R3is selected from Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -NO2, -CN, C3-i2carbocycle, and 3-to 12-membered heterocycle. In some embodiments, R3is selected from Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -NO2, -CN, C3-6carbocycle, and 3- to 6-WSGR Docket No. 61402-727.601membered heterocycle. In some embodiments, R3is selected from Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -NO2, -CN, C3-6 carbocycle, and 3- to 6-membered heterocycle. In some embodiments, R3is selected from C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -N(R14)2, -NO2, -CN, and C3-6 carbocycle. In some embodiments, R3is selected from C1-6 alkyl optionally substituted with one or more substituents independently selected from -OH, -NH2, and cyclopropyl. In some embodiments, R3is selected from

[0173] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (ILA), (ILB), (III), (IILA), (III-B), (IILC), or (IILD), R2is selected from hydrogen, halogen, -OR12, -SR12, -N(R12)2, -C(O)R12, -C(O)N(R12)2, -N(R12)C(O)R12, -C(O)OR12, -OC(O)R12, -N(R12)C(O)OR12, -OC(O)N(R12)2, -N(R12)C(O)N(R12)2, -S(O)R12, -S(O)2R12, -N(R12)S(O)2R12, -S(O)2N(R12)2, -NO2, and -CN; and C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR12, -SR12, -N(R12)2, -C(O)R12, -C(O)N(R12)2, -C(O)OR12, -OC(O)R12, -NO2, and -CN. In some embodiments, R2is selected from hydrogen, halogen, -OR12, -SR12, -N(R12)2, -C(O)R12, -C(O)N(R12)2, -C(O)OR12, -OC(O)R12, -NO2, and -CN; and C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR12, -SR12, -N(R12)2, -C(O)R12, -C(O)N(R12)2, -C(O)OR12, -OC(O)R12, -NO2, and -CN. In some embodiments, R2is selected from hydrogen, halogen, -OR12, -SR12, -N(R12)2, -C(O)R12, -C(O)N(R12)2, -N(R12)C(O)R12, -C(O)OR12, -OC(O)R12, -N(R12)C(O)OR12, -OC(O)N(R12)2, -N(R12)C(O)N(R12)2, -S(O)R12, -S(O)2R12, -N(R12)S(O)2R12, -S(O)2N(R12)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R2is selected from hydrogen, halogen, -OR12, -SR12, -N(R12)2, -C(O)R12, -C(O)N(R12)2, -C(O)OR12, -OC(O)R12, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R2is selected from hydrogen, halogen, -OR12, -SR12, -N(R12)2, -C(O)R12, -C(O)N(R12)2, -C(O)OR12, -OC(O)R12, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R2is selected from hydrogen, halogen, -OR12, -SR12, -N(R12)2, -C(O)R12, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R2is selected from hydrogen, halogen, -OR12, -N(R12)2, -C(O)R12, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R2is selected from hydrogen, halogen, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R2is selected from hydrogen, halogen, and C1-6 alkyl. In some embodiments, R2is selected from hydrogen, halogen, and C1-3 alkyl. In some embodiments, R2is halogen. In some embodiments, R2is C1-3 alkyl. In some embodiments, R2is hydrogen.WSGR Docket No. 61402-727.601

[0174] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (ILA), (ILB), (III), (IILA), (III-B), (IILC), or (IILD), R2is selected from halogen, -OR13, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN. In some embodiments, R2is selected from halogen, -OR13, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -C(O)OR10, -OC(O)R10, -NO2, and -CN. In some embodiments, R2is selected from halogen, -OR13, -SR10, -N(R10)2, -C(O)R10, -NO2, and -CN. In some embodiments, R2is selected from halogen, -OR13, -N(R10)2, and -CN.

[0175] In some embodiments, for the compound or salt of Formula (I), (LA), (LB), (LC), (I-D), (II), (ILA), (ILB), (III), (IILA), (III-B), (IILC), or (IILD), R2is -OR13. In some embodiments, R2is -OR13; and R13is selected from C1-6 alkyl, C1-6 haloalkyl, and C3-6 carbocycle. In some embodiments, R2is -OR13; and R13is selected from C1-6 alkyl and C3-6 carbocycle. In some embodiments, R2is -OR13; and R13is selected from methyl and carbocycle.In some embodiments, R2is selected fromO and O

[0176] In some embodiments, for the compound or salt of Formula (I), (LA), (LB), (LC), (I-D), (II), (ILA), (ILB), (III), (IILA), (III-B), (IILC), or (IILD), R2is selected from C3-12 carbocycle and 3- to 12-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, - SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, - N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, - N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl.

[0177] In some embodiments, for the compound or salt of Formula (I), (LA), (LB), (LC), (I-D), (II), (ILA), (ILB), (III), (IILA), (III-B), (IILC), or (IILD),, R2is 3- to 12-membered heterocycle. In some embodiments, R2is 3- to 12-membered heterocycle comprising at least oneWSGR Docket No. 61402-727.601heteroatom selected from oxygen, nitrogen, and sulfur. In some embodiments, R2is 3- to 12-membered unsaturated heterocycle. In some embodiments, R2is 3- to 12-membered heteroaryl. In some embodiments, R3is selected from 3 -membered heterocycle, 4-membered heterocycle, 5-membered heterocycle, 6-membered heterocycle, 7-membered heterocycle, 8-membered heterocycle, 9-membered heterocycle, 10-membered heterocycle, and 11 -membered heterocycle, each of which is optionally substituted with substituents as defined in Formula (I), (I-A), (LB), (I-C), (I-D), (II), (II-A), (II-B), (III), (III-A), (III-B), (III-C), or (III-D). In some embodiments, R2is selected from 3- to 4-membered heterocycle, 3- to 5-membered heterocycle, 3- to 6-membered heterocycle, 3- to 7-membered heterocycle, 3- to 8-membered heterocycle, 3-to 9-membered heterocycle, 3- to 10-membered heterocycle, 3- to 11 -membered heterocycle, and 3- to 12-membered heterocycle, each of which is optionally substituted with substituents as defined in Formula (I), (I-A), (LB), (I-C), (I-D), (II), (II-A), (II-B), (III), (III-A), (III-B), (III-C), or (III-D). In some embodiments, R2is selected from 3- to 8-membered monocyclic heterocycle and 4- to 12-membered bicyclic heterocycle, each of which is optionally substituted with substituents as defined in Formula (I), (I-A), (I-B), (I-C), (I-D), (II), (II-A), (II-B), (III), (III-A), (III-B), (III-C), or (III-D). In some embodiments, R2is selected from 3- to 8-membered monocyclic heterocycle and 8- to 12-membered bicyclic heterocycle, each of which is optionally substituted with substituents as defined in Formula (I), (I-A), (I-B), (I-C), (I-D), (II), (II-A), (II-B), (III), (III-A), (III-B), (III-C), or (III-D). In some embodiments, R2is selected from 3- to 8-membered monocyclic heterocycle and 8- to 12-membered bicyclic heterocycle. In some embodiments, the 4- to 12-membered bicyclic heterocycle of R2is selected from 4- to 12-membered fused heterocycle, 4- to 12-membered bridged heterocycle, and 4- to 12-membered spirocyclic heterocycle, each of which is optionally substituted with substituents as defined in Formula (I), (I-A), (I-B), (I-C), (I-D), (II), (II-A), (II-B), (III), (III-A), (III-B), (III-C), or (III-D).

[0178] In some embodiments, for the compound or salt of Formula (I), (I-A), (I-B), (I-C), (I-D), (II), (II-A), (II-B), (III), (III-A), (III-B), (III-C), or (III-D), R2is selected from a 3- to 10-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN;WSGR Docket No. 61402-727.601andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, - SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, - N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, - N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl.

[0179] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (ILA), (ILB), (III), (IILA), (III-B), (IILC), or (IILD), R2is selected from a 3- to 10-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, - SR10, -N(R10)2, -C(O)R10, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl.

[0180] In some embodiments, for the compound or salt of Formula (I), (LA), (LB), (LC), (I-D), (II), (ILA), (ILB), (III), (IILA), (III-B), (IILC), or (IILD), R2is selected from a 3- to 10-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -C(O)OR10, - NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, - SR10, -N(R10)2, -C(O)R10, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl.WSGR Docket No. 61402-727.601

[0181] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (ILA), (ILB), (III), (IILA), (III-B), (IILC), or (IILD), R2is selected from a 3- to 10-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -C(O)OR10, - OC(O)R10, -NO2, and -CN;Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -C(O)OR10, - NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, - SR10, -N(R10)2, -C(O)R10, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl.

[0182] In some embodiments, for the compound or salt of Formula (I), (LA), (LB), (LC), (I-D), (II), (ILA), (ILB), (III), (IILA), (III-B), (IILC), or (IILD), R2is selected from a 3- to 10-membered heterocycle optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -C(O)OR10, -OC(O)R10, -NO2, -CN, Ci-6 alkyl, Ci-6 haloalkyl, C5-12carbocycle, and 3- to 12-membered heterocycle.

[0183] In some embodiments, for the compound or salt of Formula (I), (LA), (LB), (LC), (I-D), (II), (ILA), (ILB), (III), (IILA), (III-B), (IILC), or (IILD), R2is selected from a 3- to 6-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, - SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, - N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, - N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl.WSGR Docket No. 61402-727.601

[0184] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (ILA), (ILB), (III), (IILA), (III-B), (IILC), or (IILD), R2is selected from a 3- to 6-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, - SR10, -N(R10)2, -C(O)R10, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl.

[0185] In some embodiments, for the compound or salt of Formula (I), (LA), (LB), (LC), (I-D), (II), (ILA), (ILB), (III), (IILA), (III-B), (IILC), or (IILD), R2is selected from a 3- to 6-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -C(O)OR10, - NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, - SR10, -N(R10)2, -C(O)R10, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl.

[0186] In some embodiments, for the compound or salt of Formula (I), (LA), (LB), (LC), (I-D), (II), (ILA), (ILB), (III), (IILA), (III-B), (IILC), or (IILD), R2is selected from a 3- to 6-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -C(O)OR10, - OC(O)R10, -NO2, and -CN;Ci-6 alkyl optionally substituted with one or more substituents independentlyWSGR Docket No. 61402-727.601selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -C(O)OR10, - NO2, and -CN; andC3-i2carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, - SR10, -N(R10)2, -C(O)R10, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl.

[0187] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (ILA), (ILB), (III), (IILA), (III-B), (IILC), or (IILD), R2is selected from a 3- to 6-membered heterocycle optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -C(O)OR10, -OC(O)R10, -NO2, -CN, Ci-6 alkyl, Ci-6 haloalkyl, C3-i2carbocycle, and 3- to 12-membered heterocycle. In some embodiments, R2is selected from a 5- to 6-membered heterocycle optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -C(O)OR10, -OC(O)R10, -NO2, -CN, Ci-6 alkyl, Ci-6 haloalkyl, C3-i2carbocycle, and 3- to 12-membered heterocycle.

[0188] In some embodiments, for the compound or salt of Formula (I), (LA), (LB), (LC), (I-D), (II), (ILA), (ILB), (III), (IILA), (III-B), (IILC), or (IILD), R2is selected from a 5- to 6-membered heteroaryl optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andC3-i2carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, - SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, - N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, - N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl.

[0189] In some embodiments, for the compound or salt of Formula (I), (LA), (LB), (LC), (I-D), (II), (ILA), (ILB), (III), (IILA), (III-B), (IILC), or (IILD), R2is selected from a 5- to 6-membered heteroaryl optionally substituted with one or more substituents independently selected from:WSGR Docket No. 61402-727.601halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, - SR10, -N(R10)2, -C(O)R10, -N02, -CN, Ci-6 alkyl, and Ci-6 haloalkyl.

[0190] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (ILA), (ILB), (III), (IILA), (III-B), (IILC), or (IILD), R2is selected from a 5- to 6-membered heteroaryl optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -C(O)OR10, - NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, - SR10, -N(R10)2, -C(O)R10, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl.

[0191] In some embodiments, for the compound or salt of Formula (I), (LA), (LB), (LC), (I-D), (II), (ILA), (ILB), (III), (IILA), (III-B), (IILC), or (IILD), R2is selected from a 5- to 6-membered heteroaryl optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -C(O)OR10, - OC(O)R10, -NO2, and -CN;Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -C(O)OR10, - NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, -WSGR Docket No. 61402-727.601SR10, -N(R10)2, -C(O)R10, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl.

[0192] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (ILA), (ILB), (III), (IILA), (III-B), (IILC), or (IILD), R2is selected from a 5- to 6-membered heteroaryl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -C(O)OR10, -OC(O)R10, -NO2, -CN, C1-6 alkyl, C1-6 haloalkyl, C3-12 carbocycle, and 3- to 12-membered heterocycle.

[0193] In some embodiments, for the compound or salt of Formula (I), (LA), (LB), (LC), (I-D), (II), (ILA), (ILB), (III), (IILA), (III-B), (IILC), or (IILD), R2is selected from pyrazolyl, triazolyl, and pyridyl, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, - SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, - N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, - N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl.

[0194] In some embodiments, for the compound or salt of Formula (I), (LA), (LB), (LC), (I-D), (II), (ILA), (ILB), (III), (IILA), (III-B), (IILC), or (IILD), R2is selected from pyrazolyl, triazolyl, and pyridyl, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andWSGR Docket No. 61402-727.601C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, - SR10, -N(R10)2, -C(O)R10, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl.

[0195] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (ILA), (ILB), (III), (IILA), (III-B), (IILC), or (IILD), R2is selected from pyrazolyl, triazolyl, and pyridyl, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle.

[0196] In some embodiments, for the compound or salt of Formula (I), (LA), (LB), (LC), (I-D), (II), (ILA), (ILB), (III), (IILA), (III-B), (IILC), or (IILD), R2is selected from pyrazolyl, triazolyl, and pyridyl, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN; and C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN.

[0197] In some embodiments, for the compound or salt of Formula (I), (LA), (LB), (LC), (I-D), (II), (ILA), (ILB), (III), (IILA), (III-B), (IILC), or (IILD), R2is selected from pyrazolyl, triazolyl, and pyridyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN; and C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -C(O)OR10, =0, -NO2, and -CN.WSGR Docket No. 61402-727.601

[0198] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (II-A), (II-B), (III), (III-A), (III-B), (III-C), or (III-D), R2is selected from pyrazolyl, triazolyl, and pyridyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -C(O)OR10, -OC(O)R10, -NO2, and -CN; and C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -C(O)OR10, =0, -NO2, and -CN.

[0199] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (II-A), (II-B), (III), (III-A), (III-B), (III-C), or (III-D), R2is selected from pyrazolyl, triazolyl, and pyridyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -C(O)OR10, -OC(O)R10, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R2is selected from pyrazolyl, triazolyl, and pyridyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl.

[0200] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (II-A), (II-B), (III), (III-A), (III-B), (III-C), or (III-D), R2is selected from pyrazolyl, triazolyl, and pyridyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, -N(R10)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R2is selected from pyrazolyl, triazolyl, and pyridyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R2is selected from pyrazolyl, triazolyl, and pyridyl, each of which is optionally substituted with one or more substituents independently selected from fluoro, -OCH3, -OCHF2, -O-cyclopropyl, methyl, and -CHF2. Insome embodiments, R2is selected fromWSGR Docket No. 61402-727.601

[0201] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (II-A), (II-B), (III), (III-A), (III-B), (III-C), or (III-D), R2is selected from pyrazolyl and pyridyl, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, - SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, - N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, - N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl.

[0202] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (II-A), (II-B), (III), (III-A), (III-B), (III-C), or (III-D), R2is selected from pyrazolyl and pyridyl, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -WSGR Docket No. 61402-727.601S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, =0, =S, =N(R10), -N02, and -CN.

[0203] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (II-A), (II-B), (III), (III-A), (III-B), (III-C), or (III-D), R2is selected from pyrazolyl and pyridyl, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN; andCi-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -C(O)OR10, - OC(O)R10, =0, =S, =N(R10), -NO2, and -CN.

[0204] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (II-A), (II-B), (III), (III-A), (III-B), (III-C), or (III-D), R2is selected from pyrazolyl and pyridyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -C(O)OR10, -OC(O)R10, -NO2, and -CN; and Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -C(O)OR10, -OC(O)R10, =0, =S, =N(R10), -NO2, and -CN. In some embodiments, R2is selected from pyrazolyl and pyridyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -C(O)OR10, -OC(O)R10, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl. In some embodiments, R2is selected from pyrazolyl and pyridyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl.

[0205] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (II-A), (II-B), (III), (III-A), (III-B), (III-C), or (III-D), R2is selected from pyrazolyl and pyridyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, -N(R10)2, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl. In some embodiments, R2is selected from pyrazolyl and pyridyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, -N(R10)2, Ci-6 alkyl, and Ci-6 haloalkyl. In some embodiments, R2is selected from pyrazolyl and pyridyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, Ci-6 alkyl, and Ci-6 haloalkyl. In some embodiments, R2is selected from pyrazolyl and pyridyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, C1-3 alkyl, and C1-3 haloalkyl. In someWSGR Docket No. 61402-727.601embodiments, R2is selected from pyrazolyl and pyridyl, each of which is optionally substituted with one or more substituents independently selected from fluoro, methoxy, methyl, and -CHF2. In some embodiments, R2is pyrazolyl optionally substituted with one or more substituents independently selected from fluoro, methoxy, methyl, and -CHF2. In some embodiments, R2is pyridyl.

[0206] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-Z'? D), (II), (ILA), (ILB), (III), (IILA), (III-B), (IILC), or (IILD), R2is selected fromIn some embodiments, R2is

[0207] In some embodiments, for the compound or salt of Formula (I), (LA), (LB), (LC), (I-D), (II), (ILA), (ILB), (III), (IILA), (III-B), (IILC), or (IILD), R2is selected from pyrazolyl and pyridyl, each of which is optionally substituted with one or more substituents independently selected from C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R2is selected from pyrazolyl and pyridyl, each of which is optionally substituted with one or more substituents independently selected from 3- to 12-membered heterocycle optionally substituted with one or moreWSGR Docket No. 61402-727.601substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R2is selected from pyrazolyl and pyridyl, each of which is optionally substituted with 3- to 8-membered heterocycle optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, each of which is optionally substituted with 3-to 8-membered heterocycle optionally substituted with one or more substituents independently selected from halogen, -OR10, -N(R10)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R2is selected from pyrazolyl and pyridyl, each of which is optionally substituted with 3- to 6-membered heterocycle optionally substituted with one or more substituents independently selected from halogen, -OR10, -N(R10)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R2is selected from pyrazolyl and pyridyl, each of which is optionally substituted with 6-membered heterocycle optionally substituted with one or more substituents independently selected from halogen, -OR10, -N(R10)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl.. In some embodiments,

[0208] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (ILA), (ILB), (III), (IILA), (III-B), (IILC), or (IILD), R2is pyrazolyl optionally substituted with one or more substituents independently selected from C3-6 carbocycle optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R2is pyrazolyl optionally substituted with one or more substituents independently selected from C3-6 carbocycle optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -C(O)OR10, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R2is pyrazolyl optionally substituted with one or more substituents independently selected from C3-6 carbocycle optionally substituted with one or more substituents independentlyWSGR Docket No. 61402-727.601selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R2is pyrazolyl optionally substituted with one or more substituents independently selected from cyclopropyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R2is pyrazolyl optionally substituted with one or more substituents independently selected from cyclopropyl optionally substituted with one or more substituents independently selected from halogen, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R2is pyrazolyl optionally substituted with one or more substituents / / 'independently selected from cyclopropyl. In some embodiments,R2is

[0209] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (II-A), (II-B), (III), (III-A), (III-B), (III-C), or (III-D), R2is selected from pyrazolyl and pyridyl, each of which is optionally substituted with morpholinyl. In some embodiments, R2iseach of which is optionally substituted withmorpholinyl. In some embodiments, R2is selected from

[0210] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (II-A), (II-B), (III), (III-A), (III-B), (III-C), or (III-D), R2is C3-12 carbocycle. In some embodiments, R2is C3-12 saturated carbocycle. In some embodiments, R2is C3-12 unsaturated carbocycle. In some embodiments, R2is C6-12 aryl. In some embodiments, R2is selected from C3 carbocycle, C4 carbocycle, Cs carbocycle, Ce carbocycle, C7 carbocycle, Cs carbocycle, C9 carbocycle, C10 carbocycle, C11 carbocycle, and C12 carbocycle, each of which is optionally substituted with substituents as defined in Formula (I). In some embodiments, R2is selected from C3-4 carbocycle, C3-5 carbocycle, C3-6 carbocycle, C3-7 carbocycle, C3-8 carbocycle, C3-9 carbocycle, C3-10 carbocycle, C3-11 carbocycle, and C3-12 carbocycle, each of which is optionally substituted with substituents as defined in Formula (I). In some embodiments, R2is selected from C3-8 monocyclic carbocycle and C4-12 bicyclic carbocycle, each of which is optionallyWSGR Docket No. 61402-727.601substituted with substituents as defined in Formula (I). In some embodiments, the C3-8 monocyclic carbocycle of R2is selected from C3-8 cycloalkyl and phenyl, each of which is optionally substituted with substituents as defined in Formula (I). In some embodiments, the C4-12 bicyclic carbocycle of R2is selected from C4-12 fused carbocycle, C4-12 bridged carbocycle, and C4-12 spirocyclic carbocycle, each of which is optionally substituted with substituents as defined in Formula (I).

[0211] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (ILA), (ILB), (III), (IILA), (III-B), (IILC), or (IILD), R2is C3-12 carbocycle optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, - SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, - N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, - N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl.

[0212] In some embodiments, for the compound or salt of Formula (I), (LA), (LB), (LC), (I-D), (II), (ILA), (ILB), (III), (IILA), (III-B), (IILC), or (IILD), R2is C3-12 carbocycle optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -C(O)OR10, -OC(O)R10, -NO2, -CN, C1-6 alkyl, C1-6 haloalkyl, C3-12 carbocycle, and 3- to 12-membered heterocycle. In some embodiments, R2is C3-12 carbocycle optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -C(O)OR10, -OC(O)R10, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R2is C3-12 carbocycle optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R2is C3-12 carbocycle.WSGR Docket No. 61402-727.601

[0213] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (ILA), (ILB), (III), (IILA), (III-B), (IILC), or (IILD), R2is C3-8 carbocycle optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, - SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, - N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, - N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl.

[0214] In some embodiments, for the compound or salt of Formula (I), (LA), (LB), (LC), (I-D), (II), (ILA), (ILB), (III), (IILA), (III-B), (IILC), or (IILD), R2is C3-8 carbocycle optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -C(O)OR10, -OC(O)R10, -NO2, -CN, C1-6 alkyl, C1-6 haloalkyl, C3-12 carbocycle, and 3- to 12-membered heterocycle. In some embodiments, R2is C3-8 carbocycle optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -C(O)OR10, -OC(O)R10, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R2is C3-8 carbocycle optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R2is C3-8 carbocycle.

[0215] In some embodiments, for the compound or salt of Formula (I), (LA), (LB), (LC), (I-D), (II), (ILA), (ILB), (III), (IILA), (III-B), (IILC), or (IILD), R2is selected from cyclopropyl and phenyl, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10,WSGR Docket No. 61402-727.601-C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN;C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, - SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, - N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, - N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl.

[0216] In some embodiments, for the compound or salt of Formula (I), (LA), (LB), (LC), (I-D), (II), (ILA), (ILB), (III), (IILA), (III-B), (IILC), or (IILD), R2is selected from cyclopropyl and phenyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl. In some embodiments, R2is selected from cyclopropyl and phenyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -C(O)OR10, -OC(O)R10, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl. In some embodiments, R2is selected from cyclopropyl and phenyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl. In some embodiments, R2is selected from cyclopropyl and phenyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, -N(R10)2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl. In some embodiments, R2is selected from cyclopropyl and phenyl, each of which is optionally substituted with one or more substituents independently selected from halogen, Ci-6 alkyl, and Ci-6 haloalkyl. In some embodiments, R2is selected from cyclopropyl and phenyl, each of which is optionally substituted with one or more substituents independently selected from halogen and Ci-6 alkyl.

[0217] In some embodiments, for the compound or salt of Formula (I), (LA), (LB), (LC), (I-D), (II), (ILA), (ILB), (III), (IILA), (III-B), (IILC), or (IILD), R2is selected fromWSGR Docket No. 61402-727.601In some embodiments, R2isIn some embodiments,R2is

[0218] In some embodiments, for the compound or salt of Formula (I), (LA), (LB), (LC), (I-N'N D), (II), (ILA), (ILB), (III), (IILA), (III-B), (IILC), or (IILD), R2is selected fromWSGR Docket No. 61402-727.601

[0219] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (II- A), (II-B), (III), (III- A), (III-B), or (III-C), R13is independently selected from:Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR16, -SR16, -N(R16)2, -C(O)R16, -C(O)N(R16)2, -N(R16)C(O)R16, -C(O)OR16, -OC(O)R16, -N(R16)C(O)OR16, -OC(O)N(R16)2, -N(R16)C(O)N(R16)2, - S(O)R16, -S(O)2R16, -N(R16)S(O)2R16, -S(O)2N(R16)2, -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR16, - SR16, -N(R16)2, -C(O)R16, -C(O)N(R16)2, -N(R16)C(O)R16, -C(O)OR16, -OC(O)R16, - N(R16)C(O)OR16, -OC(O)N(R16)2, -N(R16)C(O)N(R16)2, -S(O)R16, -S(O)2R16, - N(R16)S(O)2R16, -S(O)2N(R16)2, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl.

[0220] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-D), (II), (II-A), (II-B), (III), (III- A), (III-B), (III-C), or (III-D), R15is independently selected from:Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR16, -SR16, -N(R16)2, -C(O)R16, -C(O)N(R16)2, -N(R16)C(O)R16, -C(O)OR16, -OC(O)R16, -N(R16)C(O)OR16, -OC(O)N(R16)2, -N(R16)C(O)N(R16)2, - S(O)R16, -S(O)2R16, -N(R16)S(O)2R16, -S(O)2N(R16)2, -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR16, - SR16, -N(R16)2, -C(O)R16, -C(O)N(R16)2, -N(R16)C(O)R16, -C(O)OR16, -OC(O)R16, - N(R16)C(O)OR16, -OC(O)N(R16)2, -N(R16)C(O)N(R16)2, -S(O)R16, -S(O)2R16, - N(R16)S(O)2R16, -S(O)2N(R16)2, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl.

[0221] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (ILA), (ILB), (III), (IILA), (III-B), (IILC), or (IILD), each R13and R15is independently selected from Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR16, -SR16, -N(R16)2, -C(O)R16, -C(O)N(R16)2, -N(R16)C(O)R16, -C(O)OR16, -OC(O)R16, -N(R16)C(O)OR16, -OC(O)N(R16)2, -N(R16)C(O)N(R16)2, -S(O)R16, -S(O)2R16, -N(R16)S(O)2R16, -S(O)2N(R16)2, -NO2, and -CN; and C3-i2carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR16, -SR16, -N(R16)2, -C(O)R16, -C(O)N(R16)2, -C(O)OR16, -OC(O)R16, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl.

[0222] In some embodiments, for the compound or salt of Formula (I), (LA), (LB), (I-C), (I-D), (II), (ILA), (ILB), (III), (IILA), (III-B), (IILC), or (IILD), each R13and R15is independently selected from Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR16, -SR16, -N(R16)2, -C(O)R16, -C(O)N(R16)2, -C(O)OR16, -OC(O)R16,WSGR Docket No. 61402-727.601-NO2, and -CN; and C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR16, -SR16, -N(R16)2, -C(O)R16, -C(O)N(R16)2, -C(O)OR16, -OC(O)R16, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl.

[0223] In some embodiments, for the compound or salt of Formula (I), (II), (II- A), (II-B), (III), (III- A), (III-B), or (III-C), R10, R11, R12, R14, and R16are each independently selected at each occurrence from:hydrogen;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -O-C1-6 alkyl, -O-C1-6 haloalkyl, -NH2, -NO2, =0, -CN, C3-10 carbocycle, and 3- to 10-membered heterocycle, the C3-10 carbocycle and 3- to 10- membered heterocycle are each optionally substituted with one or more substituents independently selected from: halogen, -OH, C1-6 alkyl, C1-6 haloalkyl, -O-C1-6 alkyl, -O- C1-6 haloalkyl, -NH2, -NO2, =0, and -CN; andC3-10 carbocycle and 3- to 10-membered heterocycle.

[0224] In some embodiments, for the compound or salt of Formula (I), (II), (II- A), (II-B), (III), (III- A), (III-B), or (III-C), R10, R11, R12, R14, and R16are each independently selected at each occurrence from:hydrogen;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -O-C1-6 alkyl, -O-C1-6 haloalkyl, -NH2, -NO2, =0, -CN, C3-10 carbocycle, and 3- to 10-membered heterocycle; andC3-10 carbocycle and 3- to 10-membered heterocycle.

[0225] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (ILA), (ILB), (III), (III- A), (III-B), (IILC), or (IILD), R10, R11, R12, R14, and R16are each independently selected at each occurrence from hydrogen, halogen, C1-6 alkyl, C1-6 haloalkyl, C3-10 carbocycle, and 3- to 10-membered heterocycle. In some embodiments, R10, R11, R12, R14, and R16are each independently selected at each occurrence from hydrogen, halogen, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R10, R11, R12, R14, and R16are each independently selected at each occurrence from hydrogen.

[0226] In some embodiments, for the compound or salt of Formula (I), (LA), (II), (ILA), (II-B), (III), (IILA), (IILB), or (IILC), R10, R11, R12, R14, and R16are each independently selected at each occurrence from:hydrogen;C1-6 alkyl optionally substituted with one or more substituents independentlyWSGR Docket No. 61402-727.601selected from halogen, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, -NH2, -NO2, =0, C3-10 carbocycle, and 3- to 10-membered heterocycle, the C3-10 carbocycle and 3- to 10- membered heterocycle are each optionally substituted with one or more substituents independently selected from: halogen, -OH, C1-6 alkyl, C1-6 haloalkyl, -O-Ci-6 alkyl, -O- C1-6 haloalkyl, -NH2, -NO2, and =0; andC3-10 carbocycle and 3- to 10-membered heterocycle.

[0227] In some embodiments, for the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (ILA), (ILB), (III), (III- A), (III-B), (IILC), or (IILD), R10, R11, R12, R14, and R16are each independently selected at each occurrence from:hydrogen;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, -NH2, -NO2, =0, C3-10 carbocycle, and 3- to 10-membered heterocycle; andC3-10 carbocycle and 3- to 10-membered heterocycle.

[0228] In some embodiments, for the compound or salt of Formula (I), (LA), (LB), (LC), (I-D), (II), (ILA), (ILB), (III), (IILA), (III-B), (IILC), or (IILD), R10, R11, R12, R14, and R16are each independently selected at each occurrence from hydrogen, halogen, C1-6 alkyl, C1-6 haloalkyl, C3-10 carbocycle, and 3- to 10-membered heterocycle. In some embodiments, R10, R11, R12, R14, and R16are each independently selected at each occurrence from hydrogen, halogen, C1-6 alkyl, and C1-6 haloalkyl. In some embodiments, R10, R11, R12, R14, and R16are each independently selected at each occurrence from hydrogen.

[0229] In some embodiments, the compound of Formula (I) is represented by Formula (IV-A):(IV-A);or a pharmaceutically acceptable salt thereof, wherein:R1is hydrogen;R2is 5- to 6-membered heteroaryl optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;C1-6 alkyl optionally substituted with one or more substituents independentlyWSGR Docket No. 61402-727.601selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, - SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, - N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, - N(R10)S(O)2R10, -S(O)2N(R10)2, -N02, -CN, Ci-6 alkyl, and Ci-6 haloalkyl;Ring B is 5- to 6-membered heteroaryl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(0)Rn, -C(0)N(Rn)2, - N(R11)C(0)R11, -N02, -CN, Ci-6 alkyl and Ci-6 haloalkyl;R3is selected C3-6 carbocycle and 3- to 6-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(0)R14, -C(O)N(R14)2, - N(R14)C(O)R14, -C(0)0R14, -0C(0)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, - N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, and - N02; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(0)R14, - C(O)N(R14)2, -N(R14)C(O)R14, -C(0)0R14, -0C(0)R14, -N(R14)C(O)OR14, - OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, - S(O)2N(R14)2, and -N02;R10and R11are each independently selected at each occurrence from:hydrogen;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -O-C1-6 alkyl, -O-C1-6 haloalkyl, -NH2, -N02, =0, -CN, C3-10 carbocycle, and 3- to 10-membered heterocycle, the C3-10 carbocycle and 3- to 10- membered heterocycle are each optionally substituted with one or more substituents independently selected from: halogen, -OH, C1-6 alkyl, C1-6 haloalkyl, -O-C1-6 alkyl, -O- C1-6 haloalkyl, -NH2, -N02, =0, and -CN; andC3-10 carbocycle and 3- to 10-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OH, Ci- 6 alkyl, C1-6 haloalkyl, -O-C1-6 alkyl, -O-C1-6 haloalkyl, -NH2, -N02, =0, and -CN; and R14is independently selected at each occurrence from:WSGR Docket No. 61402-727.601hydrogen;Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, -NH2, -NO2, C3-10 carbocycle, and 3- to 10-membered heterocycle, the C3-10 carbocycle and 3- to 10-membered heterocycle are each optionally substituted with one or more substituents independently selected from: halogen, -OH, C1-6 alkyl, C1-6 haloalkyl, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, - NH2, and -NO2; andC3-10 carbocycle and 3- to 10-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OH, Ci- 6 alkyl, C1-6 haloalkyl, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, -NH2, and -NO2.

[0230] In some embodiments, the compound of Formula (I) is represented by Formula (IV-A):(IV-A);or a pharmaceutically acceptable salt thereof, wherein:R1is hydrogen;R2is 5- to 6-membered heteroaryl optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, - SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, - N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, - N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl, for example R2is pyrazole optionally substituted with one or more substituents independently selected from halogen, C1-6 alkyl, and C1-6 haloallkyl;WSGR Docket No. 61402-727.601Ring B is 5- to 6-membered heteroaryl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(0)N(Rn)2, - N(R11)C(O)R11, -NO2, -CN, C1-6 alkyl and C 1-6 haloalkyl, for example Ring B is pyridyl optionally susbtituted with one or more -N(Rn)2;R3is selected C3-6 carbocycle and 3- to 6-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, - N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, - N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, and - NO2; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, - C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, - OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, - S(O)2N(R14)2, and -NO2, for example R3is cyclobutyl optionally substituted with one or more substituents independently selected from -OR14, -N(R14)2, and C1-6 alkyl;R10and R11are each independently selected at each occurrence from:hydrogen;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -O-C1-6 alkyl, -O-C1-6 haloalkyl, -NH2, -NO2, =0, -CN, C3-10 carbocycle, and 3- to 10-membered heterocycle, the C3-10 carbocycle and 3- to 10- membered heterocycle are each optionally substituted with one or more substituents independently selected from: halogen, -OH, C1-6 alkyl, C1-6 haloalkyl, -O-C1-6 alkyl, -O- C1-6 haloalkyl, -NH2, -NO2, =0, and -CN; andC3-10 carbocycle and 3- to 10-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OH, Ci- 6 alkyl, C1-6 haloalkyl, -O-C1-6 alkyl, -O-C1-6 haloalkyl, -NH2, -NO2, =0, and -CN; and R14is independently selected at each occurrence from:hydrogen;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -O-C1-6 alkyl, -O-C1-6 haloalkyl, -NH2, -NO2, C3-10 carbocycle, and 3- to 10-membered heterocycle, the C3-10 carbocycle and 3- to 10-membered heterocycle are each optionally substituted with one or more substituents independently selected from: halogen, -OH, C1-6 alkyl, C1-6 haloalkyl, -O-C1-6 alkyl, -O-C1-6 haloalkyl, -WSGR Docket No. 61402-727.601NH2, and -NO2; andC3-10 carbocycle and 3- to 10-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OH, Ci- 6 alkyl, C1-6 haloalkyl, -O-C1-6 alkyl, -O-C1-6 haloalkyl, -NH2, and -NO2.

[0231] In some embodiments, the compound of Formula (I) is represented by Formula (IV-B):or a pharmaceutically acceptable salt thereof, wherein:R1is hydrogen;R2is 5- to 6-membered heteroaryl optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, - SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, - N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, - N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl;Ring B is 5- to 6-membered heteroaryl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, - N(R11)C(O)R11, -NO2, -CN, C1-6 alkyl and C1-6 haloalkyl;is optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -WSGR Docket No. 61402-727.601OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, - S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN;R10and R11are each independently selected at each occurrence from:hydrogen;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -O-C1-6 alkyl, -O-C1-6 haloalkyl, -NH2, -NO2, =0, -CN, C3-10 carbocycle, and 3- to 10-membered heterocycle, the C3-10 carbocycle and 3- to 10- membered heterocycle are each optionally substituted with one or more substituents independently selected from: halogen, -OH, C1-6 alkyl, C1-6 haloalkyl, -O-C1-6 alkyl, -O- C1-6 haloalkyl, -NH2, -NO2, =0, and -CN; andC3-10 carbocycle and 3- to 10-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OH, Ci- 6 alkyl, C1-6 haloalkyl, -O-C1-6 alkyl, -O-C1-6 haloalkyl, -NH2, -NO2, =0, and -CN; and R14is independently selected at each occurrence from:hydrogen; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -O-C1-6 alkyl, -O-C1-6 haloalkyl, -NH2, -NO2, C3-10 carbocycle, and 3- to 10-membered heterocycle, the C3-10 carbocycle and 3- to 10-membered heterocycle are each optionally substituted with one or more substituents independently selected from: halogen, -OH, C1-6 alkyl, C1-6 haloalkyl, -O-C1-6 alkyl, -O-C1-6 haloalkyl, - NH2, and-N02.

[0232] In some embodiments, the compound of Formula (I) is represented by Formula (IV-B):or a pharmaceutically acceptable salt thereof, wherein:R1is hydrogen;R2is 5- to 6-membered heteroaryl optionally substituted with one or more substituentsWSGR Docket No. 61402-727.601independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, - SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, - N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, - N(R10)S(O)2R10, -S(O)2N(R10)2, -N02, -CN, Ci-6 alkyl, and Ci-6 haloalkyl, for example R2is pyrazole optionally substituted with one or more substituents independently selected from halogen, Ci-6 alkyl, and Ci-6 haloallkyl;Ring B is 5- to 6-membered heteroaryl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(0)Rn, -C(0)N(Rn)2, - N(R11)C(0)R11, -N02, -CN, Ci-6 alkyl and Ci-6 haloalkyl, for example Ring B is pyridyl optionally susbtituted with one or more -N(Rn)2;R? N^ - / _R is optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -C(0)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(0)0R14, - 0C(0)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, - S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andCi-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN;R10and R11are each independently selected at each occurrence from:hydrogen;Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, -NH2, -N02, =0, -CN, C3-10 carbocycle, and 3- to 10-membered heterocycle, the C3-10 carbocycle and 3- to 10-WSGR Docket No. 61402-727.601membered heterocycle are each optionally substituted with one or more substituents independently selected from: halogen, -OH, Ci-6 alkyl, Ci-6 haloalkyl, -O-Ci-6 alkyl, -O- Ci-6 haloalkyl, -NH2, -NO2, =0, and -CN; andC3-10 carbocycle and 3- to 10-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OH, Ci- 6 alkyl, C1-6 haloalkyl, -O-C1-6 alkyl, -O-C1-6 haloalkyl, -NH2, -NO2, =0, and -CN; and R14is independently selected at each occurrence from hydrogen; and C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -O-C1-6 alkyl, -O-C1-6 haloalkyl, -NH2, -NO2, C3-10 carbocycle, and 3- to 10-membered heterocycle, the C3-10 carbocycle and 3- to 10-membered heterocycle are each optionally substituted with one or more substituents independently selected from: halogen, -OH, C1-6 alkyl, C1-6 haloalkyl, -O-C1-6 alkyl, -O-C1-6 haloalkyl, -NH2, and -NO2, for example, each R14is hydrogen.

[0233] In some embodiments, the compound of Formula (I) is represented by Formula (IV-C):or a pharmaceutically acceptable salt thereof, wherein:R2is 5- to 6-membered heteroaryl optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, - SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, - N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, - N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl;WSGR Docket No. 61402-727.601Ri4^rN - / _R is optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, - OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, - S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN;R10is selected at each occurrence from:hydrogen;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -O-C1-6 alkyl, -O-C1-6 haloalkyl, -NH2, -NO2, =0, -CN, C3-10 carbocycle, and 3- to 10-membered heterocycle, the C3-10 carbocycle and 3- to 10- membered heterocycle are each optionally substituted with one or more substituents independently selected from: halogen, -OH, C1-6 alkyl, C1-6 haloalkyl, -O-C1-6 alkyl, -O- C1-6 haloalkyl, -NH2, -NO2, =0, and -CN; andC3-10 carbocycle and 3- to 10-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OH, Ci- 6 alkyl, C1-6 haloalkyl, -O-C1-6 alkyl, -O-C1-6 haloalkyl, -NH2, -NO2, =0, and -CN; and R14is independently selected at each occurrence from:hydrogen; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -O-C1-6 alkyl, -O-C1-6 haloalkyl, -NH2, -NO2, C3-10 carbocycle, and 3- to 10-membered heterocycle, the C3-10 carbocycle and 3- to 10-membered heterocycle are each optionally substituted with one or more substituents independently selected from: halogen, -OH, C1-6 alkyl, C1-6 haloalkyl, -O-C1-6 alkyl, -O-C1-6 haloalkyl, - NH2, and-NO2.

[0234] In some embodiments, the compound of Formula (I) is represented by Formula (IV-C):WSGR Docket No. 61402-727.601(IV-C);or a pharmaceutically acceptable salt thereof, wherein:R2is 5- to 6-membered heteroaryl optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN;C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, - SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, - N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, - N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl, for example R2is pyrazole optionally substituted with one or more substituents independently selected from halogen, C1-6 alkyl, and C1-6 haloallkyl;is optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, - OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, - S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN;R10is independently selected at each occurrence from:WSGR Docket No. 61402-727.601hydrogen;Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, -NH2, -NO2, =0, -CN, C3-10 carbocycle, and 3- to 10-membered heterocycle, the C3-10 carbocycle and 3- to 10- membered heterocycle are each optionally substituted with one or more substituents independently selected from: halogen, -OH, C1-6 alkyl, C1-6 haloalkyl, -O-Ci-6 alkyl, -O- C1-6 haloalkyl, -NH2, -NO2, =0, and -CN; andC3-10 carbocycle and 3- to 10-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OH, Ci- 6 alkyl, C1-6 haloalkyl, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, -NH2, -NO2, =0, and -CN; and R14is independently selected at each occurrence from hydrogen; and C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, -NH2, -NO2, C3-10 carbocycle, and 3- to 10-membered heterocycle, the C3-10 carbocycle and 3- to 10-membered heterocycle are each optionally substituted with one or more substituents independently selected from: halogen, -OH, Ci- 6 alkyl, C1-6 haloalkyl, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, -NH2, and-N02, for example, each R14is hydrogen.

[0235] In some embodiments, the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (ILA), (ILB), (III), (III- A), (III-B), (IILC), or (IILD), is a compound of Table 1. * Denotes a stereocenter with undetermined absolute stereochemistry of a single enantiomer or diastereomer.

[0236] Table 1. Chemical structures of selected compounds.WSGR Docket No. 61402-727.601WSGR Docket No. 61402-727.601Cpd CpdStructure Structure No. No.H2N-7 ^ Uzk'1w}^ z z Z Z. H13F\ 'N^ 18ZZ-H29 / / Ar 4 / NH2N-7 — H2N-7 —14 19^A HfV 1 C / / —z \ A / ^N^~N>=N H2N H2NH2N-7 — H2N-715 9 20 r” V "'"' V rQH2N " Ppp H2N P H2N-7 H2N-7N^. \x _ IJ16 21 r- 9H2N 9 H2N P H2N^ — -2 F--F 17N^X / N N 22H2NpWSGR Docket No. 61402-727.601WSGR Docket No. 61402-727.601CpdStructureNo.33zzz z z z--- z z z z z zH H Q / Y ™^ z Z / Z Zy\xv^^HYUY2l YN y X^ ho _,A I z34 ' f0H2N P35QH2N-736°yH2N P37WSGR Docket No. 61402-727.601WSGR Docket No. 61402-727.601WSGR Docket No. 61402-727.601Cpd CpdStructure Structure No. No.Q C QX>- Yi I T z zvx °NH / ^ / kZZZZ^ v^^^^H Hz z z z97 < / 6762 z z- Z ZZZ-- z= ^ / / z z \V H -H )H2N0.. 9 pHI VI'o 9SH2NH2N'y — 68 / =NNNZrS63 / =^N Y I W 72 — N N N H2N ^isr 'N )=NH2N6964NH2\ *rS H2N-7 70 / =N \===^ Z 1 / 65 9N n —H2N XX-^QNH2H2N\ * H2N'7 —71 rS Z^N \=^ Z 1 / 66C’ V.€XIH 5 W Q H2N H2NWSGR Docket No. 61402-727.601

[0237] In some embodiments, the compound or salt of Formula (I), (I- A), (I-B), (I-C), (I-D), (II), (II-A), (II-B), (III), (III-A), (III-B), (III-C), or (III-D), is a compound selected fromWSGR Docket No. 61402-727.601WSGR Docket No. 61402-727.601WSGR Docket No. 61402-727.601WSGR Docket No. 61402-727.601salt of each thereof.WSGR Docket No. 61402-727.601

[0238] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.

[0239] Chemical entities having carbon-carbon double bonds or carbon-nitrogen double bonds may exist in Z- or E- form (or cis- or trans- form). Furthermore, some chemical entities may exist in various tautomeric forms. Unless otherwise specified, compounds or salts of Formula (I), (I- A), (I-C), (I-D), (II), (II- A), (II-B), (III), (III-A), (III-B), (III-C), (III-D), (IV- A), (IV-B), or (IV-C) are intended to include all Z-, E- and tautomeric forms as well.

[0240] “Isomers” are different compounds that have the same molecular formula.“Stereoisomers” are isomers that differ only in the way the atoms are arranged in space.“Enantiomers” are a pair of stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a “racemic” mixture. The term “(±)” is used to designate a racemic mixture where appropriate. “Diastereoisomers” or “diastereomers” are stereoisomers that have at least two asymmetric atoms but are not mirror images of each other. The absolute stereochemistry is specified according to the Cahn-Ingold-Prelog R-S system. When a compound is a pure enantiomer, the stereochemistry at each chiral carbon can be specified by either R or S. Resolved compounds whose absolute configuration is unknown can be designated (+) or (-) depending on the direction (dextro- or levorotatory) in which they rotate plane polarized light at the wavelength of the sodium D line. Certain compounds described herein contain one or more asymmetric centers and can thus give rise to enantiomers, diastereomers, and other stereoisomeric forms, the asymmetric centers of which can be defined, in terms of absolute stereochemistry, as (R)- or (S)-. The present chemical entities, pharmaceutical compositions and methods are meant to include all such possible stereoisomers, including racemic mixtures, optically pure forms, mixtures of diastereomers and intermediate mixtures. Optically active (R)- and (S)-isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. The optical activity of a compound can be analyzed via any suitable method, including but not limited to chiral chromatography and polarimetry, and the degree of predominance of one stereoisomer over the other isomer can be determined.WSGR Docket No. 61402-727.601

[0241] The compounds or salts for Formula (I), (I-A), (I-C), (I-D), (II), (II-A), (II-B), (III), (III-A), (III-B), (III-C), (III-D), (IV-A), (IV-B), or (IV-C), herein may in some cases exist as diastereomers, enantiomers, or other stereoisomeric forms. The compounds presented herein include all diastereomeric, enantiomeric, and epimeric forms as well as the racemates, mixtures of diastereomers, and other mixtures thereof, to the extent they can be made by one of ordinary skill in the art by routine experimentation. Separation of stereoisomers may be performed by chromatography or by forming diastereomers and separating by recrystallization, or chromatography, or any combination thereof. (Jean Jacques, Andre Collet, Samuel H. Wilen, “Enantiomers, Racemates and Resolutions,” John Wiley And Sons, Inc., 1981, herein incorporated by reference for this disclosure). Stereoisomers may also be obtained by stereoselective synthesis. Furthermore, a mixture of two enantiomers enriched in one of the two can be purified to provide further optically enriched form of the major enantiomer by recrystallization and / or trituration.

[0242] In certain embodiments, compounds or salts for Formula (I), (I-A), (I-C), (I-D), (II), (II-A), (II-B), (III), (III-A), (III-B), (III-C), (III-D), (IV-A), (IV-B), or (IV-C), may comprise two or more enantiomers or diastereomers of a compound wherein a single enantiomer or diastereomer accounts for at least about 70% by weight, at least about 80% by weight, at least about 90% by weight, at least about 98% by weight, or at least about 99% by weight or more of the total weight of all stereoisomers. Methods of producing substantially pure enantiomers are well known to those of skill in the art. For example, a single stereoisomer, e.g., an enantiomer, substantially free of its stereoisomer may be obtained by resolution of the racemic mixture using a method such as formation of diastereomers using optically active resolving agents (Stereochemistry of Carbon Compounds, (1962) by E. L. Eliel, McGraw Hill; Lochmuller (1975) J. Chromatogr., 113(3): 283-302). Racemic mixtures of chiral compounds can be separated and isolated by any suitable method, including, but not limited to: (1) formation of ionic, diastereomeric salts with chiral compounds and separation by fractional crystallization or other methods, (2) formation of diastereomeric compounds with chiral derivatizing reagents, separation of the diastereomers, and conversion to the pure stereoisomers, and (3) separation of the substantially pure or enriched stereoisomers directly under chiral conditions. Another approach for separation of the enantiomers is to use a Diacel chiral column and elution using an organic mobile phase such as done by Chiral Technologies (www.chiraltech.com) on a fee for service basis.

[0243] A “tautomer” refers to a molecule wherein a proton shift from one atom of a molecule to another atom of the same molecule is possible. In certain embodiments, the compounds or salts for Formula (I), (I-A), (I-C), (I-D), (II), (II-A), (II-B), (III), (III-A), (III-B), (III-C), (III-D),WSGR Docket No. 61402-727.601(IV-A), (IV-B), or (IV-C) exist as tautomers. In circumstances where tautomerization is possible, a chemical equilibrium of the tautomers may exist. The exact ratio of the tautomers depends on several factors, including physical state, temperature, solvent, and pH. Some nonlimiting examples of tautomeric equilibrium include:

[0244] The compounds disclosed herein, in some embodiments, are used in different enriched isotopic forms, e.g., enriched in the content of2H,3H,11C,13C and / or14C. In one particular embodiment, the compound may be deuterated in at least one position. Such deuterated forms can be made by the procedure described in U. S. Patent Nos. 5,846,514 and 6,334,997. As described in U. S. Patent Nos. 5,846,514 and 6,334,997, deuteration can improve the metabolic stability and or efficacy, thus increasing the duration of action of drugs.

[0245] In certain embodiments, the compounds disclosed herein have some or all of the 'H atoms replaced with2H atoms. The methods of synthesis for deuterium-containing compounds are known in the art and include, by way of non-limiting example only, the following synthetic methods.

[0246] Deuterium substituted compounds are synthesized using various methods such as described in: Dean, Dennis C.; Editor. Recent Advances in the Synthesis and Applications of Radiolabeled Compounds for Drug Discovery and Development. [In: Curr., Pharm. Des., 2000; 6(10)] 2000, 110 pp; George W.; Varma, Rajender S. The Synthesis of Radiolabeled Compounds via Organometallic Intermediates, Tetrahedron, 1989, 45(21), 6601-21; and Evans, E. Anthony. Synthesis of radiolabeled compounds, J. Radioanal. Chem., 1981, 64(1-2), 9-32.WSGR Docket No. 61402-727.601

[0247] Deuterated starting materials are readily available and are subjected to the synthetic methods described herein to provide for the synthesis of deuterium-containing compounds. Large numbers of deuterium-containing reagents and building blocks are available commercially from chemical vendors, such as Aldrich Chemical Co.

[0248] Unless otherwise stated, compounds described herein are intended to include compounds which differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by13C- or14C-enriched carbon are within the scope of the present disclosure.

[0249] The compounds of the present disclosure optionally contain unnatural proportions of atomic isotopes at one or more atoms that constitute such compounds. For example, the compounds may be labeled with isotopes, such as for example, deuterium (2H), tritium (3H), iodine-125 (125I) or carbon-14 (14C). Isotopic substitution with2H,11C,13C,14C,15C,12N,13N,15N,16N,16O,17O,14F,15F,16F,17F,18F,33S,34S,35S,36S,35C1,37C1,79Br,81Br, and125I are all contemplated. All isotopic variations of the compounds of the present invention, whether radioactive or not, are encompassed within the scope of the present invention.

[0250] Included in the present disclosure are salts, particularly pharmaceutically acceptable salts, of the compounds of Formula (I), (LA), (LC), (LD), (II), (ILA), (ILB), (III), (III- A), (IIL B), (IILC), (IILD), (IV-A), (IV-B), or (IV-C). The compounds of the present disclosure may possess a sufficiently acidic, a sufficiently basic, or both functional groups, can react with any of a number of inorganic bases, and inorganic and organic acids, to form a salt. Alternatively, compounds that are inherently charged, such as those with a quaternary nitrogen, can form a salt with an appropriate counterion, e.g., a halide such as bromide, chloride, or fluoride, particularly bromide.

[0251] The methods and compositions of Formula (I), (LA), (LC), (LD), (II), (ILA), (ILB), (III), (IILA), (IILB), (IILC), (IILD), (IV-A), (IV-B), or (IV-C) include the use of amorphous forms as well as crystalline forms (also known as polymorphs). The compounds described herein may be in the form of pharmaceutically acceptable salts. As well, in some embodiments, active metabolites of these compounds having the same type of activity are included in the scope of the present disclosure. In addition, the compounds described herein can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. The solvated forms of the compounds presented herein are also considered to be disclosed herein.

[0252] Included in the present disclosure are salts, particularly pharmaceutically acceptable salts, of compounds represented by Formula (I), (LA), (LC), (LD), (II), (ILA), (ILB), (III), (III-WSGR Docket No. 61402-727.601A), (III-B), (III-C), (III-D), (IV-A), (IV-B), or (IV-C). The compounds of the present invention that possess a sufficiently acidic, a sufficiently basic, or both functional groups, can react with any of a number of inorganic bases, and inorganic and organic acids, to form a salt.Alternatively, compounds that are inherently charged, such as those with a quaternary nitrogen, can form a salt with an appropriate counterion, e.g., a halide such as bromide, chloride, or fluoride, particularly bromide.

[0253] In certain embodiments, compounds or salts of Formula (I), (I- A), (I-C), (I-D), (II), (II-A), (II-B), (III), (III-A), (III-B), (III-C), (III-D), (IV-A), (IV-B), or (IV-C) may be prodrugs, e.g, wherein a hydroxyl in the parent compound is presented as an ester or a carbonate, or carboxylic acid present in the parent compound is presented as an ester. The term “prodrug” is intended to encompass compounds which, under physiologic conditions, are converted into pharmaceutical agents of the present disclosure. One method for making a prodrug is to include one or more selected moieties which are hydrolyzed under physiologic conditions to reveal the desired molecule. In other embodiments, the prodrug is converted by an enzymatic activity of the host animal such as specific target cells in the host animal. For example, esters or carbonates (e.g., esters or carbonates of alcohols or carboxylic acids and esters of phosphonic acids) are preferred prodrugs of the present disclosure.

[0254] Pharmaceutical Formulations

[0255] In some aspects, the present disclosure provides a pharmaceutical composition comprising a compound or salt of Formula (I), (I-A), (I-C), (I-D), (II), (II-A), (II-B), (III), (III-A), (III-B), (III-C), (III-D), (IV-A), (IV-B), or (IV-C), and at least one pharmaceutically acceptable excipient.

[0256] Pharmaceutical compositions can be formulated using one or more physiologically-acceptable carriers comprising excipients and auxiliaries. Formulation can be modified depending upon the route of administration chosen. Pharmaceutical compositions comprising a compound, salt or conjugate can be manufactured, for example, by lyophilizing the compound, salt or conjugate, mixing, dissolving, emulsifying, encapsulating or entrapping the conjugate. The pharmaceutical compositions can also include the compounds, salts or conjugates in a free-base form or pharmaceutically-acceptable salt form.

[0257] A compound or salt of Formula (I), (I-A), (I-C), (I-D), (II), (II-A), (II-B), (III), (III-A), (III-B), (III-C), (III-D), (IV-A), (IV-B), or (IV-C), may be formulated in any suitable pharmaceutical formulation. A pharmaceutical formulation of the present disclosure typically contains an active ingredient (e.g., compound or salt of any one of Formula (I), (I-A), (I-C), (I-D), (II), (II-A), (II-B), (III), (III-A), (III-B), (III-C), (III-D), (IV-A), (IV-B), or (IV-C), and one or more pharmaceutically acceptable excipients or carriers, including but not limited to: inertWSGR Docket No. 61402-727.601solid diluents and fillers, diluents, sterile aqueous solution and various organic solvents, permeation enhancers, antioxidants, solubilizers, and adjuvants.

[0258] Methods of Treatment

[0259] The compounds described herein can be used in the preparation of medicaments for the prevention or treatment of diseases or conditions. In addition, a method for treating any of the diseases or conditions described herein in a subject in need of such treatment, involves administration of pharmaceutical compositions containing at least one compound described herein, or a pharmaceutically acceptable salt, pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate thereof, in therapeutically effective amounts to said subject.

[0260] The compositions containing the compound(s) described herein can be administered for prophylactic and / or therapeutic treatments. In therapeutic applications, the compositions are administered to a patient already suffering from a disease or condition, in an amount sufficient to cure or at least partially arrest the symptoms of the disease or condition. Amounts effective for this use will depend on the severity and course of the disease or condition, previous therapy, the patient's health status, weight, and response to the drugs, and the judgment of the treating physician.

[0261] In prophylactic applications, compositions containing the compounds described herein are administered to a patient susceptible to or otherwise at risk of a particular disease, disorder or condition. Such an amount is defined to be a “prophylactically effective amount or dose.” In this use, the precise amounts also depend on the patient's state of health, weight, and the like. When used in a patient, effective amounts for this use will depend on the severity and course of the disease, disorder or condition, previous therapy, the patient's health status and response to the drugs, and the judgment of the treating physician.

[0262] In some aspects, the present disclosure provides a method for treatment, comprising administering to a subject in need thereof an effective amount of a compound or salt of Formula (I), (I- A), (LC), (LD), (II), (ILA), (ILB), (III), (IILA), (IILB), (IILC), (IILD), (IV- A), (IV-B), or (IV-C). In some aspects, the present disclosure provides a method for treating cancer in a patient in need thereof, comprising administering to the subject an effective amount of a compound or salt of Formula (I), (I- A), (LC), (LD), (II), (ILA), (ILB), (III), (IILA), (IILB), (IIL C), (IILD), (IV-A), (IV-B), or (IV-C).

[0263] In certain embodiments, the present disclosure can be used as a method of modulating activity of AKT1 comprising administering to a subject in need thereof a compound or salt of Formula (I), (LA), (LC), (LD), (II), (ILA), (ILB), (III), (IILA), (IILB), (IILC), (IILD), (IV-A), (IV-B), or (IV-C), or a pharmaceutical composition of Formula (I), (LA), (LC), (LD), (II), (II-A), (ILB), (III), (IILA), (IILB), (IILC), (IILD), (IV-A), (IV-B), or (IV-C). In someWSGR Docket No. 61402-727.601embodiments, the AKTI is wild-type AKTI. In some embodiments, the AKTI is a mutant AKTI. In some embodiments, the administrating modulates the activity of mutant AKT1. In some embodiments, the mutant AKTI is AKTI E17K. In some embodiments, the administrating modulates the activity of wild-type AKTI.

[0264] In certain embodiments, the present disclosure can be used as a method of modulating activity of wild-type AKTI over wild-type AKT2 comprising administering to a subject in need thereof a compound or salt of Formula (I), (I- A), (I-C), (I-D), (II), (II- A), (II-B), (III), (III- A), (IILB), (IILC), (III-D), (IV-A), (IV-B), or (IV-C), or a pharmaceutical composition of Formula (I), (I- A), (I-C), (I-D), (II), (ILA), (II-B), (III), (IILA), (IILB), (IILC), (III-D), (IV-A), (IV-B), or (IV-C).

[0265] In certain embodiments, the present disclosure can be used as a method of treating cancer comprising administering to a subject in need thereof a compound or salt of Formula (I), (I-A), (LC), (LD), (II), (ILA), (ILB), (III), (IILA), (IILB), (IILC), (IILD), (IV-A), (IV-B), or (IV-C), or a pharmaceutical composition of Formula (I), (LA), (LC), (LD), (II), (ILA), (ILB), (III), (IILA), (IILB), (IILC), (IILD), (IV-A), (IV-B), or (IV-C).

[0266] In certain embodiments, the present disclosure can be used as a method of modulating activity of AKTI comprising administering to a subject in need thereof a compound or salt of Table 1 or a pharmaceutical composition thereof. In some embodiments, the AKTI is wild-type AKTI. In some embodiments, the AKTI is a mutant AKTI. In some embodiments, the administrating modulates the activity of mutant AKTI. In some embodiments, the mutant AKTI is AKTI E17K. In some embodiments, the administrating modulates the activity of wild-type AKTI.

[0267] In certain embodiments, the present disclosure can be used as a method of modulating activity of wild-type AKTI over wild-type AKT2 comprising administering to a subject in need thereof a compound or salt of Table 1 or a pharmaceutical composition thereof.

[0268] In certain embodiments, the present disclosure can be used as a method of treating cancer comprising administering to a subject in need thereof a compound or salt of Table 1 or a pharmaceutical composition thereof.EXAMPLES

[0269] The invention now being generally described, it will be more readily understood by reference to the following examples which are included merely for purposes of illustration of certain aspects and embodiments of the present invention and are not intended to limit the invention in any way.

[0270] Chemical SynthesisWSGR Docket No. 61402-727.601

[0271] The following examples describe illustrate various methods of preparation of compounds described herein. Examples are exemplary and not exhaustive. It is understood that one skilled in the art may be able to synthesize described compounds by similar methods.Acronyms: EA: ethyl acetate; PE: petroleum ether

[0272] Example 1: Synthesis of Intermediates

[0273] Intermediate 1: 7V-(3-amino-5-chloropyrazin-2-yl)-2-pivalamidonicotinamideIntermediate 1

[0274] Synthetic Route:

[0275] Step 1: Synthesis of N-(3-bromo-5-chloropyrazin-2-yl)-2-(2, 2-dimethylpropanamido)pyridine-3 -carboxamide: To a stirred solution of 3-bromo-5-chloropyrazin-2-amine (35.29 g, 169.297 mmol, 1 equiv) in Toluene (400 mL) was added Trimethylaluminium (127 mL, 253.945 mmol, 1.5 equiv) at 0 °C under N2. The reaction mixture was stirred at rt for 30 min, then at 50 °C for 1 h. A solution of methyl 2-(2,2-dimethylpropanamido)pyridine-3-carboxylate (40 g, 169.297 mmol, 1 equiv) in Toluene (100 mL) was added dropwise to the reaction mixture at 50°C under N2. The reaction mixture was stirred at 110 °C for 2h. To this mixture, EtOAc (1000 mL) and water (300 mL) were added. The resulting mixture was filtered; the filter cake was washed with EtOAc (3x1500 mL). After separation of phases, the aqueous phase was extracted with EtOAc (300 mL x 2). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by trituration with PE (lOOOmL). The precipitated solids were collected by filtration and washed with PE (3x100 mL) to afford N-(3-bromo-5-chloropyrazin-2-yl)-2-(2,2-WSGR Docket No. 61402-727.601dimethylpropanamido)pyridine-3-carboxamide (60 g, 85.8% yield, 83% purity) as a yellow solid. The crude product was used in the next step directly without further purification. Observed mass (ESI): 412.15 [M+H]+.

[0276] Step 2: Synthesis of N-(5-chloro-3-((2,4-dimethoxybenzyl)amino)pyrazin-2-yl)-2-pivalamidonicotinamide: To a stirred solution of N-(3-bromo-5-chloropyrazin-2-yl)-2-(2,2-dimethylpropanamido)pyridine-3-carboxamide (20 g, 48.465 mmol, 1 equiv) and l-(2,4-dimethoxyphenyl)methanamine (14.56 mL, 96.930 mmol, 2 equiv) in tert-Butanol (100 mL) was added DIEA (16.88 mL, 96.930 mmol, 2 equiv). The reaction mixture was stirred at 140°C for 5h. The resulting mixture was concentrated under reduced pressure. The residue was purified by trituration with Et2O (100 mL) and stirred overnight at room temperature. The resulting mixture was filtered to afford N-(5-chloro-3-((2,4-dimethoxybenzyl)amino)pyrazin-2-yl)-2-pivalamidonicotinamide (20 g) as a yellow solid. The crude product was used in the next step directly without further purification. Observed mass (ESI): 499.15 [M+H]+.

[0277] Step 3: Synthesis of A-(3-amino-5-chloropyrazin-2-yl)-2-pivalamidonicotinamide (Intermediate 1): To a stirred solution of N-(5-chloro-3-{[(2,4-dimethoxyphenyl)methyl]amino}pyrazin-2-yl)-2-(2,2-dimethylpropanamido)pyridine-3-carboxamide (30 g, 60.124 mmol, 1 equiv) in DCM (300 mL) was added TFA (60 mL). The reaction mixture was stirred at rt for 3h. The mixture was concentrated. The residue was purified by trituration with Et2O (100 mL) and stirred overnight at room temperature. The resulting mixture was filtered to afford N-(3-amino-5-chloropyrazin-2-yl)-2-(2,2-dimethylpropanamido)pyridine-3 -carboxamide (Intermediate 1) (25 g) as a yellow solid. The crude product was used in the next step directly without further purification. Observed mass (ESI): 349.25 [M+H]+.

[0278] Intermediate 2: Zc / V-butyl (l-(4-(2-(2-aminopyridin-3-yl)-6-chloro-lJ / -imidazo[4,5-Z»]pyrazin-l-yl)phenyl)cyclobutyl)carbamateri2iN)=NI / NHIntermediate 2

[0279] Synthetic Route:WSGR Docket No. 61402-727.601BrIntermediate 1Intermediate 2

[0280] Step 1: Synthesis of tert-butyl (l-(4-((6-chloro-3-(2-pivalamidonicotinamido)pyrazin-2-yl)amino)phenyl)cyclobutyl)carbamate: A stirred solution of N-(3-amino-5-chloropyrazin-2-yl)-2-pivalamidonicotinamide (Intermediate 1) (5 g, 14.335 mmol, 1 equiv), tert-butyl (l-(4-bromophenyl)cyclobutyl)carbamate (4.8 g, 14.713 mmol, 1.03 equiv), Ephos Pd G4 (0.7 g, 0.762 mmol, 0.05 equiv), CS2CO3 (19 g, 58.315 mmol, 4.07 equiv) and Ephos (0.4 g, 0.748 mmol, 0.05 equiv) in DMAc (50 mg, 0.574 mmol, 0.04 equiv) was stirred for 2h at 90°C under N2 atmosphere. The mixture was allowed to cool down to rt. The resulting mixture was diluted with H2O (200 mL). The precipitated solids were collected by filtration and washedwith H2O (3x200 mL) to afford tert-butyl (l-(4-((6-chloro-3-(2-pivalamidonicotinamido)pyrazin-2-yl)amino)phenyl)cyclobutyl)carbamate (7.5 g, 88.06%yield, 70% purity) as brown solid. Observed mass (ESI): 594.20 [M+H]+.

[0281] Step 2: Synthesis of 3-(l-(4-(l-aminocyclobutyl)phenyl)-6-chloro-lH-imidazo[4,5-b]pyrazin-2-yl)pyridin-2-amine: A solution of tert-butyl (l-(4-((6-chloro-3-(2-pivalamidonicotinamido)pyrazin-2-yl)amino)phenyl)cyclobutyl)carbamate (1 g, 1.683 mmol, 1 equiv) in HC1 (20 mL, 60.000 mmol, 3M in H2O) was stirred overnight at 110°C. The mixture was allowed to cool down to rt. The mixture was extracted with DCM (3x100 ml). The crude product was a solution in water, the solution was used in the next step directly without further purification. Observed mass (ESI): 392.10 [M+H]+.

[0282] Step 3: Synthesis of tert-butyl (l-(4-(2-(2-aminopyridin-3-yl)-6-chloro-lH-imidazo[4,5-b]pyrazin-l-yl)phenyl)cyclobutyl)carbamate (Intermediate 2): The solution of 3-(l-(4-(l-aminocyclobutyl)phenyl)-6-chloro-lH-imidazo[4,5-b]pyrazin-2-yl)pyridin-2-amine (650 mg, 1.659 mmol, 1 equiv, in 20 mL H2O) was adjusted to pH = 8 with sat. NaHCOs. To theWSGR Docket No. 61402-727.601above mixture was added DCM (20 mL) and NaHCCh (300 mg, 3.571 mmol, 2.15 equiv) followed by di-tert-butyl dicarbonate (700 mg, 3.207 mmol, 1.93 equiv). The resulting mixture was stirred at rt for Ih. The resulting mixture was extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na2SC>4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with EA / PE (0-60%) to afford tert-butyl (l-(4-(2-(2-aminopyridin-3-yl)-6-chloro-lH-imidazo[4,5-b]pyrazin-l-yl)phenyl)cyclobutyl)carbamate (Intermediate 2) (240 mg, 29.41% yield, 85% purity) as a yellow solid....

Claims

1. WSGR Docket No. 61402-727.601CLAIMS WHAT IS CLAIMED IS:

1. A compound represented by the structure of Formula (I):or a pharmaceutically acceptable salt thereof, wherein:R2is selected from (a) and (b):a) halogen, -OR13, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN; and b) C3-12 carbocycle and 3- to 12-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, - N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, - N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, - C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, - OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, - S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -N02, -CN, Ci-6 alkyl, and Ci-6 haloalkyl;Ring B is selected from C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR11, -SR11, -N(Rn)2, -C(0)Rn, -C(0)N(Rn)2, -N(R11)C(0)R11, - C(0)0Rn, -0C(0)Rn, -N(R11)C(0)0R11, -0C(0)N(Rn)2, -N(R11)C(0)N(R11)2, -WSGR Docket No. 61402-727.601S(O)Rn, -S(0)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, -NO2, and -CN; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(0)N(Rn)2, -N(R11)C(O)R11, -C(O)ORn, -OC(O)Rn, -N R^C^OR11, -0C(0)N(Rn)2, -N(R11)C(O)N(R11)2, - S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, =0, =S, =N(Rn), -NO2, and -CN; R1is selected from:hydrogen, halogen, -OR12, -SR12, -N(R12)2, -C(O)R12, -C(O)N(R12)2, - N(R12)C(O)R12, -C(O)OR12, -OC(O)R12, -N(R12)C(O)OR12, -OC(O)N(R12)2, - N(R12)C(O)N(R12)2, -S(O)R12, -S(O)2R12, -N(R12)S(O)2R12, -S(O)2N(R12)2, -NO2, and - CN; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR12, -SR12, -N(R12)2, -C(O)R12, -C(O)N(R12)2, -N(R12)C(O)R12, -C(O)OR12, -OC(O)R12, -N(R12)C(O)OR12, -OC(O)N(R12)2, -N(R12)C(O)N(R12)2, - S(O)R12, -S(O)2R12, -N(R12)S(O)2R12, -S(O)2N(R12)2, -NO2, and -CN;R3is selected from (i), (ii), and (iii):i. halogen, -OR15, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN;ii. C1-6 alkyl optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, - N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, - N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl; andiii. C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, - N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, - N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2,WSGR Docket No. 61402-727.601and -CN; andCi-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, - C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, - OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, - S(O)2N(R14)2, -NO2, and -CN; andC3-6 carbocycle and 3- to 6-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN;each R13and R15is independently selected from:C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR16, -SR16, -N(R16)2, -C(O)R16, -C(O)N(R16)2, -N(R16)C(O)R16, -C(O)OR16, -OC(O)R16, -N(R16)C(O)OR16, -OC(O)N(R16)2, -N(R16)C(O)N(R16)2, - S(O)R16, -S(O)2R16, -N(R16)S(O)2R16, -S(O)2N(R16)2, -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR16, - SR16, -N(R16)2, -C(O)R16, -C(O)N(R16)2, -N(R16)C(O)R16, -C(O)OR16, -OC(O)R16, - N(R16)C(O)OR16, -OC(O)N(R16)2, -N(R16)C(O)N(R16)2, -S(O)R16, -S(O)2R16, - N(R16)S(O)2R16, -S(O)2N(R16)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl; andR10, R11, R12, R14, and R16are each independently selected at each occurrence from:hydrogen;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -O-C1-6 alkyl, -O-C1-6 haloalkyl, -NH2, -NO2, =0, -CN, C3-10 carbocycle, and 3- to 10-membered heterocycle, the C3-10 carbocycle and 3- to 10- membered heterocycle are each optionally substituted with one or more substituents independently selected from: halogen, -OH, C1-6 alkyl, C1-6 haloalkyl, -O-C1-6 alkyl, -O- C1-6 haloalkyl, -NH2, -NO2, =0, and -CN; andC3-10 carbocycle and 3- to 10-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OH, Ci- 6 alkyl, C1-6 haloalkyl, -O-C1-6 alkyl, -O-C1-6 haloalkyl, -NH2, -NO2, =0, and -CN.

2. The compound or salt of claim 1, wherein R2is selected from (a) and (b):a) -OR13; andWSGR Docket No. 61402-727.601b) C3-12 carbocycle and 3- to 12-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, - N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, - N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, - C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, - OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, - S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl.

3. The compound or salt of claim 1 or claim 2, wherein R3is selected from C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(0)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(0)0R14, -0C(0)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(0)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(0)0R14, -0C(0)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andC3-6 carbocycle and 3- to 6-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, - SR14, -N(R14)2, -C(0)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(0)0R14, -0C(0)R14, - N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, - N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN.

4. The compound or salt of claim 3, wherein R3is selected from C3-12 carbocycle optionally substituted with one or more substituents independently selected from:WSGR Docket No. 61402-727.601halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN;Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andC3-6 carbocycle and 3- to 6-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, - SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, - N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, - N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN.

5. The compound or salt of claim 4, wherein R3is selected from C5-12carbocycle optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -NO2, and -CN, C1-6 alkyl, C1-6 haloalkyl, C3-6 carbocycle, and 3- to 6-membered heterocycle.

6. The compound or salt of claim 5, wherein R3is selected from C3-6 carbocycle optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -NO2, and -CN, C1-6 alkyl, C1-6 haloalkyl, C3-6 carbocycle, and 3- to 6-membered heterocycle.NH2The compound or salt of claim 6, whereinR3is HO8. The compound or salt of claim 1, wherein the structure of Formula (I) is represented by the structure of Formula (II):RLN^Nr3(ii);or a pharmaceutically acceptable salt thereof, wherein:R2is selected from (a) and (b):WSGR Docket No. 61402-727.601a) halogen, -OR13, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN; and b) C3-12 carbocycle and 3- to 12-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, - N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, - N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, - C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, - OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, - S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -N02, -CN, Ci-6 alkyl, and Ci-6 haloalkyl;Ring B is selected from C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR11, -SR11, -N(Rn)2, -C(0)Rn, -C(0)N(Rn)2, -N(R11)C(0)R11, - C(0)0Rn, -0C(0)Rn, -N(R11)C(0)0R11, -0C(0)N(Rn)2, -N(R11)C(0)N(R11)2, -S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, -NO2, and -CN; and Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(0)Rn, -C(0)N(Rn)2, -N(R11)C(0)R11, -C(0)0Rn, -0C(0)Rn, -N R^C^OR11, -0C(0)N(Rn)2, -N(R11)C(0)N(R11)2, - S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(R11)2, =0, =S, =N(Rn), -NO2, and -CN; R1is selected from:hydrogen, halogen, -OR12, -SR12, -N(R12)2, -C(0)R12, -C(O)N(R12)2, - N(R12)C(O)R12, -C(0)0R12, -0C(0)R12, -N(R12)C(O)OR12, -OC(O)N(R12)2, - N(R12)C(O)N(R12)2, -S(O)R12, -S(O)2R12, -N(R12)S(O)2R12, -S(O)2N(R12)2, -N02, and - CN; andCi-6 alkyl optionally substituted with one or more substituents independentlyWSGR Docket No. 61402-727.601selected from halogen, -OR12, -SR12, -N(R12)2, -C(O)R12, -C(O)N(R12)2, -N(R12)C(O)R12, -C(O)OR12, -OC(O)R12, -N(R12)C(O)OR12, -OC(O)N(R12)2, -N(R12)C(O)N(R12)2, - S(O)R12, -S(O)2R12, -N(R12)S(O)2R12, -S(O)2N(R12)2, -NO2, and -CN;R3is selected from (i), (ii), and (iii):i. halogen, -OR15, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN;ii. Ci-6 alkyl optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, - N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, - N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl; andiii. C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, - N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, - N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andCi-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, - C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, - OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, - S(O)2N(R14)2, -NO2, and -CN;each R13and R15is independently selected from:Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR16, -SR16, -N(R16)2, -C(O)R16, -C(O)N(R16)2, -N(R16)C(O)R16, -C(O)OR16, -OC(O)R16, -N(R16)C(O)OR16, -OC(O)N(R16)2, -N(R16)C(O)N(R16)2, - S(O)R16, -S(O)2R16, -N(R16)S(O)2R16, -S(O)2N(R16)2, -NO2, and -CN; andWSGR Docket No. 61402-727.601C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR16, - SR16, -N(R16)2, -C(O)R16, -C(O)N(R16)2, -N(R16)C(O)R16, -C(O)OR16, -OC(O)R16, - N(R16)C(O)OR16, -OC(O)N(R16)2, -N(R16)C(O)N(R16)2, -S(O)R16, -S(O)2R16, - N(R16)S(O)2R16, -S(O)2N(R16)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl; andR10, R11, R12, R14, and R16are each independently selected at each occurrence from:hydrogen;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -O-C1-6 alkyl, -O-C1-6 haloalkyl, -NH2, -NO2, =0, -CN, C3-10 carbocycle, and 3- to 10-membered heterocycle, the C3-10 carbocycle and 3- to 10- membered heterocycle are each optionally substituted with one or more substituents independently selected from: halogen, -OH, C1-6 alkyl, C1-6 haloalkyl, -O-C1-6 alkyl, -O- C1-6 haloalkyl, -NH2, -NO2, =0, and -CN; andC3-10 carbocycle and 3- to 10-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OH, Ci- 6 alkyl, C1-6 haloalkyl, -O-C1-6 alkyl, -O-C1-6 haloalkyl, -NH2, -NO2, =0, and -CN.

9. The compound or salt of claim 8, wherein the structure of Formula (II) is represented by the structure of Formula (II- A):or a pharmaceutically acceptable salt thereof, wherein:R2is selected from (a) and (b):a) -OR13; andb) C3-12 carbocycle and 3- to 12-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, - N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, - N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -WSGR Docket No. 61402-727.601C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, - OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, - S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl;Ring B is selected from C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR11, -SR11, -N(Rn)2, -C(0)Rn, -C(0)N(Rn)2, -N(R11)C(0)R11, - C(0)0Rn, -0C(0)Rn, -N(R11)C(0)0R11, -0C(0)N(Rn)2, -N(R11)C(0)N(R11)2, - S(O)Rn, -S(0)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, -NO2, and -CN; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(0)Rn, -C(0)N(Rn)2, -N(R11)C(0)R11, -C(0)0Rn, -0C(0)Rn, -N R^C^OR11, -0C(0)N(Rn)2, -N(R11)C(0)N(R11)2, - S(O)R11, -S(O)2R11, -N(R11)S(O)2R11, -S(O)2N(R11)2, =O, =S, =N(R11), -NO2, and -CN; R1is selected from:hydrogen, halogen, -OR12, -SR12, -N(R12)2, -C(0)R12, -C(O)N(R12)2, - N(R12)C(O)R12, -C(0)0R12, -0C(0)R12, -N(R12)C(O)OR12, -OC(O)N(R12)2, - N(R12)C(O)N(R12)2, -S(O)R12, -S(O)2R12, -N(R12)S(O)2R12, -S(O)2N(R12)2, -NO2, and - CN; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR12, -SR12, -N(R12)2, -C(0)R12, -C(O)N(R12)2, -N(R12)C(O)R12, -C(0)0R12, -0C(0)R12, -N(R12)C(O)OR12, -OC(O)N(R12)2, -N(R12)C(O)N(R12)2, - S(O)R12, -S(O)2R12, -N(R12)S(O)2R12, -S(O)2N(R12)2, -NO2, and -CN;R3is selected from (i), (ii), and (iii):i. halogen, -OR15, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN;ii. C1-6 alkyl optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, - N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -WSGR Docket No. 61402-727.601N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl; andiii. C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, - N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, - N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andCi-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, - C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, - OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, - S(O)2N(R14)2, -NO2, and -CN;each R13and R15is independently selected from:Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR16, -SR16, -N(R16)2, -C(O)R16, -C(O)N(R16)2, -N(R16)C(O)R16, -C(O)OR16, -OC(O)R16, -N(R16)C(O)OR16, -OC(O)N(R16)2, -N(R16)C(O)N(R16)2, - S(O)R16, -S(O)2R16, -N(R16)S(O)2R16, -S(O)2N(R16)2, -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR16, - SR16, -N(R16)2, -C(O)R16, -C(O)N(R16)2, -N(R16)C(O)R16, -C(O)OR16, -OC(O)R16, - N(R16)C(O)OR16, -OC(O)N(R16)2, -N(R16)C(O)N(R16)2, -S(O)R16, -S(O)2R16, - N(R16)S(O)2R16, -S(O)2N(R16)2, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl; andR10, R11, R12, R14, and R16are each independently selected at each occurrence from:hydrogen;Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, -NH2, -NO2, =0, -CN, C3-10 carbocycle, and 3- to 10-membered heterocycle, the C3-10 carbocycle and 3- to 10- membered heterocycle are each optionally substituted with one or more substituentsWSGR Docket No. 61402-727.601independently selected from: halogen, -OH, Ci-6 alkyl, Ci-6 haloalkyl, -O-Ci-6 alkyl, -O- Ci-6 haloalkyl, -NH2, -NO2, =0, and -CN; andC3-10 carbocycle and 3- to 10-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OH, Ci- 6 alkyl, C1-6 haloalkyl, -O-C1-6 alkyl, -O-C1-6 haloalkyl, -NH2, -NO2, =0, and -CN.

10. The compound or salt of claim 9, wherein R2is -OR13.

11. The compound or salt of claim 10, wherein R2is selected from12. The compound or salt of any one of claims 8-11, wherein the structure of Formula (II) is represented by Formula (II-B):

13. The compound or salt of claim 1 or claim 12, wherein Ring B is C3-12 carbocycle optionally substituted with one or more substituents independently selected from:halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -N(R11)C(0)R11, - C(O)ORn, -OC(O)Rn, -N(R11)C(0)0R11, -OC(O)N(Rn)2, -N(R11)C(0)N(R11)2, - S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, -NO2, and -CN; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -N(R11)C(0)R11, -C(O)ORn, -OC(O)Rn, -N(R11)C(O)OR11, -OC(O)N(Rn)2, -N(R11)C(0)N(R11)2, - S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, =0, =S, =N(Rn), -NO2, and -CN.

14. The compound or salt of claim 13, wherein Ring B is C3-6 carbocycle optionally substituted with one or more substituents independently selected from:halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(0)N(Rn)2, -N(R11)C(0)R11, - C(O)ORn, -OC(O)Rn, -N(R11)C(0)0R11, -0C(0)N(Rn)2, -N(R11)C(0)N(R11)2, - S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, -NO2, and -CN; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(0)N(Rn)2, -N(R11)C(0)R11,WSGR Docket No. 61402-727.601-C(O)ORn, -OC(O)Rn, -N R^ C OR11, -OC(O)N(Rn)2, -N(R11)C(O)N(R11)2, - S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, =0, =S, =N(Rn), -NO2, and -CN.

15. The compound or salt of claim 14, wherein Ring B is phenyl optionally substituted with one or more substituents independently selected from:halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(0)N(Rn)2, -N(R11)C(0)R11, - C(O)ORn, -OC(O)Rn, -N(R11)C(0)0R11, -0C(0)N(Rn)2, -N(R11)C(0)N(R11)2, - S(O)Rn, -S(0)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, -NO2, and -CN; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(0)N(Rn)2, -N(R11)C(0)R11, -C(O)ORn, -OC(O)Rn, -N(R11)C(O)OR11, -0C(0)N(Rn)2, -N(R11)C(0)N(R11)2, - S(O)Rn, -S(0)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, =0, =S, =N(Rn), -NO2, and -CN.

16. The compound or salt of claim 15, wherein Ring B is phenyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(0)N(Rn)2, -N R^ O11, -C(O)ORn, -OC(O)Rn, -N R^C^OR11, -0C(0)N(Rn)2, -N(R11)C(0)N(R11)2, -S(O)Rn, -S(0)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl.

17. The compound or salt of claim 16, wherein Ring B is phenyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(0)N(Rn)2, -C(O)ORn, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl.

18. The compound or salt of claim 17, wherein Ring B is phenyl.

19. The compound or salt of claim 17, wherein Ring B is selected fromanc[20. The compound or salt of any one of claims 1-12, wherein Ring B is selected from a 3- to 12-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(0)N(Rn)2, -N(R11)C(0)R11, - C(O)ORn, -OC(O)Rn, -N(R11)C(0)0R11, -0C(0)N(Rn)2, -N(R11)C(0)N(R11)2, - S(O)Rn, -S(0)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, -NO2, and -CN; andC1-6 alkyl optionally substituted with one or more substituents independentlyWSGR Docket No. 61402-727.601selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -N(R11)C(O)R11, -C(O)ORn, -OC(O)Rn, -N(R11)C(O)OR11, -OC(O)N(Rn)2, -N(R11)C(O)N(R11)2, - S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, =0, =S, =N(Rn), -NO2, and -CN.

21. The compound or salt of claim 20, wherein Ring B is selected from a 3- to 6-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -N(R11)C(O)R11, - C(O)ORn, -OC(O)Rn, -N(R11)C(O)OR11, -OC(O)N(Rn)2, -N(R11)C(0)N(R11)2, -S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, -NO2, and -CN; and C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -N(R11)C(O)R11, -C(O)ORn, -OC(O)Rn, -N(R11)C(O)OR11, -OC(O)N(Rn)2, -N(R11)C(0)N(R11)2, -S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, =0, =S, =N(Rn), -NO2, and -CN.

22. The compound or salt of claim 21, wherein Ring B is selected from pyrrolyl, pyridyl, and pyrazinyl, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(0)N(Rn)2, -N(R11)C(0)R11, - C(O)ORn, -OC(O)Rn, -N(R11)C(0)0R11, -0C(0)N(Rn)2, -N(R11)C(0)N(R11)2, - S(O)Rn, -S(0)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, -NO2, and -CN; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(0)N(Rn)2, -N(R11)C(0)R11, -C(O)ORn, -OC(O)Rn, -N R^C^OR11, -0C(0)N(Rn)2, -N(R11)C(0)N(R11)2, - S(O)Rn, -S(0)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, =0, =S, =N(Rn), -NO2, and -CN.

23. The compound or salt of claim 22, wherein Ring B is selected from pyrrolyl, pyridyl, and pyrazinyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(0)N(Rn)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl.I I— (zI« \^N24. The compound or salt of claim 23, wherein Ring B is selected fromH2NWSGR Docket No. 61402-727.60125. The compound or salt of claim 21, wherein Ring B is pyridyl optionally substituted with one or more substituents independently selected from:halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(0)N(Rn)2, -N(R11)C(O)R11, - C(O)ORn, -OC(O)Rn, -N(R11)C(O)OR11, -0C(0)N(Rn)2, -N(R11)C(O)N(R11)2, -S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, -NO2, and -CN; and C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(0)N(Rn)2, -N(R11)C(O)R11, -C(O)ORn, -OC(O)Rn, -N R^C^OR11, -OC(O)N(Rn)2, -N(R11)C(O)N(R11)2, - S(O)Rn, -S(O)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, =0, =S, =N(Rn), -NO2, and -CN.

26. The compound or salt of claim 25, wherein Ring B is pyridyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(0)N(Rn)2, -NCR^QOX11, -C(O)ORn, -OC(O)Rn, -N(R11)C(O)OR11, -0C(0)N(Rn)2, -N(R11)C(0)N(R11)2, -S(O)Rn, -S(0)2Rn, -N(R11)S(O)2R11, -S(O)2N(RU)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl.

27. The compound or salt of claim 26, wherein Ring B is pyridyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -SR11, -N(Rn)2, -C(O)Rn, -C(O)N(Rn)2, -C(O)ORn, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl.

28. The compound or salt of claim 27, wherein Ring B is pyridyl substituted with -N(Rn)2.

29. The compound or salt of claim 28, wherein Ring Bis30. The compound or salt of any one of claims 1-12, wherein Ring B is selected from31. The compound or salt of any one of claims 1, 8, 9, or 12, wherein the structure of Formula (I), (II), (II-A), or (II-B) is represented by Formula (III):WSGR Docket No. 61402-727.60132. The compound or salt of any one of claims 1-31, wherein R1is selected from hydrogen, halogen, -OR12, -SR12, -N(R12)2, -C(O)R12, -C(O)N(R12)2, -N(R12)C(O)R12, -C(O)OR12, -OC(O)R12, -N(R12)C(O)OR12, -OC(O)N(R12)2, -N(R12)C(O)N(R12)2, -S(O)R12, -S(O)2R12, -N(R12)S(O)2R12, -S(O)2N(R12)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl.

33. The compound or salt of claim 32, wherein R1is selected from hydrogen, halogen, -OR12, -N(R12)2, -C(O)R12, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl.

34. The compound or salt of claim 33, wherein R1is selected from hydrogen and methyl.

35. The compound or salt of claim 33, wherein R1is hydrogen.

36. The compound or salt of any one of claims 31-35, wherein the structure of Formula (III) is represented by Formula (III-A):3(III-A).

37. The compound or salt of any one of claims 1-36, wherein R3is selected from C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14,WSGR Docket No. 61402-727.601-C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -N02, and -CN.

38. The compound or salt of claim 37, wherein R3is 3- to 12-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andCi-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN.

39. The compound or salt of claim 38, wherein R3is 3- to 8-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andCi-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN.

40. The compound or salt of claim 39, wherein R3is 3- to 8-membered heterocycle optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl.

41. The compound or salt of claim 40, wherein R3is selected from azetidinyl, oxetanyl, pyrrolidinyl, tetrahydropyranyl, and 2-oxa-5-azabicyclo[2.2.2]octanyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl.WSGR Docket No. 61402-727.601H2N-V 42. The compound or salt of claim 41, wherein R3is selected fromHu, " T " T " TNH,l\K \ / j ( V ( \ / >°NH2NHZ, W, and43. The compound or salt of claim 37, wherein R3is C3-12 carbocycle optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN.

44. The compound or salt of claim 43, wherein R3is C3-8 carbocycle optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN.

45. The compound or salt of claim 44, wherein R3is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and spiro[2.3]hexanyl, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -WSGR Docket No. 61402-727.601S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -N02, and -CN.

46. The compound or salt of claim 45, wherein R3is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and spiro[2.3]hexanyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl.

47. The compound or salt of claim 46, wherein R3is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and spiro[2.3]hexanyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl.

49. The compound or salt of claim 44, wherein R3is cyclobutyl optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andCi-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN.

50. The compound or salt of claim 49, wherein R3is cyclobutyl substituted with -N(R14)2and further optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -WSGR Docket No. 61402-727.601OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, - S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN.R14^N - / _51. The compound or salt of claim 49, wherein R3isR and further optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, - OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, - S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andC1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN.

52. The compound or salt of any one of claims 31-51, wherein the structure of Formula (III) or Formula (III-A) is represented by Formula (III-B):R2Ri4^rN - / _whereinR is further optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, - OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, -WSGR Docket No. 61402-727.601S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andCi-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN.

53. The compound or salt of claims 50-52, wherein the one or more optional substituents are selected from halogen, -OR14, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl. / _ 54. The compound or salt of claim 52, wherein the optionally substitutedR is56. The compound or salt of any one of claims 1-36, wherein R3is selected from halogen, - OR15, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, - S(O)2N(R14)2, -NO2, and -CN.

57. The compound or salt of claim 56, wherein R3is selected from halogen, -OR15, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -NO2, and -CN.

58. The compound or salt of claim 57, wherein R3is -OR15.WSGR Docket No. 61402-727.601H2N59. The compound or salt of claim 58, wherein R3is60. The compound or salt of any one of claims 1-36, wherein R3is selected from C1-6 alkyl optionally substituted with one or more substituents independently selected from:halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, - C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, - S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR14, - SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, - N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, - N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl.

61. The compound or salt of claim 60, wherein R3is Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -N(R14)C(O)R14, -C(O)OR14, -OC(O)R14, -N(R14)C(O)OR14, -OC(O)N(R14)2, -N(R14)C(O)N(R14)2, -S(O)R14, -S(O)2R14, -N(R14)S(O)2R14, -S(O)2N(R14)2, -NO2, -CN, C3-12 carbocycle, and 3- to 12-membered heterocycle.

62. The compound or salt of claim 61, wherein R3is Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR14, -SR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, -C(O)OR14, -NO2, -CN, C3-6 carbocycle, and 3- to 6-membered heterocycle.

63. The compound or salt of claim 62, wherein R3is selected from64. The compound or salt of claim 1 or claim 8, wherein R2is selected from halogen, -OR13, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN.WSGR Docket No. 61402-727.60165. The compound or salt of any one of claims 1-9 or 12 to 63, wherein R2is selected from C3-12 carbocycle and 3- to 12-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, - SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, - N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, - N(R10)S(O)2R10, -S(O)2N(R10)2, -N02, -CN, C1-6 alkyl, and C1-6 haloalkyl.

66. The compound or salt of claim 65, wherein R2is 3- to 10-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, - SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, - N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, - N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl.

67. The compound or salt of claim 66, wherein R2is 3- to 6-membered heterocycle optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -WSGR Docket No. 61402-727.601C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, - SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, - N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, - N(R10)S(O)2R10, -S(O)2N(R10)2, -N02, -CN, Ci-6 alkyl, and Ci-6 haloalkyl.

68. The compound or salt of claim 67, wherein R2is 5- to 6-membered heteroaryl optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, - SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, - N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, - N(R10)S(O)2R10, -S(O)2N(R10)2, -N02, -CN, Ci-6 alkyl, and Ci-6 haloalkyl.

69. The compound or salt of claim 68, wherein R2is selected from pyrazolyl, triazolyl, and pyridyl, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;Ci-6 alkyl optionally substituted with one or more substituents independentlyWSGR Docket No. 61402-727.601selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, - SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, - N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, - N(R10)S(O)2R10, -S(O)2N(R10)2, -N02, -CN, Ci-6 alkyl, and Ci-6 haloalkyl.

70. The compound or salt of claim 69, wherein R2is selected from pyrazolyl, triazolyl, and pyridyl, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN; andCi-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN.

71. The compound or salt of claim 70, wherein R2is selected from pyrazolyl, triazolyl, and pyridyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, N(R10)2, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl.

72. The compound or salt of claim 71, wherein R2is selected fromWSGR Docket No. 61402-727.60173. The compound or salt of claim 68, wherein R2is selected from pyrazolyl and pyridyl, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, - SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, - N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, - N(R10)S(O)2R10, -S(O)2N(R10)2, -N02, -CN, Ci-6 alkyl, and Ci-6 haloalkyl.

74. The compound or salt of claim 73, wherein R2is selected from pyrazolyl and pyridyl, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN; andCi-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, =0, =S, =N(R10), -N02, and -CN.

75. The compound or salt of claim 74, wherein R2is selected from pyrazolyl and pyridyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, N(R10)2, -N02, -CN, Ci-6 alkyl, and Ci-6 haloalkyl.WSGR Docket No. 61402-727.60176. The compound or salt of claim 75, wherein R2is selected from77. The compound or salt of claim 73, wherein R2is selected from pyrazolyl and pyridyl, each of which is optionally substituted with one or more substituents independently selected from C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl.

78. The compound or salt of claim 77, wherein R2is pyrazolyl optionally substituted with one or more substituents independently selected from C3-6 carbocycle optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, -CN, C1-6 alkyl, and C1-6 haloalkyl. / ^N / / '79. The compound or salt of claim 78, wherein R2is80. The compound or salt of claim 77, wherein R2is selected from pyrazolyl and pyridyl, each of which is optionally substituted with one or more substituents independently selected from 3- to 12-membered heterocycle optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -WSGR Docket No. 61402-727.601N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, -CN, C1-6 alkyl, and Ci-6 haloalkyl.

81. The compound or salt of claim 80, wherein R2is selected from pyrazolyl and pyridyl, each of which is optionally substituted with 3- to 8-membered heterocycle optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl.

82. The compound or salt of claim 81, wherein R2is selected from pyrazolyl and pyridyl, each of which is optionally substituted with 3- to 8-membered heterocycle optionally substituted with one or more substituents independently selected from halogen, -OR10, -N(R10)2, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl.

83. The compound or salt of claim 82, wherein R2is selected from84. The compound or salt of claim 65, wherein R2is C3-12 carbocycle optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;Ci-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, - SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, - N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, - N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, -CN, Ci-6 alkyl, and Ci-6 haloalkyl.WSGR Docket No. 61402-727.60185. The compound or salt of claim 84, wherein R2is C3-8 carbocycle optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, - SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, - N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, - N(R10)S(O)2R10, -S(O)2N(R10)2, -N02, -CN, C1-6 alkyl, and C1-6 haloalkyl.

86. The compound or salt of claim 85, wherein R2is selected from cyclopropyl and phenyl, each of which is optionally substituted with one or more substituents independently selected from:halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, - C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -NO2, and -CN;C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, - S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, =0, =S, =N(R10), -NO2, and -CN; andC3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, - SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -OC(O)R10, - N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, - N(R10)S(O)2R10, -S(O)2N(R10)2, -N02, -CN, C1-6 alkyl, and C1-6 haloalkyl.

87. The compound or salt of claim 86, wherein R2is selected from cyclopropyl and phenyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)N(R10)2, -N(R10)C(O)R10, -C(O)OR10, -WSGR Docket No. 61402-727.601OC(O)R10, -N(R10)C(O)OR10, -OC(O)N(R10)2, -N(R10)C(O)N(R10)2, -S(O)R10, -S(O)2R10, -N(R10)S(O)2R10, -S(O)2N(R10)2, -N02, -CN, CI-6 alkyl, and Ci-6 haloalkyl.

88. The compound or salt of claim 87, wherein R2is selected from89. The compound or salt of claim 87, wherein R2is selected from90. The compound or salt of any one of claims 1-9 or 12 to 63, wherein R2is selected from91. The compound or salt of any one of claims 1-9 or 12 to 63, wherein R2is selected fromWSGR Docket No. 61402-727.60192. The compound or salt of any one of claims 1-91, wherein the compound is selected from a compound of Table 1, or a pharmaceutically acceptable salt hereof.

93. A pharmaceutical composition comprising a compound or salt of any one of claims 1-92, and a pharmaceutically acceptable excipient.

94. A method of modulating activity of wild-type AKT1 comprising, administering to a subject in need thereof a compound or salt of any one of claims 1-92, or a pharmaceutical composition of claim 93.

95. A method of modulating activity of mutant AKT1 comprising, administering to a subject in need thereof a compound or salt of any one of claims 1-92, or a pharmaceutical composition of claim 93.

96. A method of modulating activity of wild-type AKT1 over wild-type AKT2 comprising, administering to a subject in need thereof a compound or salt of any one of claims 1-92, or a pharmaceutical composition of claim 93.

97. A method of modulating activity of mutant AKT1 over wild-type AKT2 comprising, administering to a subject in need thereof a compound or salt of any one of claims 1-92, or a pharmaceutical composition of claim 93.

98. A method of treating cancer, administering to a subject in need thereof a compound or salt of any one of claims 1-92, or a pharmaceutical composition of claim 93.

99. The method of any one of claims 95, 97, or 98, wherein the mutant AKT1 is E17K.

Images